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ABSTRACT

CALVIN ROBERT KEITH BLASCHKE. Developing and Utilizing Novel Biofluid Nglycan Profiling Methods for the Classification of Suspicious Mammogram
Findings. (Under the direction of RICHARD DRAKE).

Biofluids are a great source of biomarkers because they reflect the immune
and metabolic status of cells throughout the body and can be collected noninvasively. Changes in the levels and compositions of N-glycans released from
serum and plasma glycoproteins have been assessed in many diseases across
many large clinical sample cohorts. Assays used for N-glycan profiling in these
fluids currently require multiple lengthy processing steps, thus diminishing their
potential for use as standard clinical diagnostic assays. In response to this need
for rapid, simple, and high-throughput biofluid analysis, a novel slide-based biofluid
profiling platform was developed for the detection of N-glycan alterations that can
function as biomarkers of disease. This platform was initially validated for the
analysis of serum and plasma N-glycan profiles but was also adapted for the
evaluation of urine and prostatic fluid N-glycan profiles. Key to these workflows
was the immobilization of the fluid glycoproteins to a slide that was washed of all
contaminants, followed by the rapid and highly sensitive detection of enzymatically
released N-glycans by mass spectrometry. The enzyme used to release the Nglycans can be changed to target and increase the sensitivity for specific N-glycan
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classes. To demonstrate the utility and feasibility of applying this platform, serum
samples from 199 women with breast cancer and 99 women with a benign lesion
in their breast were analyzed in order to identify differences in the N-glycan
profiles. The overall N-glycan profiles of the two patient groups had no differences,
but there were several individual N-glycans with significant differences in
intensities between patients with benign lesions and ductal carcinoma in situ
(DCIS). For women aged 50 - 74 with a body mass index of 18.5 - 24.9, a model
including the intensities of two N-glycans, 1850.666 m/z and 2163.743 m/z, age,
and BMI were able to clearly distinguish the breast cancer patients from the
patients with benign lesions with an AUROC of 0.899 and an optimal cutoff with
82% sensitivity and 84% specificity. This study indicates that serum N-glycan
profiling is a promising approach for providing clarity for breast cancer screening,
especially within the subset of healthy weight women in the age group
recommended for mammograms. Overall, the workflows described in this
dissertation have displayed the sensitivity, adaptability, and throughput to be
utilized as a biomarker discovery platform with significant clinical utility.
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Chapter 1: Literature Review

1

1.1 Mass Spectrometry
Mass spectrometry (MS) is an analytical chemistry technique that
analyzes the molecular composition of a sample by measuring the abundance of
molecules identified by their physical and chemical properties. While the typical
measured characteristic of the molecules is mass, by combining MS with
chromatography, molecules can be separated and analyzed by an array of other
properties. A diverse range of scientific fields and industries have adopted the
use of MS, attesting to the utility and variety of molecular targets that can be
analyzed with MS. Rapid development and improvement in instrumentation, as
well increasing integration of other analytical chemistry instruments with MS in
the form of hyphenated techniques, have allowed for this wide applicability.

1.1.1 General Principles
To characterize analytes by MS, the mass-to-charge ratio (m/z) of the
analyte in the sample are detected. While there is a wide range of techniques
and instrumentations that can be used and combined, there are common events
that occur in every MS analysis. Mass spectrometers first convert analytes from a
sample into gas-phase charged molecules. This process of ionization can be
accomplished with a range of techniques that vary in how much energy they
transfer to the analytes. Soft ionization refers to techniques with which a low
amount of energy is transferred to the analytes and the covalent bonds in the
analytes are not disrupted. Hard ionization transfers a high amount of energy that
2

can be used to fragment analytes. For the identification of biological analytes,
electrospray ionization (ESI), matrix-assisted laser desorption/ionization (MALDI),
and desorption electrospray ionization (DESI) are the most used ionization
techniques.1
Once the ions have been generated, they are separated by their m/z using
either static or dynamic electric fields, magnetic fields, or a combination of both in
the mass analyzer. There are a variety of mass analyzers that rely on specific
physical properties and will determine the mass resolution, accuracy, and range
of the analysis. The needs of a study greatly impact which type of mass analyzer
would be most appropriate. Often higher mass resolution and mass accuracy can
be achieved, but at the expense of longer data acquisition periods and slower
overall analysis times. Compatible ion sources and cost can also limit the
selection of the mass analyzer needed for a study.
In the final phase of MS analysis, the analyte ions are detected and
converted into a signal. This can occur through the generation of a current or a
secondary ion that can be amplified. As with the other components, the type of
mass detector can vary depending on what mass analyzer is used and the
design of the study. Ultimately, the abundance of the analyte ions that have been
separated by m/z will be measured and converted into a mass spectrum.
As this general overview has displayed, nearly every stage of MS analysis
can be adapted to create the most effective approach that will provide the
necessary specificity, sensitivity, and speed to investigate the analyte(s) of
interest. The widespread adoption of MS can be at least partially attributed to the
3

variety of sample types, molecular classes, and physical properties that can be
targeted. Additional discussion of the specific techniques and instruments used in
this dissertation are included below.

1.1.2 MALDI
Soft ionization techniques are useful when performing exploratory analysis
of the molecular composition of samples, as they will not fragment the analytes
and the m/z ratio can be used to identify the analytes by accurate mass. MALDI
is a soft ionization technique that has been used to analyze a range of molecular
targets. To analyze a sample by MALDI, a matrix, usually a weak organic acid
that absorbs UV, is cocrystallized with the sample.2 Typically, the matrix is
applied in excess concentrations compare to the sample. The matrix can be
applied by mixing with the sample in solution, spotted on top of a dried sample,
or sprayed in an even coating across a sample mounted to a slide or other
surface. When the sample is irradiated with laser pulse, the matrix absorbs the
light energy and converts it into heat, and both the matrix and the sample are
vaporized and released from the surface.3 This process is shown in Figure 1.
Additionally, the matrix acts as a proton donor and receptor once struck by the
laser pulse, which will ionize a portion of the sample molecules into either
negative or positive ions, respectively.4 MALDI minimizes the fragmentation of
analytes because the majority of the energy from the laser pulse is absorbed by
the matrix.

4

Figure 1. A schematic diagram of the MALDI process. This was adapted from
Dreisewerd, K. Recent methodological advances in MALDI mass spectrometry.
Anal. Bioanal. Chem. 406, 2261–2278 (2014).3
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ESI and MALDI are some of the most used soft ionization techniques.
MALDI is more compatible with complex sample mediums than ESI because it
can tolerate more contaminants, such as salts and detergents.5 As MS measures
the m/z ratio of analytes, ionization processes that create multiply charged ions,
such as ESI, make analysis more complex. The ions produced using MALDI are
primarily singly charged, making the m/z ratio equal to the mass of the analytes
in Daltons (Da). However, MALDI often generates ions with M+H isomers and
with metal adducts. These create multiple m/z ratios for a single analyte and can
complicate analysis. Additionally, low molecular weight analytes can be difficult to
analyze using MALDI because the matrix ions are highly abundant in the lower
m/z ratio range.6
The ionization efficiency of the analyte is heavily dependent on the type of
analyte, e.g., metabolites, drugs, lipids, peptides, proteins, or glycans, and the
choice of matrix. Sinapinic acid (SA), 2,5-dihydroxybenzoic acid (DHB), and αcyano-4-hydroxycinnamic acid (CHCA) are widely used matrices.3 Reactive
MALDI matrices are being investigated for their ability to participate in a chemical
reaction with the analyte during laser irradiation and improve ionization
efficiency.7 By dissolving or suspending conventional matrices in a vacuumstable liquid, researchers have created ionic liquid matrices (ILMs).8 These ILMs
create a more homogenous mixture with the analytes, have a precisely controlled
pH, and cause less fragmentation than traditional matrices.9
Historically, use of MALDI mass spectrometry for clinical diagnostic
applications is frequently criticized for issues of reproducibility and laser
6

performance over time. Modern MALDI mass spectrometers use Nd:Yag lasers
that have improved lifespans, throughput, and consistency compared to nitrogen
lasers. It should be noted that in the last decade use of MALDI instruments has
completely transformed clinical microbiology laboratories and clinical diagnostic
workflows.10–12 Key to those methods are the signature analyte barcodes used to
identify individual bacterial genus species and other microorganisms.
MALDI has been coupled with Imaging Mass Spectrometry (IMS) to allow
for a spatial analysis of a diverse set of biomolecules in a variety of sample
types.13–15 MALDI IMS involves applying matrix to a sample and ionizing the
analyte molecules with a laser pulse in a raster across the sample. A mass
spectrum is generated for each coordinate, and the intensity of each ion can be
visualized across the sample in a heat map. Initially developed for the analysis of
fresh frozen and formalin-fixed paraffin-embedded (FFPE) tissue sections,
MALDI IMS displayed great utility in linking analyte distributions with
histopathological classifications of tissue subtypes by standard histology and
immunohistochemistry stains.16–18 The sensitivity and robust nature of MALDI
IMS has led to the development of novel applications of this technology for the
analysis of cells and antibody-panels.19,20

7

1.1.4 Mass Spectrometers in Dissertation

1.1.4.1 Bruker SolariX 7T FT-ICR
The novel technique described in Chapter 1 of this dissertation was
initially developed using a Bruker SolariX 7 Tesla FT-ICR MS. This mass
spectrometer has both an ESI and a MALDI source, 2000 Hz SmartBeam II
ultraviolet laser, and utilizes an ion cyclotron resonance (ICR) cell. After
ionization in the MALDI source, DC and RF voltages are used to focus the ions
that have desorbed from the sample into an ion beam. The ion beam is guided
from a low vacuum environment to the ultra-high vacuum analyzer by moving
through a quadruple, which will filter out any ions not within a user-specified m/z
range, and a collision cell, which can be used to fragment specific ions for
MS/MS analysis. Before entering the ICR cell, optical lenses are used to focus
the ions. The ICR utilizes three sets of electrodes that are within a 7 Tesla
magnet to analyze the ions. The magnetic field confines the ions to the cell and
induces a cyclotron motion. The trapping plates generate a small electoral field to
prevent the ions from escaping the ICR. The excitation plates use a RF
frequency sweep to increase the radius of the ions’ motions. The detection plates
register the charge induced by the passing ions. A schematic of the ICR cell can
be seen in Figure 2.
The ion’s motion in a circular orbit creates a signal in the form of a
sinusoidal wave, commonly referred to as a transient, with a periodicity related to
the ion’s m/z ratio. Longer transients, that is the time that the ions oscillate in the
8

Figure 2. Schematic of a typical ICR cell geometry. This figure was adapted from
Bruker Daltonics Inc. SolariX User Manual. Revision 3 (2017).21

9

ICR cell, will make the peaks of the detected ions narrower and increase the
resolution of the data collected. As there are typically a mixture of ions and their
naturally occurring stable isotopes with discrete m/z ratios that are being
detected simultaneously, this complex time domain waveform is converted into a
frequency domain spectrum, which corresponds with the m/z ratios, by a Fourier
transform. This form of analysis, Fourier transform ion cyclotron resonance (FTICR), has high mass accuracy and the SolariX’s collision cell allows for MS/MS
validation of target analytes.

1.1.4.2 Bruker timsTOF fleX
The bulk of the data generated and presented in this dissertation was
collected with a Bruker timsTOF fleX MS. This instrument has a dual MALDI/ESI
source with a SmartBeam 3D laser operating with a 20 μm spot size and at
10,000 Hz. The timsTOF fleX also contains a collision cell that allows for MS/MS
analysis. This instrument has the capability to perform ion mobility spectrometry,
where the ions are separated and characterized by their movement through a
buffer gas in the presence of an electric field.22 This allows for analysis of ions
not only based on their m/z, but their three dimensional structure. This type of
analysis is particularly helpful for differentiating isomers or analytes with small
differences in molecular weight. The ion mobility functions of this instrument has
not been utilized in the studies discussed in this dissertation, as there were limits
in software capabilities, instrument performance, and optimizations of integrating
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this type data. Instead, the timsTOF fleX was operated as a standard quadruple
time-of-flight MS.
In this mode the ions are propelled by a static electric field, which
provides greater acceleration to molecules that are lower in mass or higher in
charge, into a field-free region of a drift tube. The time that it takes for the ion to
reach the detector at the end of the drift tube is directly proportional to the
velocity of the ion, which itself is dependent on the m/z of the ion. The process of
measuring the ions time-of-flight is shorter than measuring the cyclotron
resonance. This form of time-of-flight (TOF) analysis results in a faster data
acquisition speed for the timsTOF fleX MS compared to the SolariX 7T FT-ICR
MS, but at the expense of lower mass resolution.

1.2 N-Glycosylation
The metabolic utilization and interconversion of saccharides (also called
glycans) are an essential component of all living organisms. Glucose is used as
an energy source and ribose and deoxyribose sugars are key components of the
nucleic acid genetic code found in every organism ranging from the simplest
prokaryote to the most complex eukaryotes. Complex biochemical arrangements
of glycans as polysaccharides serve as structural components in plants, fungi,
and animals. The attachment of a single saccharide or chain of saccharides to
another class of molecule is often relevant to the function of that molecule and
found in Eukaryota, Bacteria, and Archaea.23,24 This process, called
glycosylation, is one of the most common post-translational modifications in
11

humans.25 There are many different classes of glycosylation that are categorized
based on the composition of the glycans, the composition of the non-glycan
components, and the attachment site of the glycan. Examples of glycans are
glycosphingolipids, glycosaminoglycans, glycosides, O-linked glycans, and Nglycans.
N-glycans are non-linear oligosaccharides covalently bound to proteins at
the amide nitrogen of asparagine residues, and the process for synthesizing and
attaching N-glycans is called N-glycosylation. Being the most common form of
glycosylation, the structure, synthesis, and biological functions of N-glycans have
been studied extensively.25 As the studies detailed in this dissertation analyze
samples from human patients, the background information provided here will
focus on the glycosylation processes and structures that occur in humans unless
stated otherwise, although much of this discussion will translate to other
vertebrates.

1.2.1 Composition and Structure
Fully processed human N-glycans are comprised of primarily Nacetylglucosamine, mannose, galactose, N-acetylneuraminic acid, and fucose.
Additional monosaccharides may be present in humans or other vertebrates,
such as N-acetylgalactosamine, N-glycolylneuraminic acid, and glucose. The
hexose monosaccharides are mannose, galactose, and glucose. They are
isomers of a 6-carbon sugar with a molecular weight of 180.063 Da. Nacetylglucosamine and N-acetylgalactosamine are N-acetylhexosamines, 612

carbon sugars with an acetyl group, and have a molecular weight of 221.090 Da.
Fucose is a deoxyhexose, a 6-carbon sugar with one less hydroxyl group, and
has a molecular weight of 164.069 Da. The sialic acids are N-acetylneuraminic
acid and N-glycolylneuraminic acid, which weigh 309.106 Da and 325.101 Da
respectively, and are charged monosaccharides. Since N-glycolylneuraminic acid
is not found in humans and is not investigated in any of the studies included in
this dissertation, any use of the term “sialic acid” is referring to Nacetylneuraminic acid.
As representing N-glycans with entire chemical structures becomes
unproductive with larger structures, the glycobiology field has taken to using
colored symbols to represent the monosaccharides.26,27 The symbol’s and other
relevant information of the common monosaccharides present in human Nglycans are displayed in Figure 3. The monosaccharides in N-glycans are
covalently bound by glycosidic linkages. This results in the loss of water and
correspondingly, decreases the weight of the monosaccharide by 18 Da when
added to the N-glycan.
N-glycans can have a variety of structures, but all contain a base structure
of two N-acetylglucosamine residues and three mannose residues. The broadest
categorizations of N-glycans are based on what monosaccharide residues are
present other than the core structure. These broad classes are high-mannose,
hybrid, and complex (Figure 4 A). High-mannose structures have only mannose
residues. Hybrid structures have at least one mannose residue and one Nacetylglucosamine residue. Complex residues have at least one N13

acetylglucosamine residue and no mannose residues. Fucosylation,
galactosylation, and sialylation are N-glycan classes defined by the presence of
fucose, galactose, and sialic acid residues, respectively (Figure 4 B). N-glycans
can have antenna, which are a series of linked monosaccharides starting with a
N-acetylglucosamine attached to the core structure. N-glycans with two antenna,
three antenna with one antenna on each mannose residues, three antenna on
the outer most mannose residues, and four antenna are in the biantennary,
bisecting, triantennary, and tetraantennary, respectively (Figure 4 C). While Nglycans with other structures are present in humans, such as polylactosamines
and alpha-galactoses, the N-glycan classes displayed in Figure 4 are the most
common.

Figure 3. The symbols, chemical structure, and weight of the common
monosaccharides found in human N-glycans.
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Figure 4. Representations of the N-glycan classes. A) N-glycan classes based
on the presence of mannose, N-acetylglucosamine, or both on the core structure,
B) the presence of specific monosaccharides, and C) the number of Nacetylglucosamines attached to the core structure.
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1.2.2 Biosynthesis
N-glycan biosynthesis is a well-defined, yet complex process involving a
series of enzymatic modifications to a N-glycan precursor attached to a protein in
the endoplasmic reticulum (ER) and further modified in the Golgi. The enzymes
that add and remove monosaccharide residues are called glycosyltransferases
and glycosidases, respectively. For monosaccharides to be incorporated into an
N-glycan, they must be in the form of a high-energy donor. The monosaccharides
can be either salvaged from degraded glycans, imported into the cell, or
enzymatically converted from other sugars within the cell. A nucleoside
triphosphate and a monosaccharide with a phosphate are used to create
nucleotide sugar donors which the glycosyltransferases can add via a glycosidic
bond to a N-glycan structure. The nucleotide sugar donors typically used in
human N-glycans are UDP-Glucose, UDP-Galactose, UDP-N-acetylglucosamine,
GDP-Mannose, GDP-Fucose, and CMP-Sialic acid.
There is a complex array of N-glycan structures, and accordingly,
glycosyltransferases are a large family of enzymes. The donor and acceptor
substrates for glycosyltransferases are typically very specific, and
glycosyltransferases will catalyze a bond between specific carbons of the
monosaccharides. Glycosidases catalyze the breaking of the glycosidic bond
between two specific monosaccharides either within (called endoglycosidases) or
at the terminal end of the N-glycan (called exoglycosidases) and are important
for the degradation of N-glycan structures for uptake and metabolism of sugars,
turnover of glycoproteins, and even, regulating protein folding.
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The N-glycan structure is initially constructed on a lipid carrier, a dolichol
phosphate, in the membrane of the ER. An oligosaccharide with two Nacetylglucosamines, nine mannoses, and three glucoses is formed on the
dolichol phosphate. The precursor is partially formed on the cytoplasmic side of
the ER and then translocated across the ER membrane by a flippase where it is
further processed. A protein complex called oligosaccharyltransferase (OST)
transfers the N-glycan precursor to an asparagine residue on a polypeptide that
is being translated and entering the ER.
Once the N-glycan has been attached to the protein, the trimming and
addition of the glucose residues on the N-glycan precursor are incorporated into
the cell’s quality control of the protein’s folding. Calnexin (CNX) and calreticulin
(CRT) are ER chaperone proteins that prevent incompletely folded glycoproteins
from exiting the ER by binding to the N-glycan precursors. If the glycoprotein fails
to fold correctly after multiple iterations of this process, the precursor N-glycan
will be truncated into a specific structure that will mark the protein for
transportation to the cytoplasm where it will be degraded by a proteosome.
In the Golgi, the N-glycan will be progressively modified by
glycosyltransferases and glycosidases to create a mature N-glycan with features
distinctive of the N-glycan classes. The N-glycan enters the Golgi as a highmannose N-glycan with nine mannose residues. At this point, the glycoprotein
may travel through the Golgi with no further modifications to the N-glycan. As the
glycoprotein is transported through the cis-Golgi mannose residues can be
trimmed off and N-acetylglucosamine residues can be added to initiate the
17

formation of antenna or hybrid N-glycans. Additional N-acetylglucosamine
residues and fucose residues can be incorporated in the medial-Golgi, and
galactose and sialic acid residues can be added in the trans-Golgi. At this stage,
N-glycans can also be modified by the addition of sulfate and phosphate groups.
Sulfotransferases will catalyze the transfer of a sulfate group from 3’phosphoadenosine-5’-phosphosulfate (PAPS) to primarily galactose or Nacetylglucosamine residues.28 Phosphorylation of N-glycans occurs through a
phosphate being transferred from a UDP-N-acetylglucosamine donor to a
mannose residue on an N-glycan. This is primarily used to select, segregate, and
traffic lysosomal enzymes through the Golgi to lysosomes.29 Once the N-glycan
is fully processed in the Golgi, the glycoprotein is transported to the cell
membrane for incorporation or secretion.
A glycoprotein can have a set of glycoforms that are defined by the
presence, structure, and composition of the N-glycans present. There are many
complex and interdependent factors that influence the number and relative
abundances of the glycoforms for a glycoprotein. It is important to note that while
the biosynthesis of N-glycans has been described here as segmented and
sequential, multiple processing steps can occur simultaneously, in a competitive
manner, or in a dependent manner. Some of the factors that influence the large
range of glycoforms are the concentration of sugar nucleotide donors, the
localization and abundance of the glycotransferases and glycosidases, and the
amount of time the glycoprotein spends in the ER and Golgi.
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The variability of N-glycans that can be detected at a single site, known as
N-glycosylation microheterogeneity, can be greatly impacted by the metabolic
state of the cell. The hexosamine biosynthetic pathway, which synthesizes UDPN-acetylglucosamine, is sensitive to the concentrations of UTP, glucose,
glutamine, and acetyl-CoA.30 This links the presence of several nucleotide sugar
donors to a cell’s metabolism of the four major macromolecules. As many of the
monosaccharides used to build N-glycans are also used in other forms of
glycosylation, the different processes are intricately linked as well.
The complexity and heterogeneity of N-glycosylation is present even at a
single N-glycosylation site. N-glycans are attached to asparagine residues within
an asparagine-X-serine/threonine sequon, where X is any amino acid except
proline, but even when this sequon is present, it may not be N-glycosylated. It is
estimated that approximately one third of the sequons are not N-glycosylated.31
This variability in site occupancy is called N-glycosylation macroheterogeneity,
and it can be influenced by several factors. Asparagine-X-Threonine sites are
more efficiently N-glycosylated than Asparagine-X-Serine sites.32,33 Acidic amino
acids in the X position can decrease site occupancy, while an aromatic amino
acid two residues before the asparagine can increase site occupancy.34,35 The
secondary and tertiary structure of the protein also impact the efficiency of Nglycosylation. Sequons located in flexible domains of the protein are more likely
to be N-glycosylated, but a majority of the sequons are found in β-sheets.35,36
OST can have two different catalytic subunits that either glycosylate polypeptides
as they enter or after they enter the ER. If a N-glycosylation site is not
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glycosylated as the polypeptide enters the ER, the tertiary structure of the protein
can affect whether the N-glycosylation site is accessible for OST. Even if a Nglycan is added to a protein in the ER, the tertiary structure of the protein can
inhibit glycan-processing enzymes in the Golgi from accessing the N-glycan.
Regulation of glycosyltransferases and glycosidases can influence the Nglycan profiles of a cell’s glycoproteins. Transcriptomic analysis by large-scale
microarray analysis identified distinct N-glycosylation processing enzymes for
different cell types.37–39 Additionally, to be fully active many of these enzymes
must be post-translationally modified as well by either phosphorylation or
glycosylation.40,41 Specific N-glycan biosynthetic enzymes involved in creating
high mannose and fucosylated structures are regulated by microRNA at the
transcriptional level.42 The biosynthesis of N-glycans is a heavily regulated
process that can be influenced by numerous cellular processes and
environmental cues. This allows for a dynamic modulation of the glycoforms
present on the glycoproteins and creates a diverse set of N-glycan structures.

1.2.3 Biological Functions
The impact of N-glycosylation can be identified early in the development of
an organism. The different developmental stages of vertebrates have been linked
to distinct N-glycan profiles.43 Genetic modifications that affect the early stages of
N-glycan processing are often embryonic lethal.44 Mutations that affect enzymes
involved in adding sialic acid residues often have less dramatic effects, since
sialylation occurs in the later stage of N-glycan processing and affects only the
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terminal ends of the structures.45 The rarity of human congenital disorders of
glycosylation (CDGs), inherited human diseases that are caused by defects in
glycan biosynthesis and metabolism, highlight the importance of glycosylation in
embryonic development. CDGs can have highly variable impacts, even in the
same mutation, but usually affect multiple organ systems.46
The linkages, or the carbons that form the glycosidic bond between the
monosaccharides, of an N-glycan can impact its effect on its carrier protein.
Some of the most well-documented linkage specific effects are centered around
sialic acids and fucoses. Fucose residues can be bound to the asparagine linked
N-acetylglucosamine in a α1,6 linkage or the N-acetylglucosamine on the Nglycan branches in a α1,3 or α1,4 linkage. These are called core fucosylation and
outer arm fucosylation, respectively. Sialic acids can be attached to a terminal
galactose by a α2,3 or α2,6 linkage.
N-glycans have important effects on proteins at the structural level due to
their hydrophilic and flexible chemical nature. As previously described, N-glycan
binding with calnexin and calreticulin play integral roles in assuring correct
protein folding before the protein is secreted or integrated into the plasma
membrane. The presence of the core N-glycan structure has been shown to
improve both the kinetics and thermodynamics of protein folding.47 The presence
of these hydrophilic, bulky, noncharged N-glycan structures aids in keeping the
protein in solution during folding. N-glycans can facilitate oligomerization or
stabilize oligomers through interactions with the protein subunits, and can even
aid in the fibrilization of prion proteins.48,49 Investigation of aquaporin-2 found that
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N-glycans stabilize mutated versions of the protein in the ER, allowing for more
time for the protein to fold in a manner that minimizes the effect of the mutations
instead of being targeted for degradation.50 Site-directed mutagenesis of Nglycan sites of a bile acid transporter, ASBT, resulted in an increased sensitivity
to proteolysis and decrease in function when the protein was unglycosylated.51
The N-glycans of a protein can also impact the localization, enzymatic
activity, substrate specificity, and binding affinity.52 Placenta bikunin (PB) is a
serine protease inhibitor with two glycoforms that determine its subcellular
distribution and consequently, access to target proteases.53 Receptor
oligomerization, ligand binding, and signaling can be significantly altered by a
change in or lack of N-glycans. Tumor necrosis factor-α receptor 1 (TNFR1) is a
key mediator in the inflammatory-activation of microglia which contributes to the
pathogenesis of several central nervous system (CNS) diseases. N-glycosylation
of TNFR1 did not impact the intracellular localization, but has been found to be
integral to the ligand-binding affinity and downstream signaling.54 Epidermal
growth factor receptor (EGFR) is an important mediator for cell proliferation
signaling pathways. In order for EGFR to dimerize and bind growth factors, there
have to be specific strong non-covalent interactions near the growth factor
binding site between the N-glycans and the extracellular domain of EGFR.55
N-glycans play significant roles in the development and functioning of
multiple physiological systems. Murine embryonic stem cells that lack complex Nglycans were unable to form bronchial epithelium.56 Mice incapable of
fucosylating the N-acetylglucosamine closest to the reducing end of the N-glycan
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could not develop fully functional lungs and displayed emphysema-like
symptoms.57 Glucose-stimulated insulin secretion depends upon N-glycans
maintaining glucose transporters in the proper orientation.58 Correspondingly, the
N-glycosylation of pancreatic beta cell glucose transporter-2 (Glut-2) is altered in
type 2 diabetes.59 Thyroglobulin is the protein backbone for synthesis of thyroid
hormones, and is modified with N-glycans that aid in the transport of
thyroglobulin into the follicular lumen of the thyroid.60 N-glycosylation, specifically
galactosylation and sialylation, is dynamically regulated in the myogenesis and
has been experimentally manipulated in mice to increase muscle mass.61 The
prevalence of cognitive and/or neurological abnormalities in patients with CDGs
are indicative of the role of N-glycosylation in neural development and function.62
By inhibiting the formation of complex or hybrid N-glycans, a study found that the
sodium channels and electrical signaling were altered in cardiac tissue and that
these changes accelerated the progression of heart disease.63
The glycoproteins on the surface of cells in the immune system work with
glycan-binding proteins to sense environmental signals. B cells and T cells
heavily express the glycoproteins CD43 and CD45 on their surface. These Nglycosylation of these proteins are crucial for their ability to regulate cellular
migration, T cell receptor signaling, apoptosis, and cell survival.64 Galectins,
soluble proteins that will bind to glycans that have galactose residues, are
involved in many roles of the immune system. Galectin 1 will bind to the Nglycans of CD45 to induce apoptosis, but this interaction is dependent on the
number of antenna and extent of sialylation of the N-glycans present.65 Galectins
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can also bind to receptors on the cell surface and oligomerize with other
galectins to form a lattice that will cluster the receptors and influence cell-cell
interactions. The result of this type of interaction is a regulation of the strength of
immune cell signaling that is dependent on the N-glycan profile of different
receptors. Similar to galectins, siglecs are sialic acid-binding proteins that are
commonly expressed on immune cells. Once bound to an antigen, B cell receptor
nanocluster formation is dependent on the action of CD22, a α2,6-linked sialic
acid-binding siglec.66 Additionally, CD22 is essential for regulating self-tolerance
as indicated by the high amounts of autoreactive IgG antibodies in CD-22
deficient mice.67 Selectins are cell adhesion molecules that recognize sialylated
and fucosylated N-glycans. Selectins are crucial for targeting leukocytes to a site
of injury by binding to the leukocytes in circulation to the endothelium for
extravasation.68 As they are critical for the initiation of inflammation, selectins
have even been targeting as therapeutic targets for inflammatory diseases.69,70
Immunoglobulins, specifically Immunoglobulin G (IgG), have significantly altered
functions depending on the N-glycans present on the their heavy chains. This will
be further discussed in a later section.

1.3 N-Glycan Profiling
Historically, the structural complexities and non-template directed
synthesis of oligosaccharides have made them more difficult to study than the
other major classes of biomolecules.71 Glycobiology has relied on technological
advancements to discover and explore the different classes of N-glycan
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structures and their functions. The analysis of determining the totality of N-glycan
structures present in a sample is called N-glycan profiling. N-glycan profiling
techniques differ based on the physical and chemical characteristics of the
sample.
N-glycan profiling of samples for clinical applications requires a technique
with a high-throughput and a high sensitivity to robustly analyze large cohorts
and identify potentially slight alterations in specific N-glycans or N-glycan
classes. While analysis of intact glycoproteins and glycopeptides can link Nglycan alterations found in clinical datasets back to the carrier protein, the
purification and/or data processing typically needed for these levels of analysis
can hinder their suitability for clinical applications. Alternatively, complete Nglycan structures can be enzymatically released from glycoproteins using
peptide-N-glycosidase F (PNGase F). PNGase F will cleave all N-glycans at the
site of their attachment to the asparagine residue on the carrier protein
regardless of N-glycan class. The released N-glycans can then be profiled using
a variety of analytical techniques depending on the sample type.

1.3.1 Serum and Plasma
The composition of serum and plasma collected during blood draws
reflects dynamic decellularized biofluids comprised of thousands of proteins and
metabolites. A major component of the fluids are multiple high abundance
glycoproteins produced by the liver and immunoglobulins secreted by B-cells.
Extensive characterization of the proteomes of serum and plasma has indicated
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a 10-fold order of magnitude concentration difference from the most abundant
proteins, i.e. albumin and immunoglobulins, to the lowest concentration ones.72,73
Current proteomic mass spectrometry studies have identified over 4300
individual proteins present in serum, yet by percentage of abundance, 22
proteins represent 99% of the content.72–74 Except for albumin, which is not a
glycoprotein and accounts for approximately 50% of the total protein content, the
majority of the 22 most abundant proteins and next 30 are glycoproteins secreted
by the liver and B-cells.
Interrogation of the glycan composition of these most abundant
glycoproteins for potential clinical application to differentiate healthy from disease
states has been ongoing for decades.75–77 The serum or plasma N-glycan profile
is very stable in an individual over time which is important for establishing the
rationale behind investigating N-glycan changes as diagnostics for disease.78
Large-scale studies have identified certain biological factors, such as age, sex,
and ethnicity, that have associated alterations in the serum or plasma N-glycan
profile.79–83 Additionally, smoking and dietary habits, physical activity, and
pregnancy can impact the N-glycans in these blood-based samples.84–86
Changes in the N-glycan profiles of serum or plasma that are associated with a
disease are frequently being identified. Major metabolic diseases, immunological
disorders, and many cancers have been linked to discrete changes in the levels
of N-glycans and N-glycan classes.77
Due to the variability between individuals and numerous effects of other
biological factors, studies aiming to identify N-glycan profile changes due to the
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presence of a disease or condition require large cohorts and a high-throughput
method that can analyze the numerous samples within a reasonable timeline.
The currently used methods for high throughput serum N-glycan analysis are
hydrophilic-interaction ultra-high-performance liquid chromatography (HILICUHPLC-FLD), multiplexed capillary gel electrophoresis with laser-induced
fluorescence detection (xCGE-LIF), and MALDI-TOF- MS.87–91
For HILIC-UHPLC-FLD, enzymatically released N-glycans are
fluorescently labelled, typically with 2-aminobenzamide (2-AB), by reductive
amination. The labelled N-glycans are then purified from the rest of the sample
and reagents using HILIC, which relies upon the interaction of the multiple
hydroxyl groups of the N-glycans with the amine, amide, or zwiterrion-bonded
silica stationary phase. The N-glycans can then be analyzed by UHPLC. The
sample retention times can be calibrated on an external run of dextran ladder to
obtain Glucose Unit (GU) values that have established assignments of certain Nglycans. While 2-AB has been the traditional choice of fluorescent derivatizing
agent, novel derivatizing agents are actively being investigated, such as 2(diethylamino) ethyl 4-({[(2,5-dioxopyrrolidin-1-yl) oxy] carbonyl} amino) benzoate
(named InstantPC) which improves this step greatly by lowered the sample
processing time and increased the fluorescence intensity of the labelled Nglycans.92
The sample preparation for xCGE-LIF is similar to that of HILIC-UHPLCFLD. N-glycans are released from the serum or plasma glycoproteins by PNGase
F. For this technique, the most commonly used reagent for fluorescent labelling
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is 8-aminopyrene-1,3,6-trisulfonic acid (APTS). HILIC is commonly used for the
solid-phase extraction of the N-glycans prior to xCGE-LIF during which the Nglycans are separated inside a polymer-filled capillary by their charge, size, and
shape and detected by the emitted light. The migration times of the N-glycans
can be annotated with established database values.
One of the largest plasma N-glycan studies analyzed over 2144
individuals by MALDI-MS to identify associations of plasma N-glycans with
markers of inflammation and metabolic health.93 The MALDI-MS workflow
involved the release of N-glycans with PNGase F, sialic acid stabilization by ethyl
esterification, purification by HILIC, incorporation of chemical matrix, and spotting
onto a MALDI target plate, with many of the steps completed with an automated
liquid handling robot.94 This workflow would be further optimized by limiting
derivatization side-reactions, decreasing batch-to-batch variances by changing
the HILIC stationary phase, and using MALDI-FTICR instead of MALDI-TOF.90 A
non-automated form of this workflow was adapted for dried blood spot N-glycan
analysis, which represents an even less-invasive collection strategy.95 These
strategies have been used to investigate a wide array of diseases, including
multiple myeloma,96 inflammatory bowel disease,97 rheumatoid arthritis,91 and
colorectal cancer.98 These extensive studies on large sample cohorts have
established N-glycan detection in plasma by MALDI-IMS as a clinically relevant
assay for us in clinical diagnostic laboratories.
Another method for MALDI-TOF-MS analysis of serum or plasma N-glycans
utilizes an enrichment strategy termed glycoblotting, in which beads conjugated
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with hydrazide groups bind N-glycans released from serum samples.99 Not only
are the bead-bound N-glycans purified with a series of washes, but the sialic acids
are stabilized by methyl esterification. The hydrazide groups with attached Nglycans are released from the bead by reduction with dithiothreitol. The enriched
N-glycans are spotted directly onto a MALDI target plate, mixed with matrix, and
analyzed by MALDI-TOF MS. The processing time of this workflow was reduced
when combined with an automated sample-processing system that can carry out
the majority of the steps.100 Glycoblotting-based serum analysis has been used
extensively to find many disease-specific N-glycan alterations.101–106 The clinical
utility of this workflow is distinguished by the minimal hands-on-time.

1.3.2 Urine
Urine is an attractive clinical sample for disease biomarkers because of its
non-invasive collection. Urine proteins and metabolites have been used to detect
decreased kidney function, diabetes, heart failure, multiple myeloma, and
multiple cancers.107–109 Specifically, nuclear matrix protein 22 is approved by the
United States Food and Drug Administration for the detection and monitoring of
bladder cancer.110 The function of multiple organs can be directly or indirectly
associated with urine proteins and their post-translational modifications.
Approximately 2,600 glycoproteins have been identified in urine, a portion of
which are trafficked through extracellular vesicles (EVs).111 Most of these
proteins are filtered from the blood or secreted from the kidney or urinary tract.
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While several glycoforms of urinary proteins have been investigated, there
have been few comprehensive studies of the urine N-glycan profile.
Theoretically, the high-throughput N-glycan profiling methods for serum can be
translated over to urine analysis, but this has rarely been done without first
isolating a glycoprotein of interest. The few studies that analyze the entire urine
N-glycan profile utilizes a method that can be adapted for high-throughput
analysis.112,113 Centrifugation and molecular weight centrifuge filters are typically
used to isolate the proteins from the other particles and cell debris. The isolated
proteins can be reduced, alkylated, and deglycosylated still on the filter. The
released N-glycans can be labelled with 2-aminobenzoic acid (2-AA) for
enhanced ionization efficiency and methylamidated for purification before liquid
chromatography-mass spectrometry analysis (LC-MS). The urine N-glycan
profiles of healthy individuals have similar compositions to serum and plasma
profiles, except for the presence of a small portion of sulfated N-glycans that are
not typically detected in serum and plasma samples.

1.3.3 Prostatic Fluids
The human prostate is a small organ that links both the male urinary tract
and reproductive tract organs as it encompasses the urethra and ejaculatory duct
junction. It functions as male accessory sex gland that produces fluids containing
glycoproteins, zinc, and citric acid. The components of these prostatic fluids have
important roles in the activation and motility of sperm and the liquefaction
process of ejaculate. As prostatic fluids can contain secreted proteins and shed
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cells from diseased tissue, prostatic fluids have been increasingly investigated as
source for biomarkers of prostate diseases.
Two glycoproteins, prostate-specific antigen (PSA) and prostatic acid
phosphatase (PAP), have been assessed for decades as detection biomarkers of
prostate cancer, but have limited ability to distinguish between prostate cancer
and noncancer prostatic disease.114,115 Proteomic analysis of prostatic fluids
found different expression levels of seven proteins, including PSA and PAP.116
Incorporation of the N-glycan profile of PSA have displayed promise in improving
its performance as a diagnostic and prognostic biomarker.117,118 While there have
been several studies of the serum N-glycan profile alterations between benign
prostate hyperplasia and prostate cancer, castration-resistant and castrationsensitive prostate cancer, and indolent and aggressive prostate cancer, there
have been very few studies investigated the N-glycan profile of prostatic
fluids.119–122 Similar to the methods used for high-throughput serum N-glycan
profiling, prostatic fluids can be analyzed by normal-phase high-performance
liquid chromatography (HPLC) of 2-AB labeled N-glycans, MALDI-TOF of
permethylated N-glycans, and multi-capillary electrophoresis of APTS-labelled Nglycans.123–125 From the few studies that have implemented these
methodologies, decreases in several triantennary and tetraantennary N-glycans
and the fucosylation N-glycan class have been associated with the prostate
cancer presence and progression.123–125
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1.3.4 Immunoglobulin G
Immunoglobulins are a key component of the adaptive immune system
found in all vertebrates that function to provide long-term defense to antigens that
the host has already been exposed to.126 There are five different classes of
immunoglobulin Immunoglobulin G (IgG), Immunoglobulin M (IgM),
Immunoglobulin A (IgA), Immunoglobulin E (IgE), and Immunoglobulin D (IgD).
Each immunoglobulin has a heavy chain and a light chain that forms a structure
that can be broken down into the crystallizable fragment (Fc) and antigen-binding
fragment (Fab). IgG is one of the most abundant in serum with 10-15 mg/ml of
IgG being secreted by B cells into circulation, accounting for about 10-20% of
plasma protein.127 There are four subclasses of IgG that differ in the amino acid
sequence of heavy chain and the number of disulphide bonds present.128 The
Fab domain contains the antigen-binding site that recognizes specific molecular
structures of antigens. The Fc domain plays an important role for mediating the
effector functions of the adaptive immune system. Once IgG has bound to a
pathogen, macrophages, neutrophils, and dendritic cells can engulf and destroy
the pathogen through phagocytosis. Key to this process is the recognition of the
Fc domain of the IgG by Fcγ receptors on these cells.129 Fcγ receptors can also
be found on natural killer cells to induce a cytotoxic response after binding to
IgG. Additionally, IgG can activate the three complement cascades: the classical
pathway, the alternative pathway, and the lectin pathway. Bacteria and viruses
can also be blocked from binding to cell surfaces by IgG through steric
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hinderance or inhibition of pathogen conformational changes, a process called
neutralization.
As is often the case for glycoproteins, IgG’s function is greatly affected by
its N-glycan profile. Each heavy chain has a N-glycosylation site at asparagine
residue 297 in the Fc domain. The N-glycans are in the interstitial space between
the heavy chains and each takes part in approximately 70 noncovalent
interactions with the protein surface.127 It is estimated the Fab domain is also Nglycosylated in 15-20% of IgG molecules.130–132 The most abundant IgG
glycoform has a biantennary N-glycan with a core fucose.133 This structure is
most often modified by the addition of galactose residues (50% of IgG molecules)
and a bisecting N-acetylglucosamine residue (32% of IgG molecules).127 Sialic
acids are less commonly attached to the N-glycan structure due to the steric
hinderance of the interstitial space and the interactions of the galactose residue
with a hydrophobic pocket of the protein.127 The many interactions of the Nglycans with the protein backbone aid in maintaining the quaternary structure of
the Fc domain. Accordingly, the composition of the N-glycans can greatly
influence the function of the IgG by altering the binding affinity for certain Fcγ
receptors.
The presence and composition of IgG N-glycans have well-established
associations with inflammatory responses. Sialylation has been linked with antiinflammatory activity, possibly through the decreased affinity for Fcγ receptors on
innate immune cells, and has been exploited for the use of therapeutic
antibodies.134,135 The core fucose of IgG N-glycans dampens the antibody33

dependent cellular cytotoxicity (ADCC) due to interactions with the N-glycans on
the Fcγ receptor III.136,137 A core fucose and a bisecting N-acetylglucosamine are
typically not present on the same IgG molecule so their opposing roles are
difficult to disentangle.133 IgG N-glycans without galactoses on the non-reducing
end of the antenna are generally associated with pro-inflammatory responses by
activation of the complement system.138–141 Galactosylation of IgG has been
shown to have both pro- and anti-inflammatory effects depending on the disease
or condition and immune cell interactions.133 Aging has been strongly linked to an
increase in non-galactosylated and bisected N-glycans and a decrease in
digalactosylated and sialylated N-glycans.142
The identification of IgG N-glycan alterations in diseases have prompted
the development of high-throughput techniques for large-scale biomarker
discovery studies. The same methods that have been discussed for serum Nglycan profiling can be applied for IgG N-glycan profiling after IgG has been
isolated, often by using protein G for affinity chromatography. IgG glycopeptides
can also be analyzed using a trypsin digestion instead of using PNGase F and
followed by a solid-phase extraction and ESI-MS analysis.143,144

1.4 Breast Cancer
Breasts are organs that are composed primarily of adipose, connective, and
glandular tissue. The glandular tissue is more abundant in females and contain
lobes that contain smaller lobules that are connected via milk ducts.145 Breast
cancer can occur in many different areas of the breast. Some of the lower
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incidence breast cancers are mucinous, medullary, and Paget’s disease.146 The
most common locations for breast cancer are the lobules (lobular) and milk ducts
(ductal).146 Due to the significant differences in disease progression and
prognosis, the other categorization for breast cancers is based on if the tumor is
invading other tissues (invasive) or if it the tumor is not invading other tissues (in
situ).

1.4.1 Incidence
In the United States and globally, breast cancer is the most commonly
diagnosed cancer in females, accounting for 31% and 24.5% of new cases,
respectively.147,148 Globally, it is even the most common cancer including both
sexes.147 In females, breast cancer is the second highest cause of cancer-related
deaths in the United States and the leading cause globally.147,148 In 2020, there
were over 685,000 deaths and 2.3 million new cases of breast cancer globally,
and it is estimated that these numbers will increase to 1 million deaths and over 3
million new cases each year by 2040 due to population growth and ageing
alone.149 While breast cancer occurs in both males and females, the lifetime risk
of breast cancer for a man is 1 in 833 compared to 1 in 10 for a woman.150 Due
to this large disparity, this dissertation will focus on breast cancer in women
throughout.
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1.4.2 Risk Factors
There have been many genes that have abnormal amplifications or
mutations that have been associated with breast cancer, the most well-known
being breast cancer associated gene 1 and 2 (BRCA1 and BRCA2). The
products of these genes are tumor suppressor proteins that aid in DNA damage
repair. While the females that are carriers of mutated BRCA1 or BRCA2 are 1030 times more likely to have breast cancer, these individuals make up only 510% of the all of the breast cancer cases.146,151,152
Other important genes associated with breast cancer incidence are HER2,
epidermal growth factor receptor (EGFR), and C-MYC. HER2 expression is
dysregulated in breast cancer by gene amplification and re-arrangement. The
HER2 and EGFR proteins are tyrosine receptor kinases that signal for cell
proliferation and survival upon ligand binding. The Myc protein encoded for by CMYC is a transcription factor that regulates genes whose products have key roles
in breast cancer initiation and progression.
The genetic predisposition to breast cancer of females that have inherited
mutated forms of these genes also makes family history an important factor in
determining risk. There is some variability in the reported incidence of breast
cancer in females with a family history of breast cancer. Reports can range from
10-25% of breast cancer cases being related to family-history.153,154 This
variability is most likely due to the significant influences of ethnicity, country,
family size, and environmental factors on the risk of breast cancer for an
individual. Breast cancer incidence in first-degree or multiple relatives is
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associated with higher risk, but to account for the multitude of factors influencing
family history, models that generate a family history score have been
developed.154
Age is an important risk factor of breast cancer for women as well. Both in
situ and invasive breast cancer incidence rates increase dramatically between
women aged 20-49 and women aged 50 and older.155 There are reproductive
factors, age at menarche, first pregnancy, and menopause,. that can be
informative for an individual’s risk of breast cancer, as well.156–158 Additionally,
exogeneous hormones delivered through contraceptives have been linked to a
small increase in risk of breast cancer.159–161 A higher breast density, a measure
of the amount of epithelial tissue and stroma compared to fat tissue, is
associated with an increased risk of invasive breast cancer in women.162 This
constitutes a clinical challenge, because the fibroglandular tissue that is more
prevalent in dense breasts can obscure or mimic breast cancers in
mammograms, the primary breast cancer screening tool.
Other risk factors of breast cancer are related to lifestyle. Estrogen
receptor pathways can be triggered by an alcohol-induced increase in estrogenrelated hormones into the blood. Obesity and diets with high intake of refined
sugar and both saturated and trans-saturated fats are associated with
inflammatory pathways and dysregulated metabolism which increases the risk of
breast cancer.163 The strength of the associations of these risk factors can differ
greatly between tumor molecular subtypes.164
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1.4.3 Molecular Subtypes
Breast cancer can also be subtyped by the molecular characteristics of the
tumor. Some of the primary markers are the presence of hormone receptors
(HR), either oestrogen receptor (ER) or progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2). Triple-negative breast cancer
(TNBC) are tumors that do not have ER, PR, or HER2 expression. The levels of
Ki67, a nuclear protein present in all active phases of the cell cycle, is a marker
of cell proliferation in breast cancer, but has little utility other than prognosis
assessment in stage I or II breast cancer.165 The combination of these molecules,
histological features, and a 50-gene expression signature (PAM50) can be used
to create subtypes that inform clinical decisions due to their differences in
prognosis and treatment sensitivities.166,167

1.4.4 Screening
Mammography is low-dose X-ray imaging of the breast tissue. The
American College of Radiology created a system to sort the results of
mammograms that is called the Breast Imaging-Reporting and Data System (BIRADS).168 BI-RADS incorporates breast composition, architectural distortion, and
the shape, margin, and density of any masses or calcifications. The assessment
categories range from 1-6 indicating the findings are 1-negative, 2-benign, 3probably benign, 4-suspicious, 5-highly suggestive of cancer, and 6-known
biopsy-proven cancer. There is an additional 0 category indicating that additional
imaging evaluations are needed. The BI-RADS 4 category is broken down into
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subcategories based on the level of suspicion for cancer, but the entire category
can indicate a finding that is between >2% and <95% likelihood of cancer. The
recommended follow up for a BI-RADS 4 finding is a tissue biopsy.
Increased mammography screening, the current standard detection
technique, has prevented many BC deaths, but it is still limited by current rates of
false positives, undetected cancers, overdiagnosis, and overtreatment.169
Overdiagnosis refers to a diagnosis of cancer that would otherwise never have
caused symptoms or death in a person’s lifetime and overtreatment is the
unnecessary use of tests and treatments.170 Of all women screened by
mammography, 2% are recommended to have a follow-up image or biopsy; 75%
of those women do not have cancer.171 Additionally, 12% of screened women are
recommended for follow up imaging or biopsy; 95% of these women do not have
cancer.171 When considering how many women have a mammogram, this results
in 585,000 women having unnecessary biopsies every year in the United
States.172 Younger women generally have more dense breasts making
diagnosing BC by mammography even more challenging.173 The combination of
false-positives and overdiagnosis can result in unnecessary biopsies, anxiety,
and costs.174
Magnetic Resonance Imaging (MRI) is recommended alongside
mammograms in women with a high-lifetime risk, but it is underutilized, possibly
due to the high cost and low specificity.175 Abnormal mammogram findings can
be followed-up with an ultrasound, but the modest increase in sensitivity is
accompanied with a significant increase in false positives.176 Given the
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importance of early detection and widespread application of mammographic
screening, there is a need for a more sensitive assay that could be used to
supplement mammography results in order to better inform clinical decision
making and limit false-positives/overdiagnosis.
The stage of breast cancer at diagnosis in the United States is displayed
in Figure 5 A. The stages are determined by the areas that the cancer has
spread to. In situ means that the cancer is noninvasive. Localized indicates the
cancer has invaded into the breast tissue and fat. If the cancer has reached the
pectoral muscle or regional lymph nodes, it was labelled regional. Distant
cancers have reaches distant lymph nodes and metastasized (primarily to the
liver, bones, and lungs). Figure 5 B shows the 5-year survival rates for patients
based on these stages at diagnosis. The vast difference between the distant
cancers to all the other stages highlights the importance of early detection and
population wide screening programs.
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Figure 5. Breast cancer clinical characteristics by stage at diagnosis. The (A)
incidence and (B) 5-year survival rates of breast cancer based on the stage at
diagnosis. Data was collected from the Surveillance, Epidemiology, and End
Results (SEER) program.177

41

1.4.5 Biomarkers
Cancer antigen (CA) 15-3 has been thoroughly investigated and found to
be useful for post-operative surveillance and prognosis.178–180 CA 15-3 detects
soluble forms of a MUC1, a large heavily glycosylated transmembrane protein
that has altered cellular localization and glycosylation during BC
development.181,182 CA 27.29 is an analogous assay that binds MUC1 and has
similar detection levels as CA15-3.183 Carcinoembryonic antigen (CEA) is
another high-molecular weight glycoprotein and one of the most used and
recommended biomarker for BC prognosis and recurrence surveillance.184 The
extracellular domain of human epidermal growth factor receptor 2 (HER2) is
proteolytically cleaved during BC progression and particularly effective at
determining the effectiveness of trastzumab therapy.185–187 Although these
traditional biomarkers have utility in these roles, a lack of sensitivity and
specificity when distinguishing patients with or without BC preclude CA 15-3,188–
192

CA 27.29,183 CEA,191,192 and soluble HER2193 from effective early detection of

BC.

1.4.6 N-glycan Alterations
Like many diseases, there are alterations to the N-glycosylation pathway
in breast cancer. The expressions of glycosyltransferases in breast cancer
tissues have been associated with certain molecular subtypes, patient prognosis,
and tumor invasion and metastasis.194–197 Reducing expression of a
sialyltransferase in a breast cancer cell line can alter the cell-cell and cell42

extracellular matrix interactions and reduce the metastatic capacity of the cancer
cells.198 These findings have been supported by N-glycan profiling of clinical
samples.

1.4.6.1 Tissue N-glycan Profiling
Lectins are glycan-binding proteins that have a degree of specificity,
typically for the terminal residues, and these proteins can be fluorescently
labelled for glycan analysis. Using Maackia amurensis lectin (MAL), lymph node
metastasis tumor samples were found to have higher expression of α2,3-sialic
acids than the matched primary tumor.199 Using IMS, another group found that
bone metastasis tumor samples had increased core-fucosylation and decreased
high-mannose N-glycans.200 N-glycan profiling of benign breast tumors and
breast cancer found a decrease in bisected and sialylated N-glycans in breast
cancer.201 Comparing invasive ductal carcinoma to adjacent normal breast tissue
in the same patient, Yaman and colleagues identified an increase in high
mannose N-glycans in the invasive ductal carcinoma tissues.202 Analysis of
HER2 positive and TNBC breast cancers by IMS detected differences in the
abundances of a series of N-glycans in the tumor region when compared to
stromal tissue.203 Additionally, this study detected polylactosamine N-glycans in
the breast cancer tissues.203

43

1.4.6.2 Serum N-glycan Profiling
Early studies, while not directly analyzing serum N-glycan profiles,
displayed the potential for changes in the serum glycome to be indicative of BC.
One of the first investigations into the changes of the glycome in BC patients
utilized multilectin affinity chromatography (M-LAC) followed by high-performance
liquid chromatography (HPLC) with tandem mass spectrometry (MS/MS) to
isolate and identify glycoproteins, respectively.204 Using gene ontology (GO)
terms, Yang and colleagues found increased abundances in proteins associated
with cell growth and maintenance, lipid metabolism and transport, cell ion
homeostasis, and a wide spectrum of protease inhibitors in the serum of patients
with invasive BC. In another early study, Kirmiz and colleagues chemically
cleaved glycans (both O- and N-glycans) on the glycoproteins found in the serum
of BC patients and disease-free controls with sodium borohydride and identified
the glycans with MALDI FTICR mass spectrometry.205 Using principal component
analysis, the group was able to distinguish patients with BC and disease-free
controls. This technique had limited use for N-glycan detection as the highest
mass N-glycan was m/z = 1442. The findings that glycoproteins and O-linked
glycans in serum are being altered in patients with BC were early indications that
serum glycomics could be a valuable area of diagnostic biomarker research.
Multiple methodologies were created to investigate the serum N-glycome
for BC biomarkers and overcome the challenges of N-glycan release, purification,
detection, and identification in a complex biofluid. The first study to specifically
investigate the N-glycan profile of BC patients’ serum found changes in the
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relative intensities of 8 N-glycans to be characteristic of BC.206 Additionally,
principal component analysis of the profile data obtained from patients could
distinguish healthy individuals from those in the early stages of BC. While this
study analyzed permethylated N-glycans by MALDI TOF mass spectrometry, a
study by Abd Hamdi and colleagues came out soon after and used normal phase
(NP) and weak anion exchange (WAX)-HPLC with fluorescence detection to
examine the N-glycan profiles of stage IV BC patient serum.207 After finding an
increase in a sialyl Lewis x epitope (sLex) (an α1,3-linked fucose attached to a Nacetylglucosamine at the nonreducing terminus) containing N-glycan in BC
patients’ serum, they isolated and quantified the triantennary, trisialylated, and
outer arm fucosylated N-glycan with sequential exoglycosidase digestions and
mass spectrometry. They found a 2-fold increase in this marker in BC patients
compared to healthy controls and a positive correlation between the N-glycan
abundance and disease progression. Additionally, they found a higher ratio of
outer arm fucose compared to core fucose on the triantennary trisialylated
fucosylated N-glycan for BC patients.
A chip-based reversed-phase liquid chromatography-mass spectrometry
method for analyzing permethylated N-glycans was created by Alley and
colleagues and used to analyze 15 stage IV BC patient serum samples.208 Of the
18 N-glycans detected, 5 were found to be significantly higher in the BC patients.
The same group developed a protocol that selectively labels α2,6-linked sialic
acids by amidation.209 They utilized this protocol to examine the abundances of
12 sialylated N-glycans with linkage information between 10 cancer free serum
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samples and 10 serum samples from stage IV BC patients.209 The additional
dimension of information proved to be diagnostically useful for several N-glycans.
For example, a biantennary bisialylated N-glycan was not significantly different if
one sialic acid was α2,3-linked while the other was α2,6-linked, but it was
significantly different if the sialic acids were either both α2,3- or α2,6-linked.
The same group that utilized chemical cleavage of glycans followed by
MALDI FTICR mass spectrometry, optimized their method to allow for more
sensitive detection of N-glycans and found an increase in high-mannose Nglycans in mouse serum during cancer progression and in BC patient serum.210
In 2005, a series of lectin arrays were developed for rapid and multiplexed
analysis of protein glycosylation.211–214 Fry and colleagues analyzed 18 serum
samples, half coming from patients with nonmetastatic BC and the other half
from patients with metastatic BC, with a lectin microarray consisting of 45 lectins
with varying binding affinities for N- and O-linked glycans.215 In metastatic
samples they found elevated binding to Aspergillus oryzae lectin (AOL) and
Galanthus nivalis agglutinin (GNA), indicative of increased fucosylation and highmannose N-glycans respectively, and decreased binding to Phaseolus vulgaris
erythroagglutinin (PHA-E), indicative of decreased bisected biantennary. While
these methodologies had their limitations in sensitivity and sample size, the
results made it clear that BC could be associated with discrete changes in the
serum N-glycan profile and encouraged the development of higher-throughput
methods for larger studies.
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Analyzing larger data sets and using more sensitive techniques improved
the potential of detecting serum N-glycome alterations associated with BC. Much
of the work done during this time period was performed by the National Institute
for Bioprocessing Research and Training (NIBRT) Glycoscience Group in Dublin.
For one of their studies, they focused on the presence of sLex epitope containing
N-glycans and core fucosylated N-glycans utilizing the strategy of
exoglycosidase digestions, 2-AB labeling, and HPLC.216 The serum cohort
consisted of a group of 52 early BC patients’ serum samples with lymph node
metastasis status reported. They found that the combined abundances of these
N-glycans were increased in lymph node positive BC, but if analyzed individually
there was no difference. They also, and more importantly for investigating BC
detection, profiled the serum of 134 patients with benign breast disease, but did
not find any individual N-glycan or combination of these N-glycans able to
distinguish the patients with benign breast disease or BC. This would indicate
that there is no difference in sLex epitope containing N-glycans in the serum Nglycome of BC patients when compared to healthy controls.
The next study for this group analyzed 27 serum samples from women
with advanced BC and 13 healthy controls.217 Their main aim was to establish
differences in bi-,tri-, and tetra-antennary sLex containing N-glycans, individually
and combined, in patients with high and low circulating tumor cells. While they
found an increase in each of these categories of N-glycans individually and
combined (with the exception of the biantennary sLex containing N-glycans) in
patients with high circulating tumor cells, they did not make any comment on the
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differences between the healthy controls and the BC samples. Without access to
the data, it is impossible to make any statistical claims but visually it seems that
all of the categories of the N-glycans are higher in the high circulating tumor cell
samples than in the controls. There may be a modest increase in the samples
with low circulating tumor cells when compared to the controls. While this study is
informative for BC prognosis or classification, the data analysis performed adds
little understanding to serum N-glycan profiling’s utility in BC detection.
The NIBRT group went on to utilize ultra-performance liquid
chromatography (UPLC) instead of HPLC for the analysis of serum from 107
healthy women and 62 women with BC.218 This increased their methods
resolution while decreasing the run time. They detected 46 N-glycan peaks and
through WAX-HPLC followed by endoglycosidase digestions, they were able to
assign 165 N-glycan structures, including 22 sialic acid containing-N-glycans with
differing linkage arrangements, to the peaks. Structural analysis of individual Nglycan peaks allows for determination of the predominant structure, but by UPLC
analysis alone, the abundance of individual structures cannot be compared.
While this method cannot directly compare specific N-glycan structures to each
other, they can make comparisons between peaks and calculate differences in
N-glycan features, such as fucosylation and sialylation. When analyzing the BC
serum, they found a decrease in high-mannose N-glycans and core-fucosylation
and an increase in sialylation, branching, and outer-arm fucosylation. The finding
of decreased high-mannose N-glycans contradicts a previous study, but may be
due to a more sensitive detection technique and larger sample size.210 The peaks
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containing the sLex epitope were increased in the BC patients and a number of
peaks containing bisected N-glycans had significantly lower abundance in
cancerous samples. Utilizing the serum N-glycan profiles detected, prediction
analysis was able to correctly classify samples with a sensitivity and specificity of
82% each.
Ju and colleagues took a different approach than the NIBRT group and
detected permethylated N-glycans using linear ion-trap quadrupole-electrospray
ionization mass spectrometry (LTQ-ESI-MS).219 For this study, 134 serum
samples were donated by Chinese women (43 from healthy controls and 91 from
BC patients). While they only detected 40 N-glycans, each peak represented a
single N-glycan and was confirmed using multistage MS for high-confidence
comparison and structural assignment. Partial least squares discriminant
analysis (PLS-DA) was used to successfully discriminate samples as either from
healthy controls or BC patients. All of the bifucosylated N-glycans detected were
higher in the BC samples than the healthy controls and when combined for
receiver-operator characteristic (ROC) analysis, had an area under the curve
(AUC) of 0.93. This indicates an accurate diagnostic performance and surpassed
the AUC for CEA (AUC = 0.79). Several of these bifucosylated N-glycans
contained sLex epitopes. The high-mannose N-glycans were higher in BC
patients but had low sensitivity and specificity. The increase in detection and
throughput of the techniques used during this time facilitated more thorough
studies with larger sample sizes.
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Two recent studies have examined the serum N-glycome of BC patients,
compared them to healthy controls, and found many detected N-glycans
significantly altered utilizing novel techniques for the BC detection field. The first
study had only Ethiopian women as subjects and analyzed 115 BC patients
ranging from stage I to IV and 33 healthy controls.102 For this method, released
N-glycans are captured on beads via reversible hydrazine bonds, washed, sialicacid stabilized by methyl esterification, released with a mild acid hydrolysis, and
tagged with O-benzyloxyamine hydrochloride (BOA). The BOA-tagged N-glycans
are then dissolved in matrix, spotted on a MALDI target plate, and analyzed by
MALDI-TOF MS. Using this method, 46 N-glycans were detected in all of the
samples, 35 of the detected N-glycans were significantly increased, and 17 of
those N-glycans were found to strongly predict and distinguish the BC patients as
determined by a ROC AUC of greater than 0.8. Of these 17 N-glycans, only 8
could distinguish the healthy controls from both stage I and II BC patients. Most
of the more abundant N-glycans in cancer patients showed more drastic
increases in the early stages (I and II) compared to the later stages (III and IV).
Almost all glycosylation classes increased in abundance in either the stage I or II
BC patients, except for the high-mannose and hybrid N-glycans. While the large
differences between the healthy and BC samples is surprising, this study
involves a method and subject set never examined for this purpose.
Lee and colleagues used a relatively simple method to analyze N-glycans
in serum that entails glycoprotein denaturation with heat, N-glycan release with
PNGase F, N-glycan purification with sold-phase extraction (SPE), and mixing
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the N-glycans with matrix for MALDI-TOF MS analysis.220 When comparing 311
healthy volunteers’ serum samples with 256 BC patients’ serum samples, 30 of
the N-glycans were significantly differentially abundant. Performing a ROC
analysis incorporating all of these N-glycans resulted in an AUC of 0.93 when
comparing the healthy samples to all the BC samples, but if broken down by
stages, the AUC increased to 0.96 for differentiating healthy samples from stage
I and II BC samples. Interestingly, the AUC when comparing healthy samples to
stage III and IV samples decreased to 0.89. Early-stage BC was found to have
more significant alterations than late-stage BC in several studies and
demonstrates the potential for early BC detection. The only significant alteration
found in the glycosylation classes was an increase in high-mannose N-glycans.
Both of these studies found many N-glycans to have altered abundances in large
BC serum sets by utilizing methods not yet attempted for serum N-glycomebased BC detection.
The findings discussed so far have investigated the total serum Nglycome, but other studies have targeted specific serum glycoproteins for Nglycan profiling and found significant differences in their glycosylation in BC. Abd
Hamid and colleagues found that α1-antichymotrypsin (ACT), haptoglobin βchain, and α1-acid glycoprotein (AGP) had N-glycans containing sLex epitopes in
the BC patient serum but not in the healthy controls serum.207 Increased
fucosylation of haptoglobin and AGP N-glycans in BC patients has been found in
several studies, while a decrease in fucosylation was seen in transferrin.221–224
Goodarzi and colleagues found α1-proteinase inhibitor (API) N-glycans had
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decreased branching and increased fucosylation in BC patient.225 Many of these
serum glycoproteins have elevated abundances in BC patients.226
There is a N-linked glycosylation site on the crystallizable fragment (Fc) of
immunoglobulin G (IgG) that can drastically alter the ability of the antibody to
bind to leukocytes and consequently, effect antibody-dependent cell-mediated
cytotoxicity (ADCC).127 A multiple logistic regression model incorporating
abundances of 7 N-glycans (4 of which were bisected) released from the IgG Fc
was able to distinguish healthy controls from BC patients with an AUC of 0.84.227
Another study found an increase in fucosylated and agalactosylated IgG Fc Nglycans in BC patients.102 By targeting the carrier proteins of the glycans
significantly changing in the total serum, these studies provide an alternative
approach for N-glycan profiling-based BC detection that still only requires a
minimally invasive and cost-effective blood draw.
A study by Haakensen and colleagues linked serum N-glycan profiling
data with transcriptomic analysis to identify associations with specific N-glycan
alterations and transcripts representing functional pathways.228 Using this
approach, triantennary trisialylated N-glycans were associated with lower levels
of focal adhesion and integrin-mediated cell adhesion involved transcripts, and
by integrating tumor characteristics and clinical outcomes, these N-glycans were
also associated with poor prognosis in ER negative tumors. While samples with
all of these forms of data may be difficult to attain, this type of integrated analysis
has the potential to provide the biological context to serum N-glycan biomarkers.
This study solely used samples from BC patients, but the promising results
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prompt the need for a study comparing BC samples to controls, preferably
donated from women with a benign breast disease.
The latest study to perform serum N-glycan profiling of 145 breast cancer
patients compared them to 171 healthy females.229 While three N-glycans (two
trisialylated triantennary and one tetrasialylated tetraantennary) were lower in the
breast cancer patients, the serum N-glycan profiles of the breast cancer patients
differed depending on their molecular subtype and stage. This, like the majority
of the serum N-glycan profiling studies discussed here, has contributed to a
greater understanding of how N-glycosylation is altered and functions in breast
cancer, but it does not address certain clinical areas of need for breast cancer,
such as improving the specificity of the screening process.

1.5 Broad Overview
The use of MS across a broad array of disciplines can be partially
attributed to the variety of mass spectrometers that utilize different ionization
sources and mass analyzers. MALDI is a form of ionization that utilizes chemical
matrix to transfer the energy of the MS laser to analyte molecules, even in the
presence of contaminants and biological samples with complex compositions.
Efforts have been made to improve the sensitivity of MALDI MS analysis for a
range of biomolecules by optimizing sample preparation steps.
One important application of MALDI MS has been for the analysis of Nglycans. The composition of enzymatically released N-glycans can be
determined using the mass of the ions detected. As N-glycans are non-linear
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structures formed without a template like proteins, the well-characterized Nglycan synthesis pathway can be used to infer the structure of the N-glycans.
MALDI MS has been used to profile the N-glycans present in tissues, cells, and
biofluids. While MALDI MS has a high data acquisition speed compared to other
analytical chemistry techniques, especially when paired with a TOF mass
analyzer, the extensive sample preparation needed for current N-glycan analysis
of biofluids has limited the throughput of these techniques.
High-throughput analysis of N-glycans in clinical samples can be a
powerful tool for biomarker discovery because N-glycans can greatly impact the
function of their carrier proteins. N-glycosylation has critical roles in nearly every
human physiological system and on a molecular level, can impact protein folding,
turnover, substrate specificity, and substrate binding efficiency. Biofluids are an
attractive sample type for biomarker discovery studies due to their low or noninvasive collection and dynamic compositions responsive to the immune and
metabolic status of the individual. In serum and plasma, nearly all of the proteins
that make up the bulk of the protein content are N-glycosylated. The combination
of functional-relevance and high-prevalence of N-glycans in serum and other
biofluids have led to increasing interest in methods capable of large-scale
biomarker studies.
One therapeutic area in need of biomarkers is breast cancer. While
mammography has become the standard tool for breast cancer screening, a lack
of specificity for suspicious findings leads many women to have unnecessary
biopsies when they do not have breast cancer. While certain molecular
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biomarkers detected in serum have utility in breast cancer subtyping, prognosis,
and determining therapeutic sensitives, there are no effective biomarkers to
clarify this clinical issue. Analysis of breast cancer patients’ tissues and sera
have identified significant alterations in N-glycosylation associated with the
presence, molecular subtype, and clinical characteristics of breast cancer
tumors, but no study has investigated the serum N-glycan profiles of women that
may be impacted by an unnecessary biopsy.
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Chapter 2: Hypothesis
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2.1 Summary
Breast cancer is responsible for the second highest number of cancerrelated deaths annually in US females, and early detection through screening
has been shown to save lives.148 Mammography is the standard screening tool
but has issues with false positives and overdiagnosis.171 The identification of a
biomarker that could be used as a supplementary tool to inform therapeutic
options. The goal of this study is to examine the N-glycan profile of a large cohort
of breast cancer patient sera to discover a glycosylation-based biomarker
(increase or decrease of the abundance of a N-glycan or glycan class) that can
distinguish between cancerous and benign tissue diagnoses. A novel slide-based
high-throughput serum N-glycan profiling method will be developed to allow for
rapid sample analysis.
The proposed method is adapted from mass spectrometry imaging
methods used for tissue N-glycan profiling. Current serum N-glycan analysis
methods lack the simplicity and speed found in the novel method, making it a
potentially valuable tool for clinical laboratory use. The workflow involves spotting
the serum on to a slide, binding the serum proteins to an amine-reactive hydrogel
coating, washing off lipids and salts, releasing N-glycans by applying an enzyme,
and coating the slide with a matrix. Each spot can be imaged using mass
spectrometry to detect a wide range of mass/charge ratios that can be annotated
to specific N-glycans. The sample will have an intensity for each N-glycan and
these values can be compared across sample groups. By adapting the enzymes
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applied to the samples, the method will be able to target specific types of Nglycans.
Once the method is fully developed and validated, it will be applied to a
unique clinical cohort that consists of serum collected in a surgical clinic from
women with biopsy-confirmed benign or cancerous masses in their breast. We
hypothesize that the proposed method will be able to determine potential
biomarker targets for breast cancer that could aid in early detection, resulting in
less false-positives and unnecessary surgeries.

2.2 Significance
Early detection drastically increases the survival of breast cancer patients
and provides multiple treatment options. When diagnosed at its earliest stage, 5year survival is 98% compared to only 27% for late stage diagnosis.177 Increased
mammography screening has prevented many breast cancer deaths, but it is still
limited by current rates of false positives, undetected cancers, overdiagnosis,
and overtreatment.230 Of all women screened by mammography, 12% are
recommended to have a follow-up image or biopsy; 95% of those women do not
have cancer.171 The combination of false-positives and overdiagnosis can result
in unnecessary biopsies, anxiety, and costs. Alternative imaging modalities have
not been able to remedy this clinical issue due to being cost-prohibitive or having
only modest improvements to specificity.175,176
Given the importance of early detection and widespread application of
mammographic screening, there is a need for a more sensitive assay that could
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be used to supplement mammography results in order to better inform clinical
decision making and limit false positives/overdiagnosis.
This issue of patient screening could be addressed by the detection of a
blood-based biomarker. The proposed method is high-throughput and sensitive
enough to discover N-glycan biomarkers by analyzing large cohorts of patient
samples, but it is also rapid enough to be used as a screening tool to supplement
mammography. This assay will not require any changes to standard blood
collection protocols. A complicated or uncertain mammogram result could be
followed with a serum N-glycan profile to give more confidence as to whether a
biopsy is necessary.

2.3 Innovation
The currently used methods for high throughput serum N-glycan analysis
are HILIC-UHPLC-FLD, xCGE-LIF, and MALDI-TOF MS.87–90 While these
methods have clear utility in understanding the role of serum N-glycans in a
variety of diseases, there are elements of each that are incompatible with use in
a clinical laboratory.91,96,97,231–235 Each of these methods requires labeling or
derivatization of released N-glycans and subsequent clean up steps. Not only do
these steps involve specialized materials, but they require additional time. To
analyze 96 samples with these methods can take from 1 to 5 days.89,90,236 The
proposed method in Aim 1 can reduce this time by using rapid N-glycan release
and avoiding additional steps involved in labelling, derivatization, and clean up.
The minimal sample preparation of this method is achieved by anchoring the
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glycoproteins directly to the slide. No fractionation or purification, during which
sample content can be lost and contaminates could be introduced, is needed
with this approach.
The method should be able to be used as a platform to analyze a wide
array of biofluids with minimal adaptions to account for different chemical
compositions. The integration of automation seems feasible for several steps to
increase the precision and throughput even further. Using ion mobility analysis
could also aid in detecting structural isomers and provide an additional dimension
of information. This method will not only aid in large-scale serum N-glycan
studies, but the simplicity, speed, sensitivity, and throughput meet the criteria for
clinical laboratory diagnostic tests more than any other method.

2.4 Specific Aim 1
The goal of this aim is to develop an N-glycan profiling method for
biofluids that could be used as a clinically diagnostic tool. The current highthroughput serum N-glycan analysis methods have significant sample
preparation steps and lengthy detection techniques that make them incompatible
with clinical laboratories and limit the potential of N-glycan biomarkers. The
workflow involves spotting the serum on an amine-reactive hydrogel coated slide,
incubating a binding reaction between the serum proteins and the hydrogel, and
washing the slide to remove substances incompatible with mass spectrometry
imaging. The N-glycans are enzymatically released and detected using MALDI
MS. The method will be evaluated by several criteria including the sensitivity to
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low abundance N-glycans, intra- and inter-batch reproducibility, and processing
time per sample.

2.5 Specific Aim 2
The goal of this aim is to examine the total serum N-glycan profile of a set
of breast cancer patients with MALDI MS and identify cancer-associated Nglycan changes. Alterations in the serum N-glycan profiling have been
associated with a variety of cancers and this cohort provides a valuable
opportunity to reveal novel N-glycan biomarkers. Specifically, there have been
several studies that have found an association between higher branching,
fucosylation, and sialyation in the serum of patients with breast
cancer.102,206,207,216–219 This aim can be accomplished with the method developed
in specific aim 1 or with alternative established techniques such as HILIC UHPLC
FLD or MALDI MS of HILIC-extracted N-glycans. As the most abundant
glycoprotein in blood, IgG contributes a large portion of the N-glycans in serum
and there have been several diseases associated with IgG glycosylation
changes.133 We can compare the N-glycan profile of IgG and total serum to
determine if there are any differences in predictive value or increased sensitivity
to N-glycan changes. A patient serum cohort of 298 samples representing benign
(n=199) and cancer (n=99) diagnoses is available.
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Chapter 3: Serum and Plasma N-glycan Profiling by MALDIIMS
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3.2 Introduction
The composition of serum and plasma collected during blood draws
reflects dynamic de-cellularized biofluids comprised of thousands of proteins and
metabolites. A major component of the fluids are multiple high abundance
glycoproteins produced by the liver and immunoglobulins secreted by B-cells.
Extensive characterization of the proteomes of serum and plasma has indicated
a 10-fold order of magnitude concentration difference from the most abundant
proteins, i.e. albumin and immunoglobulins, to the lowest concentration ones.72,73
Current proteomic mass spectrometry studies have identified over 4300
individual proteins present in serum,74 yet by percentage of abundance, 22
proteins represent 99% of the content.72,73 Except for albumin, which is not a
glycoprotein and accounts for approximately 50% of the total protein content, the
majority of the 22 most abundant proteins and next 30 are glycoproteins secreted
by the liver and B-cells. Interrogation of the glycan composition of these most
abundant glycoproteins for potential clinical application to differentiate healthy
from disease states has been ongoing for decades.75–77 In addition to advanced
high-performance liquid chromatrography (HPLC)-based methods,237 in recent
years, multiple high-resolution tandem liquid chromatography (LC) and matrixassisted laser desorption/ionization mass spectrometry (MALDI-MS) options
have been utilized for these types of analyses.238,239
Glycosylation is one of the most common types of post-translational
modifications that is estimated to occur on over 50% of proteins.240 The diversity
of monosaccharides, inter-saccharide bonding, and non-template derived
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branching structures create a large and complex glycan repertoire, called the
glycome.241 Glycosylation is a highly regulated metabolic process shown to have
essential roles in protein folding, molecular trafficking, signal transduction, and
many other processes.242,243 The most common forms of glycosylation studied for
serum or plasma glycoproteins are for those that are O-linked glycans, attached
to proteins via threonine/serine residues, and N-glycans, attached to proteins via
an asparagine residue. The majority of the most abundant serum and plasma
glycoproteins have N-glycosylation. Investigating the changes in specific glycans
or glycan structural motifs, such as branching or fucosylation, is a promising area
for biomarker identification, and the minimally invasive and cost-effective
properties of plasma and serum collection makes the total serum or plasma Nglycome an attractive area of focus.75,76 The large cohorts amenable for
biomarker discovery and potential clinical applications require high throughput
methodologies, that continue to be assessed and evolve.91
The currently used methods for high throughput serum N-glycome
analysis are hydrophilic interaction chromatography (ultra-)high-performance
liquid chromatography with fluorescence detection (HILIC-UHPLC-FLD),88
multiplexed capillary gel electrophoresis with laser-induced fluorescence
detection (xCGE-LIF),89 and matrix-assisted laser desorption/ionization time of
flight mass spectrometry (MALDI-TOF-MS).90 While these methods have clear
utility in understanding the role of serum N-glycans in a variety of diseases, there
are elements of each that are incompatible with routine use in a clinical
laboratory. Each of these methods requires labeling or derivatization of released
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glycans, and further processing and purification steps. Not only do these steps
involve specialized materials and expertise, but they require additional time, as
analysis of 96 samples with these methods can take from 1 to 5 days.89,90,236
Our collective group has developed methods for analyzing released Nglycans from tissues, cells, and immuno-captured serum glycoproteins by MALDI
imaging mass spectrometry (MALDI-IMS).19,244–248 Key to each of these methods
is the spraying of a molecular coating of peptide N-glycosidase F (PNGase F)
onto a slide surface containing the biological sample, followed by detection of
released N-glycans by MALDI-IMS. We hypothesized that we could adapt
techniques from these workflows to create a rapid and sensitive serum N-glycan
profiling method. The sensitivity and repeatability of this method was
demonstrated using different control and diseased serum samples, as well as
plasma. An additional enzyme, endoglycosidase F3 (Endo F3),249 was used to
distinguish core fucose from outer arm fucose locations on the glycan structures.
Finally, the utility of this method was demonstrated by analyzing a set of pooled
serum samples from patients with either breast cancer or a benign lesion in their
breast. The clinical applicability of this serum and plasma N-glycan profiling
method improves the potential of glycans to be used as biomarkers. The speed
and simplicity of the novel N-glycan profiling method described in this study are
compatible with the requirements of clinical laboratories.
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3.3 Methods
3.3.1 Materials
Hydrogel coated slides (Nexterion® Slide H) were obtained from Applied
Microarrays (Tempe, AZ). The rotary tool was a Dremel 200 series. The well
slide module (ProPlate Multi-Array Slide System, 64-well) was obtained from
Grace Bio-Laboratories (Bend, OR). Sodium bicarbonate, trifluoroacetic acid, and
α-cyano-4-hydroxycinnamic acid were obtained from Sigma-Aldrich (St. Louis,
MO). HPLC grade water, acetonitrile, glacial acetic acid, and chloroform were
obtained from Fisher Scientific (Hampton, NH). Ethanol was obtained from
Decon Labs (King of Prussia, PA). Peptide-N-glycosidase F (PNGase F)
PRIMETM was from N-Zyme Scientifics (Doylestown, PA). Endoglycosidase F3
(Endo F3) and sialidase was cloned, expressed, and purified in-house as
previously described.249

3.3.2 Samples
A pooled human serum sample was used that represented over 360
healthy human donors.250 A control plasma-EDTA sample was obtained from a
healthy donor. Serum from non-obese or obese patients with benign breast
lesions or breast cancer was pooled from 5 - 10 patients, derived from a
previously published study.251
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3.3.3 Array Preparation
Hydrogel coated slides were used, and wells were created by attaching a
64 (4 x 16) well module. The hydrogel coated slides were equilibrated to room
temperature in a moisture resistant pouch for 45 minutes. The slide was ground
down with a rotary tool until it fit into a Bruker MTP Slide Adapter II. The well
module was attached to the slide, the wells were outlined with a marker on the
uncoated side of the slide, and then the well module was unattached.

3.3.4 Sample Capture and Washing
A µl of serum was diluted in 2 µl of sodium bicarbonate (100 mM, pH 8.0).
After briefly mixing with the pipette, 1 µl was spotted within the outline of a well.
Only wells from the two innermost rows were used. The pooled serum standard
and plasma standard were spotted in quadruplicate, and the clinical serum
samples were spotted in triplicate. Spots were left to immobilize to the slide at
room temperature for 1 hr in a humidity chamber made from a culture dish with a
Wypall X 60 paper towel lining the bottom and two rolled KimWipes saturated
with distilled water on opposite sides. For the immobilization, the slide was
placed flat in the dish in between the two KimWipes. The slide was then dried in
a desiccator for 15 minutes and the well module was attached. Each well was
filled with 50 µl of Carnoy’s solution (10% glacial acetic acid, 30% chloroform,
60% 200 proof ethanol) without mixing or agitating for 3 minutes. The Carnoy’s
solution was dumped out of the well and the wash was repeated 2 more times.
After the 3 Carnoy’s solution washes, each well was rinsed with 50 µl of double
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distilled water without mixing or agitating for 1 minute. Following removal of
water, the slide with the well module attached was dried in a desiccator for 30
minutes.

3.3.5 N-Glycan Release and Matrix Application
To release the N-glycans from the immobilized proteins, the well module
was removed and a M5 TM-Sprayer (HTX Technologies) was used to spray a 0.1
mg/ml PNGase F PRIME solution in water with 15 passes at 25 µl/min, 1200
mm/min, 45°C, 3 mm spacing between passes with 10 psi nitrogen gas. The
slide was incubated for 2 hours at 37°C in a preheated humidity chamber. To
apply the MALDI matrix α-cyano-4-hydroxycinnamic acid (CHCA, 7 mg/mL in
50% acetonitrile/0.1% trifluoracetic acid), the same automated sprayer was used
with 10 passes at 100 µl/min, 1200 mm/min, 79°C, 2.5 mm spacing between
passes with 10 psi nitrogen gas. For Endo F3 or sialidase treatment, a mix of
10% Endo F3 or sialidase and 90% PNGase F Prime was sprayed at the same
settings as described for only PNGase F and all other steps remained the
same.247,249

3.3.6 MALDI imaging mass spectrometry
A SolariX Legacy 7T Fourier-Transform Ion Cyclotron Resonance (FTICR)
mass spectrometer (Bruker) equipped with a MALDI source was used to image
the slides. Images were collected with a SmartBeam II laser operating at 2000
Hz with a 25 µm laser spot size and a smartwalk pattern at a 250 µm raster with
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200 laser shots per pixel. Samples were analyzed in positive ion, broadband
mode using a 512k word time domain spanning a m/z range of 500-5000.
Individual regions to be imaged were manually outlined to encompass each well
with a sample, as well as one blank well that did not have any sample spotted in
it. An on-slide resolving power of 48,000 at m/z = 1136 was calculated.

3.3.7 Data Analysis
Data was imported at a 0.95 ICR reduction noise threshold and
normalized to total ion current in to FlexImaging v5.0 (Bruker) for manual Nglycan peak selection based on theoretical mass values. Data Analysis 5.0
(Bruker) was used for spectra recalibration with a linear function based on Nglycan theoretical masses. Spectra were imported into SCiLS Lab software
2017a (Bruker) for individual peak visualization and quantification. Each well was
designated a unique region and area under monoisotopic peak values were
exported from each well. Individual N-glycan area under monoisotopic peak
values were divided by the sum of the area under monoisotopic peak values of
all detected N-glycans for relative intensity values. Quantifications of N-glycan
structural classes were calculated by summing the relative intensities of the
individual N-glycans belonging to each class, as determined by the putative
structures. Each slide contained non-sample wells processed in the same
manner as wells with samples, and can be used for background signal
subtraction in subsequent data analysis steps.
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3.3.8 MS/MS
A timsTOF fleX mass spectrometer (Bruker) was used to acquire MS/MS
data by collision-induced dissociation (CID) for N-glycans directly from the
processed slides. A 2 Da window was used for MS/MS precursor selection. The
collision energies were individually optimized for consistent and sensitive
fragmentation and ranged from 100-140 eV. The number of laser shots summed
were also optimized per N-glycan for fragmentation reporting. Detected glycan
species were cross-referenced with existing in-house structural databases from
previous MALDI-FTICR-MS studies. 17,203,249

3.4 Results
This study was initiated to identify a serum and plasma glycan profiling
strategy based on direct spotting of sample on glass slides, spraying of PNGase
F to release N-glycans, followed by detection using MALDI-IMS. The goal was to
develop a protocol that was both rapid (relative to current methods used) and
reproducible. Analysis workflows for processing tissues on slides for N-glycan
MALDI-IMS analysis using sprayed PNGase F to release N-glycans are
established and used in this study. 247 It was the initial sample spotting and
processing steps prior to PNGase F spraying that required extensive evaluation
and optimization. Parameters like slide chemistry, washing and sample buffers,
sample amount, and digestion conditions were assessed. Peak intensities and
numbers of N-glycans detected by MALDI-FTICR-MS were the final
determinants.
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Initially, multiple slide chemistries were evaluated for serum spotting,
including blank glass histology slides and different modifications like indium tin
oxide (ITO), poly-lysine and nitrocellulose. Because MALDI was being used for
detection, a desalting component was needed. A denaturing component was also
required in the sample preparation due to the high concentration of protein
present in even 1 µl of human serum (~75 µg) and the complexities of releasing
N-glycans from native proteins. Each of the indicated slide chemistries had
issues with sample loss during the washing and denaturing steps leading to
inconsistent or loss of N-glycan detection across replicates (data not shown).
Attempts to fixate the samples to the slides using formalin cross-linking resulted
in sample spot hardening and flaking off of the slide after washing. To address
these limitations, amine reactive slides were assessed which provided covalent
attachment of the serum proteins, facilitating efficient desalting and denaturation
steps. These slides were used throughout the study as summarized in the
workflow schematic in shown in Figure 6.
The amine reactive hydrogel slides used contain N-hydroxysuccinimide
(NHS) esters free to covalently react with primary amines. Serum samples were
mixed with 100 mM sodium bicarbonate at pH 8 to dilute the sample for more
efficient capture on the hydrogel coated slide. After 1 hour incubation, the bound
proteins on the slide can be washed with minimal loss of sample. Carnoy’s
solution (10% glacial acetic acid, 30% chloroform, 60% ethanol) was used to
delipidate and denature the proteins, and water washes were done to remove
residual Carnoy’s solution and salts. PNGase F was sprayed evenly over the
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slide, and after a 2 hour incubation, a CHCA matrix coating was sprayed on the
slide. The slide was analyzed using MALDI-FTICR MS, resulting in an overall
mass spectrum that can be used to obtain heat map images correlating to the
intensities of specific m/z peaks across the slide. The intensities of the detected
N-glycans can be quantified for areas covering the wells of specific samples,
allowing for comparisons of N-glycans between samples.
The current workflow described here (Figure 6) will analyze 28 spots per
slide and additional slides can be prepared together up to the point of the MALDI
IMS with little additional time. The total time to prepare a slide for imaging is 6
hrs. Each spot can be imaged in 10 minutes with the given parameters. The
entire workflow can be used to analyze a single spot in less than 6.5 hours and
28 spots in less than 11 hrs. To define the breadth of N-glycans detected, a
serum and plasma standard was spotted in quadruplicate, processed and
analyzed. Using this method, 75 N-glycans were detected in human serum
(Supplemental Table 1) with an average coefficient of variation (CV) of 6% for the
20 most abundant glycans.
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Figure 6. Workflow for slide-based serum and plasma N-glycan profiling by
MALDI IMS. (A) Sample preparation steps include diluting the serum or plasma
1:2 in sodium bicarbonate (100 mM, pH 8.0) and spotting 1 microliter on to a
hydrogel-coated slide. The sample spots are put in a humidity chamber for an
hour to immobilize to the slide. Carnoy’s solution is used to delipidate the
samples for sensitive N-glycan detection. (B) The sample spots are sprayed with
PNGase F to enzymatically release N-glycans, and CHCA matrix is applied. (C)
Sample spots are imaged in distinct regions by a MALDI-FTICR-MS, allowing for
images and abundances of m/z peaks corresponding to N-glycans to be
compared across samples.
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Observed Error
Mass
(ppm )

Com position

Glycosylation
Traits

Observed Error
Mass
(ppm )

Com position

Glycosylation
Traits
Tri, Sia

1136.3936

-2.46

Hex3HexNAc3 + 1Na

2179.7617

7.2

Hex5HexNAc5NeuAc1 + 2Na

1257.4178

-3.82

Hex5HexNAc2 + 1Na

Man

2245.7654

-3.03

Hex5HexNAc4NeuAc2 + 1Na

Bi, Sia

1282.4618

5.85

Hex3dHex1HexNAc3 + 1Na

Fuc

2246.7704

-9.88

Hex5dHex2HexNAc4NeuAc1 + 1Na

Fuc, Bi, Sia

1298.4501

0.69

Hex4HexNAc3 + 1Na

2267.7636

0.71

Hex5HexNAc4NeuAc2 + 2Na

Bi, SIa

1339.471

-3.51

Hex3HexNAc4 + 1Na

Bi

2268.7652

-7.57

Hex5dHex2HexNAc4NeuAc1 + 2Na

Fuc, Bi, Sia

1419.4712

-3.03

Hex6HexNAc2 + 1Na

Man

2289.7561

10.26

Hex5HexNAc4NeuAc2 + 3Na

Bi, Sia

1444.5052

-1.32

Hex4dHex1HexNAc3 + 1Na

Fuc

2303.843

12.54

Hex5dHex1HexNAc5NeuAc1 + 1Na

Tri, Fuc, Sia
Tri, Fuc

1460.5025

0.34

Hex5HexNAc3 + 1Na

2304.8372

1.17

Hex5dHex3HexNAc5 + 1Na

1485.5323

-0.94

Hex3dHex1HexNAc4 + 1Na

Fuc, Bi

2319.828

8.19

Hex6HexNAc5NeuAc1 + 1Na

Tri, Sia

1501.5287

0.07

Hex4HexNAc4 + 1Na

Bi

2320.8293

-0.04

Hex6dHex2HexNAc5 + 1Na

Tri, Fuc
Tri, Sia, Fuc

1542.5362* -12.25

Hex3HexNAc5 + 1Na

Bis

2325.806

0.9

Hex5dHex1HexNAc5NeuAc1 + 2Na

1581.5275

-0.44

Hex7HexNAc2 + 1Na

Man

2341.7948

-1.71

Hex6HexNAc5NeuAc1 + 2Na

Tri, Sia

1606.5643

2.74

Hex5dHex1HexNAc3 + 1Na

Fuc

2391.8211

-3.76

Hex5dHex1HexNAc4NeuAc2 + 1Na

Fuc, Bi, Sia

1611.5181

-5.27

Hex4HexNAc3NeuAc1+ 2Na

Sia

2393.8442

-0.67

Hex7HexNAc6 + 1Na

Tetra

1647.5813

-3.16

Hex4dHex1HexNAc4 + 1Na

Fuc, Bi

2413.8225

1.08

Hex5dHex1HexNAc4NeuAc2 + 2Na

Fuc, Bi, Sia

1663.5813

-0.06

Hex5HexNAc4 + 1Na

Bi

2435.8429

13.63

Hex5dHex1HexNAc4NeuAc2 + 3Na

Fuc, Bi, Sia

Hex3dHex1HexNAc5 + 1Na

Fuc, Bis

2449.8932

8.65

Hex5dHex2HexNAc5NeuAc1 + 1Na

Tri, Fuc, Sia
Fuc, Tri, Sia

1688.6115* -0.89
1704.6006

-4.28

Hex4HexNAc5 + 1Na

Bis

2465.8986

12.86

Hex6dHex1HexNAc5NeuAc1 + 1Na

1743.581

0

Hex8HexNAc2 + 1Na

Man

2466.9006

5.39

Hex6dHex3HexNAc5 + 1Na

Fuc, Tri

1751.573

-13.93

Hex5HexNAc3NeuAC1 + 1Na

Sia

2487.8561

-0.24

Hex6dHex1HexNAc5NeuAc1 + 2Na

Fuc, Tri, Sia

1773.571

-9.13

Hex5HexNAc3NeuAC1 + 2Na

Sia

2610.9273

8.77

Hex6HexNAc5NeuAc2 + 1Na

Tri, Sia

1792.6277

2.06

Hex4HexNAc4NeuAc1 + 1Na

Sia, Bi

2611.9374

4.82

Hex6dHex2HexNAc5NeuAc1 + 1Na

Fuc, Tri, Sia

1809.6462

3.81

Hex5dHex1HexNAc4 + 1Na

Fuc, Bi

2632.9301

13.65

Hex6HexNAc5NeuAc2 + 2Na

Tri, Sia

1850.6678

1.03

Hex4dHex1HexNAc5 + 1Na

Fuc, Bis

2633.9313

6.34

Hex6dHex2HexNAc5NeuAc1 + 2Na

Fuc, Tri, Sia

1866.6728

6.43

Hex5HexNAc5 + 1Na

Bis

2638.9272

14.44

Hex5dHex1HexNAc5NeuAc2 + 3Na

Fuc, Tri, Sia

1905.6358

1.05

Hex9HexNAc2 + 1Na

Man

2684.9569

5.85

Hex7HexNAc6NeuAc1 + 1Na

Tetra, Sia

1938.6922

5.31

Hex4dHex1HexNAc4NeuAc1 + 1Na

Fuc, Sia, Bi

2685.9739

4.58

Hex7dHex2HexNAc6 + 1Na

Tetra, Fuc

1954.6722

-2.35

Hex5HexNAc4NeuAc1 + 1Na

Bi, Sia

2706.9205

-3.88

Hex7HexNAc6NeuAc1 + 2Na

Tetra, Sia

Hex5dHex2HexNAc4 + 1Na

Fuc, Bi

2757.9599

-8.27

Hex6dHex3HexNAc5NeuAc1 + 1Na

Tri, Fuc, Sia

2779.9401 -11.65 Hex6dHex3HexNAc5NeuAc1 + 2Na

Tri, Fuc, Sia

1955.6731 -12.32
1960.6604

-1.73

Hex4dHex1HexNAc4NeuAc1 + 2Na

Fuc, Sia, Bi

1976.6556

-5.56

Hex5HexNAc4NeuAc1 + 2Na

Sia, Bi

2902.0267

9.27

Hex6HexNAc5NeuAc3 + 1Na

2012.7304

5.81

Hex5dHex1HexNAc5 + 1Na

Fuc, Bis

2923.9973

2.63

Hex6HexNAc5NeuAc3 + 2Na

Tri, Sia

2028.7138

0.1

Hex6HexNAc5 + 1Na

Tri

Hex7HexNAc6NeuAc2 + 1Na

Tetra, Sia

2100.7473

6

Hex5dHex1HexNAc4NeuAc1 + 1Na

Fuc, Bi, Sia

2977.0911

11.45

Hex7dHex2HexNAc6NeuAc1 + 1Na Tetra, Fuc, Sia

2101.7489

-2.95

Hex5dHex3HexNAc4 + 1Na

Fuc, Bi

3049.0833

1.71

Hex6dHex3HexNAc5NeuAc2 + 1Na

2122.715

-4.48

Hex5dHex1HexNAc4NeuAc1 + 2Na

Fuc, Sia, Bi

3050.0908

5.71

Hex8HexNAc7NeuAc1 + 1Na

Tetra, Sia

2158.7939

8.01

Hex5dHex2HexNAc5 + 1Na

Fuc, Tri

3071.0456

-7.25

Hex6dHex3HexNAc5NeuAc2 + 2Na

Tri, Fuc, Sia

2174.7955

11.04

Hex6dHex1HexNAc5 + 1Na

Fuc, Tri

2976.0366* -14.85

Tri, Sia

Tri, Fuc, Sia

Table 1. N-glycans observed in serum and plasma. N-glycans marked with an
asterick (*) were only seen in serum samples from patients with benign lesions or
breast cancer. Man = high mannose, Fuc = fucosylated, Com = complex, Bi = biantennary, Tri = tri-antennary, Tetra = tetra-antennary, Bis = bisected, Sia =
sialylated.
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For sialylated N-glycans, predominant peaks detected in formalin-fixed
paraffin embedded (FFPE) tissues have an extra Na ion per each sialic acid
present.245 This serum and plasma protocol results in detection of many single
sodiated sialylated glycans, in addition to the extra Na adduct glycoforms. This is
also seen in frozen tissue analyses of N-glycans,246 and is likely related to the
Carnoy’s and water washes not done with FFPE tissues. An equivalent number
of N-glycans were detected in plasma, and the CVs for top 20 most abundant Nglycans and structural classes were 9% and 5%, respectively. The average mass
error for all detected glycans was 0.01 ± 0.01 Da. A representative spectrum
obtained from the serum standard and plasma standard is shown in Figure 7.
To evaluate the repeatability and day-to-day variation of this workflow, a
human serum standard and human plasma standard was spotted and processed
using the optimized workflow, and the workflow was repeated on the next two
successive days (day 1-3). Figure 8 displays the area of the 20 most abundant
glycan compositions in serum using area under the peak intensities compared to
the total sum of peak intensity values for all of the detected glycan peaks. The
most abundant glycan peaks included species across a broad m/z range (m/z =
1136 to m/z = 3071). For sialylated glycan species that had multiple sodiated
adducts detected, only one species was included in Figure 8. These glycans
showed little to moderate variability across the experiments, with the CV
averaging to 11.8%, with some peaks having much lower variation.

76

Figure 7. Representative spectra of a standard serum sample (top) and a
standard plasma sample (bottom) analyzed with the N-glycan profiling method by
MALDI-FTICR MS. A sample of detected N-glycans are annotated with putative
structures. The experimental layout of the slide analyzed is displayed in the
bottom right.
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Figure 8. Repeatability of the N-glycan profiling method for serum analysis. The
same serum standard sample was analyzed by MALDI-FTICR MS on three
successive days with a blank well that contained no serum on each run. (A) The
graph shows the average relative intensities detected for the twenty most
abundant N-glycans (normalized to the overall sum of N-glycan intensities) with
putative structures. For determining the most abundant N-glycans, only Nglycans with no overlap with another N-glycan peak isotope were included, and
only one species was selected for sialylated N-glycans with multiple sodiated
adducts. Structural classes were assigned to the N-glycans, and the sum of the
N-glycans for the (B) high abundance and (C) low abundance classes are
displayed. Error bars indicate the standard deviation of the four replicates.
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If the glycans were grouped based on structural features, this improved
repeatability across the three days (CV = 5%). This type of grouping and
improvement in variability has been previously reported for MALDI serum glycan
analysis.91 The average relative intensity of the most abundant unique N-glycan
peak (m/z = 1976.6666, Hex5HexNAc4NeuAc1 + 2Na) across all experiments
was 10% (SD ± 1%).
The results of the plasma standard showed larger variability within the
repeatability parameters (16% and 8% CV for the twenty most abundant unique
N-glycan peaks and N-glycan structural classes, respectively) (Figure 9). Further
optimization studies for plasma and the different anti-coagulants (EDTA, heparin,
citrate) used clinically are still ongoing.
A mixture of Endo F3 or sialidase and PNGase F was applied to the
serum and plasma samples. An overview of the enzymatic treatments is shown
in Figure 10. Endo F3 is a glycosidase that cleaves N-glycans between the first
two N-acetylglucosamines (GlcNAc) linked to asparagine, preferentially when the
first GlcNAc is fucosylated. It can be used to differentiate N-glycans containing
the core fucose versus glycans with fucose modifications on the antennae.249
Additionally, the m/z’s of Endo F3 cleaved N-glycans products can be calculated
based on the loss of 349 m.u. and confirmed by MS/MS. Use of the Endo
F3/PNGase F mix allowed comparison of the data already obtained for
fucosylated N-glycans using PNGase F alone. This modification requires no
increase in processing time and no changes to the MALDI IMS parameters.
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Figure 9. Repeatability of the N-glycan profiling method for plasma analysis. The
same plasma standard sample was analyzed on three successive days with a
blank well that contained no serum on each run. (A) The graph shows the
average relative intensities detected for the twenty most abundant N-glycans
(normalized to the overall sum of N-glycan intensities) with putative structures.
For determining the most abundant N-glycans, only N-glycans with no overlap
with another N-glycan peak isotope were included, and only one species was
selected for sialylated N-glycans with multiple sodiated adducts. Structural
classes were assigned to the N-glycans, and the sum of the N-glycans for the (B)
high abundance and (C) low abundance classes are displayed. Error bars
indicate the standard deviation of the four replicates.
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Figure 10. Overview of the enzymatic treatments applied for serum analysis.

As shown in Figure 11 A, multiple fucosylated N-glycans from serum were
decreased in abundance in the Endo F3/PNGase F treatment compared to the
PNGase F only treatment. Endo F3/PNGase F treatment did not affect the
abundances of non-fucosylated glycans in serum and plasma (Figure 11 B).
While some N-glycans could be readily identified as core fucosylated using this
method (Figure 11 C-D), the identification of several other N-glycan fucosylation
locations were obscured by several different factors. Various Endo F3 products
have the m/z of a fucosylated N-glycan, making it difficult to attribute the signal
intensity to either N-glycan. Other Endo F3 products that did not have an
overlapping m/z with another N-glycan were not detected, but their parent Nglycan abundance did decrease. Collision-induced dissociation MS/MS was also
used to ascertain structural information, with representative data examples
provided in Figure 12.
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Figure 11. Endo F3 modification of the N-glycan profiling method for serum
analysis. (A) Representative spectrum for a serum standard treated with PNGase
F (top) or PNGase F and Endo F3 (bottom) with annotations for a set of putative
N-glycan structures. The N-glycan profile of a serum standard and a plasma
standard was analyzed by MALDI-FTICR MS in quadruplicate by a treatment
with PNGase F or a PNGase F and Endo F3 mix. The intensities of a (B) noncore fucosylated N-glycan (m/z 2289.7326), (C) core-fucosylated N-glycan (m/z
1809.6393), and (D) Endo F3 product (m/z 1460.5020), respectively, are
displayed for both treatments.
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Figure 12. MS/MS of serum N-glycans by CID done directly on the slide. A) m/z
= 1419.4755, B) m/z = 1485.5337, C) m/z = 1647.5865, D) m/z = 1663.5814, and
E) m/z = 1809.6393 N-glycan structures were confirmed with MALDI-TOF
MS/MS. The collision energies and number of laser shots were individually
optimized for each N-glycan.
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An alternative enzymatic treatment of sialidase and PNGase F were
concurrently applied to the samples as well. Sialidase is an endoglycosidase that
releases sialic acid residues from the terminal end of the antennas on N-glycans.
This treatment collapses the intensity of all the differentially sialylated structures
and their alternatively sodiated structures of an N-glycan into one peak (Figure
13). In this way, the intensity of the non-sialylated branched structures can be
analyzed.
The use of these alternative enzymatic treatments increased the
sensitivity of the workflow for the detection of core fucosylated and
polylactosamines for Endo F3 and sialidase, respectively (Figure 14). Sialidase
and PNGase F treatment increases the intensity of polylactosamine N-glycans
when compared to only PNGase F treatment of the same sample (Figure 14 A).
The intensities of some core fucosylated N-glycans from a sample treated with
Endo F3 only were higher than when the sample was treated with PNGase F
only.
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Figure 13. Sialidase modification to the workflow. (A) Representative spectrum
for a serum standard treated with PNGase F (top) or PNGase F and Sialidase
(bottom) with annotations for a set of putative N-glycan structures. The N-glycan
profile of a serum standard and a plasma standard was analyzed. The intensities
of a (B) non-sialylated N-glycan (m/z 1663.5814), (C) singly sialylated N-glycan
(m/z 1976.6588), and (D) double sialylated N-glycan (m/z 2289.7361),
respectively, are displayed for both treatments.
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Figure 14. Alternative enzymatic treatments increase sensitivity to classes of Nglycans. (A) Intensities of polylactosamine N-glycans of a sample treated with
either PNGase F or PNGase F and sialidase. (B) Intensities of core fucosylated
N-glycans of a sample treated with either PNGase F or Endo F3. The m/z of the
Endo F3 products that correlate to the PNGase F products are shown in
parenthesis.
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The potential clinical application of this method was assessed by
analyzing a small set of pooled serum samples from non-obese or obese patients
with benign breast lesions or breast cancer.251 Most of the N-glycans that were
detected in the pooled serum standard were also present in these samples, and
there were N-glycans that were only found in the samples and not in the serum
standard (marked with an asterisk in Table 1). While major differences were not
detected across groups for most of the detected N-glycans, some representative
examples of differential detection per clinical group are shown in Figure 15. A
higher abundance in a core fucosylated, non-galactosylated N-glycan at m/z =
1485.5337 (Hex3dHex1HexNAc4 + 1Na) was observed in the cancerous obese
serum (Figure 15 A). A mono-galactosylated N-glycan m/z = 1501.5286
(Hex4HexNAc4 + 1Na) had a higher abundance in both non-obese samples
(Figure 15 B). The non-obese and obese benign samples also had higher
amounts of the highly abundant fucosylated bi-antennary N-glycan m/z =
1809.6393 (Hex5dHex1HexNAc4 + 1Na) (Figure 15 C). The benign obese serum
had a lower abundance of the presumably bisected N-glycan m/z = 1866.6608
(Hex5HexNAc5 + 1Na) (Figure 15 D). These N-glycans vary largely in their
average relative intensities with m/z = 1809.6393 accounting for 5.1% of the
glycan signal and m/z = 1866.6608 accounting for 0.4%. The N-glycans detected
in the clinical serum set had a similar level of variability as those found in the
serum standards. The top 20 most abundant N-glycans averaged a CV of 8%.
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Figure 15. Application of the N-glycan profiling method to the serum of breast
cancer patients. N-glycan profiles of pooled serum samples from obese and
nonobese patients that had a benign lesion or breast cancer were analyzed. The
average relative intensities of (A) m/z 1485.5337, (B) m/z 1501.5286, (C) m/z
1809.6393, and (D) m/z 1866.6608 N-glycans are shown. Error bars display the
standard deviation for the four replicates. The relative intensities of the blank
wells were used for background signal subtraction. BN = nonobese patient with a
benign lesion, BO = obese patient with a benign lesion, CN = nonobese patient
with breast cancer, CO = obese patient with breast cancer.
88

3.5 Discussion
In this study, a comparatively rapid and reproducible slide-based method
for N-glycan profiling analysis of serum and plasma N-glycan profiling was
presented. The approach possesses the advantages of related glycan profiling
protocols for tissues, cells and antibody capture arrays that our collective group
have previously reported,19,247,248 in that it requires minimal sample processing
and no derivatization or purification of PNGase F released glycans. Using only 12 µl of serum or plasma, the sensitivity of this method allows for detection of a
broad set of N-glycans, comparable to other N-glycan profiling methods, as well
as single day analysis timelines. By repeating this workflow using the same
samples on three successive days, the variation of glycan intensities day-to-day
was shown to be consistent with reported technical variation of MALDI MS
applied to serum.91 As was also reported,91 the use of MALDI facilitates rapid
analysis of structural class groupings of N-glycans as shown in Figure 8 and
Figure 9. The current study was focused more on establishing the method,
however, use of a small cohort of clinical breast cancer samples was evaluated
for proof-of-concept applications (Figure 15). Previous studies have examined
the change of the total serum N-glycome in breast cancer patients and identified
N-glycans and N-glycan structural motifs that are associated with the presence of
cancer, metastasis, and cancer stage.206,207,216–219 Of the glycans detected in our
pooled breast cancer samples, only a small set of glycans were found to have
differing levels of abundance in one or more samples (Figure 15). While
statistical analysis for clinical application is not possible with these samples, both
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the increase of the N-glycan m/z = 1485.5337 and decrease of the N-glycan m/z
= 1809.6393 have been found in previous studies.206,218,252 Larger cohort studies
are ongoing to better identify potential serum and plasma glycan biomarker
candidates related to cancer and other diseases.
The amine-reactive hydrogels that were used offered several advantages
compared to other slide chemistries tested. For example, the most direct
approach would be to spot serum on a glass histology slide and apply PNGase F
and matrix without any other processing steps. This was done in multiple
iterations, and it resulted in no glycan signal detected by MALDI-FTICR MS. Two
factors are critical: First, the salts and ions present in serum and plasma lead to
ion suppression. Second, the proteins are concentrated and non-denatured,
limiting efficient access to PNGase F. The use of the amine-reactive gel slide
provided covalent attachment of the serum and plasma proteins, which allowed
denaturing and delipidating with Carnoy’s solution, followed by removal of salts
and ions with water washes. This covalent attachment also allows any plasma
formulation to be used. Plasma with EDTA and citrate anti-coagulants have been
successfully used with this workflow. Plasma with heparin anti-coagulant has not
yet been evaluated, but should work like the other plasma samples, or due to its
highly charged sulfation characteristics, readily adaptable to additional wash step
strategies. Similarly, the workflow could serve as a starting point for analysis of
N-glycans in other types of non-blood derived biofluids. This report focused
specifically on use of glass slides, but efforts are ongoing to adapt the workflow
to standard MALDI steel plates. It should also be noted that only CHCA matrix
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was used for analyses in positive ion mode. It is certainly feasible that other
matrix compounds could be evaluated, as well as use of this method in negative
ion mode.
One of the goals in the method development was to simplify the sample
processing steps and thereby improve the timelines of analysis. There are
multiple steps in the current protocol workflow that could be further adjusted to
both improve reproducibility and decrease time of analysis. The slide-based
approach for sample spotting and washing could easily be adapted to sample
spotting platforms and automated liquid handling systems. This could potentially
decrease sample spotting and processing time, increase numbers of samples
analyzed per slide, and lower CV’s. While this was not reported herein, the
PNGase F PRIME enzyme (N-Zyme Scientifics) is stable at temperatures up to
50 oC and results in shorter reaction times. This could decrease at least 60-90
min in the processing timeline, and is under evaluation. Additionally, the MALDIFTICR-MS analysis reported herein used a larger sample and slide area for
analysis as part of the method optimization steps. As mentioned, automated
sample spotting and robotic sample handling would integrate well at this step.
The mass spectrometry detection aspects of the protocol have also been
assessed on the timsTOF fleX mass spectrometer (Bruker). Even using the
current larger sample areas, this instrument has reduced the time for data
acquisition to 30 min or less per slide. Overall, the time elapsed from sample
preparation to data analysis is very quick compared to other clinical biofluid Nglycan profiling methods.91 Using the aforementioned strategies, we expect that
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the current workflow can be adapted to a 4-5 hr analysis time frame from start to
finish per slide.
The use of MALDI for this analysis comes with multiple limitations relative
to other analytical techniques, as highlighted in the extensive multi-laboratory
evaluation of HPLC, capillary electrophoresis and MALDI mass spectrometry
evaluations of the same clinical serum cohort.91 In particular, MALDI MS is
limited in determining the many structural isomers associated with fucosylation
and sialylation, and stability of sialic acids on N-glycans is a well described issue.
High vacuum MALDI and localized heat of ionization contribute to sialic acid
lability for N-glycans. The MALDI-FTICR-MS used herein has a cooling gas in the
source that mitigates some of this loss,244–246 and chemical amidation strategies
have been reported that stabilize sialylated N-glycans and provide isomeric
linkage information.91,94,253 Adapting these amidation reactions conditions to the
slide-based workflow is currently ongoing. The application of a mixture of Endo
F3 and PNGase F to serum and plasma, shown in Figure 12, represents an initial
demonstration of feasibility for differentiating N-glycan fucose isomers within the
protocol. Another modification to this workflow that can significantly increase the
data acquired is utilizing an instrument like the timsTOF fleX (Bruker) that has ion
mobility capabilities. Determining the collision cross section of the N-glycans is
another dimension of data that could be used to confirm structure annotations
and determine linkages, especially for distinguishing isomeric species.
Alternatively, more broad interrogations of branched structures can be conducted
using this workflow by adding sialidase to the enzyme treatment. This was shown
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to increase the workflow’s sensitivity to several low abundant polylactosamines,
some of which were undetectable without sialidase treatment.
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Chapter 4: Urine and Prostatic Fluid N-glycan Profiling by
MALDI-IMS
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This chapter has been adapted from a manuscript published in Frontiers in
Chemistry, September 2021 9:e734280. CRKB, JPH, GG, LL, and RRD carried
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assisted by RRD. OJS, JDW,JEI, CHH, and JON provided the study sample
cohorts. CRKB and RRD prepared the manuscript with contributions from all
authors.

Direct N-glycosylation Profiling of Urine and Prostatic Fluid Glycoproteins
and Extracellular Vesicles
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Semmes, Jennifer D. Wu, Joseph E. Ippolito, Chanita Hughes-Halbert, Julius O.
Nyalwidhe, and Richard R. Drake.
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4.2 Introduction
In the search and characterization of disease biomarkers for use in liquid
biopsy applications, proximal fluids like blood and urine are commonly used.
Proximal fluids are found adjacent to a given tissue or organ and represent a
repertoire of secreted proteins and shed cells reflective of the physiological state
of that tissue. For prostate cancer and other genitourinary diseases, proximal
fluids are represented by seminal plasma and expressed-prostatic secretion in
urine (EPSu) 254,255. EPSu, also termed post-digital rectal exam (DRE) urine,
represents the fluid being secreted by the prostate following a digital rectal
prostate massage, which in turn can be collected in voided urine post-exam
254,256.

The prostate gland secretes many proteins and other biomolecules in a

prostatic fluid that combines with seminal fluid and sperm from the seminal
vesicles during ejaculation. Many of these prostatic proteins are glycoproteins,
like prostate specific antigen (PSA), that perform functions to activate sperm and
suppress the vaginal immune micro-environment. Our group has previously
characterized the proteomic composition of EPSu and prostatic secretions ,
identifying hundreds of different prostate-derived glycoproteins 116,256–258.
Development and evaluation of extensive targeted proteomic assays to these
proteins in EPSu are in progress for use in prostate cancer diagnosis 259,260. The
prostatic fluids, EPSu and urine are also rich in extracellular vesicles (EV), which
are a source for many ongoing non-coding RNA and related oligonucleotidetargeted diagnostic assays for prostate cancer and multiple diseases 261–263. EV
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obtained from urine and EPSu continues to be a highly active area for diagnostic
assay development 264,265.
The majority of proteins in EPSu, urine, and associated EVs are
glycosylated 116,256–258, either on asparagine residues, termed N-glycosylation, or
on serine or threonine residues, termed O-glycosylation. Changes in
glycosylation have been well documented in prostate cancer associated tissues,
cells and biofluids 117,266,267. Extensive glycoproteomic approaches, i.e.,
characterization of the glycan structures at the peptide sites of modification, have
been reported for urine and EPSu glycoprotein targets 268–270. One of the most
highly characterized glycoproteins is PSA 125,270–274, due to its known role in
prostate cancer diagnosis and relatively simple glycosylation pattern of having a
single N-glycosylation site. Although changes in glycosylation of PSA and many
other prostatic glycoproteins have diagnostic potential, assays to efficiently
characterize N-glycans in urine can be lengthy and require multiple processing
steps, precluding large scale clinical utility 275,276. Lectin arrays have been
effectively used to profile glycan motifs in large cohorts of clinical urine samples
277,278,

however this approach cannot determine full glycan compositions or

distinguish N-linked or O-linked origins. Based on an adaptation of a recently
published workflow for rapid characterization of serum and plasma N-glycans 279,
we report herein a more efficient slide-based approach combined with MALDI
imaging mass spectrometry (IMS) workflows to detect total N-glycan profiles of
urine, EPSu and prostatic fluid samples. Comparative results with N-glycans
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detected and histologically mapped in prostate cancer tissues by MALDI IMS are
also included.

4.3 Methods
4.3.1 Materials
Amicon Ultra 10k centrifugal filters were obtained from Merk Millipore
(Carrigtwohill, IRL). Hydrogel coated slides (Nexterion® Slide H) were obtained
from Applied Microarrays (Tempe, AZ). The rotary tool was a Dremel 200 series.
The well slide module (ProPlate Multi-Array Slide System, 64-well) was obtained
from Grace Bio-Laboratories (Bend, OR). Sodium bicarbonate, trifluoroacetic
acid (TFA), and α-cyano-4-hydroxycinnamic acid (CHCA) were obtained from
Sigma-Aldrich (St. Louis, MO). HPLC grade water, 1X phosphate buffered saline
(PBS), acetonitrile, citraconic anhydride, glacial acetic acid, methanol, xylene,
and chloroform were obtained from Fisher Scientific (Hampton, NH). Ethanol was
obtained from Decon Labs (King of Prussia, PA). Peptide-N-glycosidase F
(PNGase F) PRIMETM was from N-Zyme Scientifics (Doylestown, PA). H&E
stains were obtained from Cancer Diagnostics (Durham, NC).

4.3.2 Clinical Samples
All samples were collected from patients and utilized after informed
consent following Institutional Review Board-approved protocols at Urology of
Virginia, Sentara Medical School, and the Eastern Virginia Medical School. All
personal information or identifiers beyond diagnosis and lab results were not
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available to the laboratory investigators. EPS-urine samples were collected
performing a gentle massage of the prostate gland during DRE prior to biopsy, as
previously described 256. The massage consisted of three strokes on each side of
the median sulcus of the prostate and the expressed fluid from the glandular
network of the prostate was subsequently voided in urine. Pools (25-50
ml/sample) of EPSu were derived from 10 patients classified as having high
grade, Gleason 8-10 tumors and 10 patients with low grade, Gleason 6, organconfined prostate cancer as described previously 125. For isolation of EPSderived extracellular vesicles (EPSev), the two EPSu pools (45 mL) were
centrifuged at 25,000 x g for 30 minutes, and the supernatant centrifuged at
100,000 X g for 4 hours. The pelleted exosomes were washed twice with PBS
and resuspended in 0.5 ml PBS, as previously described 125. Direct EPS fluids
(EPSd) were obtained under anesthesia prior to prostatectomy as previously
described 257. A subset of 10 pairs of patient samples who provided both EPSu
and EPSd were selected. Prior to glycomic analysis, 0.125 ml aliquots of each
EPSu and EPSd sample were concentrated in a 10,000 MW filter cut-off 0.5 ml
Amicon tube by centrifugation at 11,000 rpm in a Sorvall Legend Micro 21
benchtop microcentrifuge for 25 minutes. To each filtration tube was added 0.125
ml of 1X PBS, and centrifugation was repeated for 25 minutes. The remaining
concentrated fluid, approximately 15-20 microliters, was removed to a separate
vial. Each tube was rinsed with 20 microliters of PBS, and added to the
concentrated sample vial (final volume 35-40 microliters). A de-identified prostate
tumor tissue pair of Gleason grade 8 (4+4)/stage pT3b and patient-matched
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distal non-tumor tissue was obtained from the Hollings Cancer Center Tissue and
Analysis Biorepository at the Medical University of South Carolina. A serial
section of each tissue was H&E-stained according to a standardized protocol.

4.3.3 Control Urine Standards
Commercial urine samples representing pooled samples from 4 healthy
males and 4 females were purchased from Lee BioSolutions (Maryland Heights,
MO). Prior to glycomic analysis, the control urine samples were filtered and
rinsed as described for the EPS samples, except 4 ml starting volume was used
with larger Amicon tubes.

4.3.4 EPS Fluids and Urine Preparation
The sample preparation and analysis of the EPS fluids (EPSu, EPSd, and
EPSev) and urine samples were adapted from a workflow established for the
glycomic analysis of serum and plasma 279. After a 30-minute temperature
equilibration in a moisture resistant pouch, an amine-reactive hydrogel coated
slide was ground down with a rotary tool until if could fit into a Bruker MTP Slide
Adapter II. A 64 well module was attached and outlined on to the back of the
slide. Then the well module was unattached. Two microliters of sodium
bicarbonate (100 mM, pH 8.0) was mixed with 1 microliter of the sample and
briefly mixed. Within the outline of a well, 1 microliter was spotted onto the slide.
EPSu, EPSd, and EPSev samples were spotted in technical triplicates, and the
control urine samples were spotted in technical quadruplicates. The slide was
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placed in a humidity chamber, made from a culture dish with a Wypall X 60 paper
towel lining the bottom and two rolled KimWipes saturated with distilled water on
opposite sides, for 1 hour on the benchtop to immobilize the samples to the slide.
The slide was then dried in a desiccator for 15 minutes. The well module was
reattached to the slide, matching the wells with the outlines drawn on previously.
The samples were washed with Carnoy’s solution (10% glacial acetic acid, 30%
chloroform, and 60% 200 proof ethanol) 3 times for 3 minutes each, and
subsequently washed with HPLC-grade water once for 1 minute. For the washing
and rinsing steps, 50 microliters of solution was added to each well and dumped
out of the well by inverting the slide. Following the water wash, the slide was
dried in a desiccator for 30 minutes with the slide module attached. After
detaching the slide module, a M5 TM-Sprayer (HTX Technologies) was used to
spray a 0.1 mg/mL PNGase F PRIME solution in water on to the slide for 15
passes at 25 microliters/min, 1200 mm/min, 45°C, and 3 mm spacing between
passes with 10 psi nitrogen gas. The slide was then incubated in a preheated
humidity chamber at 37°C for 2 hours. A M5 TM-Sprayer was also used to apply
the MALDI matrix solution (7mg/mL of CHCA in 50% acetonitrile/0.1% TFA) on
the slide for 10 passes at 100 microliters/min, 1200 mm/min, 79°C, and 2.5 mm
spacing between passes with 10 psi nitrogen gas.

4.3.5 Prostate Tissue Preparation
The tissues were prepared as described previously 247. Briefly, the tissues
were dewaxed by 1 hour in 60°C and xylene washes, rehydrated with a gradation
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of ethanol and water washes, and underwent antigen retrieval in citraconic
anhydride buffer (25-μl citraconic anhydride, 2-μl 12 M HCl, 50-ml HPLC-grade
water, pH 3.0 ± 0.5) in a decloaking chamber at 95°C for 30 minutes. A M5 TMSprayer (HTX Technologies) was used to spray a 0.1 mg/mL PNGase F PRIME
solution in water on to the slide for 15 passes at 25 microliters/min, 1200
mm/min, 45°C, and 3 mm spacing between passes with 10 psi nitrogen gas. The
slide was then incubated in a preheated humidity chamber at 37°C for 2 hours. A
M5 TM-Sprayer was also used to apply the MALDI matrix solution (7mg/mL of
CHCA in 50% acetonitrile/0.1% TFA) on the slide for 10 passes at 100
microliters/min, 1200 mm/min, 79°C, and 2.5 mm spacing between passes with
10 psi nitrogen gas.

4.3.6 MALDI Imaging Mass Spectrometry
A dual source timsTOF fleX MALDI-QTOF mass spectrometer (Bruker)
was used to image the slides as previously described 280. Images were collected
with a SmartBeam 3D laser operating at 10,000 Hz with a 20 µm laser spot size
at a 150 µm raster with 300 laser shots per pixel. Samples were analyzed in
positive ion mode spanning a m/z range of 700-4000.

4.3.7 Data Processing and Analysis
Mass spectra were imported in to SCiLS Lab software 2021a (Bruker),
normalized to total ion current, and manually peak selected for N-glycans based
on theoretical mass values. SCiLS was also used for individual peak visualization
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and quantification. Maximum mean values for each peak were exported for each
sample region. Each N-glycan measurement for each sample was subtracted by
the background signal in the blank well to find the absolute intensity. To account
for differences in protein concentrations that could lead to higher signal
intensities and detection of more low-abundance N-glycan species, N-glycan
relative intensities were calculated as the absolute intensity divided by the sum of
all the absolute intensities of the N-glycans found in each of the samples being
compared. Comparisons of the number of N-glycans detected in each sample is
also discussed, and the presence/absence of a N-glycan in each sample is noted
in Supplemental Table 1. N-glycan structures were labelled with a N-glycan class
or classes depending on their putative structures. Quantifications of the N-glycan
classes were calculated by summing the relative intensities of the individual Nglycans belonging to each class. N-glycan profiles were also examined by
grouping each N-glycan into a group depending on the presence and/or absence
of mannose, fucose, sialic acid, and sulphate and comparing the summed
relative intensities of the classes. When comparing individual N-glycan intensities
across samples, the multiply sodiated species of sialylated and sulfated Nglycans were added together.
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Theoretical
Mass

Composition

771.2642
933.3710
1079.3749
1095.3698
1136.3964
1257.4226
1282.4543
1298.4492
1339.4757

Hex2HexNAc2 + 1Na
Hex3HexNAc2 + 1Na
Hex3dHex1HexNAc2 + 1Na
Hex4HexNAc2 + 1Na
Hex3HexNAc3 + 1Na
Hex5HexNAc2 + 1Na
Hex3dHex1HexNAc3 + 1Na
Hex4HexNAc3 + 1Na
Hex3HexNAc4 + 1Na

1378.4060

Hex4HexNAc3 + 1SO4 + 1Na

1400.3880

Hex4HexNAc3 + 1SO4 + 1Na

1419.4755
1444.5071
1460.5020

Hex6HexNAc2 + 1Na
Hex4dHex1HexNAc3 + 1Na
Hex5HexNAc3 + 1Na

Man
Fuc
Hyb

1485.5336

Hex3dHex1HexNAc4 + 1Na

1501.5286

Hex4HexNAc4 + 1Na

1524.4639
1540.4588
1542.5551
1562.4408
1581.5283
1589.5446
1590.5650
1606.5599
1611.5266
1622.5548
1647.5865
1663.5814
1669.5014
1688.6130
1691.4834

Glycosylation Class

Presence in Samples
uEPS

dEPS

MU

FU

EPSev

PT

PL

X
X
X
X
X
X
X
X
X

X
X
X
X

X

X

X

X
X
X
X

X

X

X

X
X
X

X
X
X

X
X

X

X
X

X
X
X

Fuc, Bia

X

X

X

X

Bia

X

X

Hex4dHex1HexNAc3 + 1SO4 + 1Na

Fuc, Sul

X

Hex5HexNAc3 + 1SO4 + 1Na
Hex3HexNAc5 + 1Na
Hex5HexNAc3 + 1SO4 + 1Na
Hex7HexNAc2 + 1Na
Hex4HexNAc3NeuAc1 + 1Na
Hex4dHex2HexNAc3 + 1Na
Hex5dHex1HexNAc3 + 1Na
Hex4HexNAc3NeuAc1 + 2Na
Hex6HexNAc3 + 1Na
Hex4dHex1HexNAc4 + 1Na
Hex5HexNAc4 + 1Na
Hex4HexNAc3NeuAc1 + 1SO4 + 1Na
Hex3dHex1HexNAc5 + 1Na
Hex4HexNAc3NeuAc1 + 1SO4 + 2Na

Hyb, Sul
Bis
Hyb, Sul
Man
Sia
Fuc
Fuc, Hyb
Sia
Hyb
Fuc, Bia
Bia
Sia, Sul
Fuc, Bis
Sia, Sul

X

1702.5116
1704.6080
1708.4987

Hex6HexNAc3 + 1SO4 + 1Na
Hex4HexNAc5 + 1Na
Hex5dHex1HexNAc3 + 1SO4 + 1Na

Hyb, Sul
Bis
Fuc, Hyb, Sul

X
X
X

X

X

X

X

1713.4654

Hex4HexNAc3NeuAc1 + 1SO4 + 3Na

Sia, Sul

X

1724.4936
1735.6025
1743.5811
1745.6345
1749.5253

Hex6HexNAc3 + 1SO4 + 2Na
Hex4dHex1HexNAc3NeuAc1 + 1Na
Hex8HexNAc2 + 1Na
Hex3HexNAc6 + 1Na
Hex4dHex1HexNAc4 + 1SO4 + 2Na

Hyb, Sul
Fuc, Sia
Man
Tet
Fuc, Bia, Sul

X
X
X
X
X

X

X

X

X

1751.5974
1757.5845
1765.5202

Hex5HexNAc3NeuAc1 + 1Na
Hex4dHex1HexNAc3NeuAc1 + 2Na
Hex5HexNAc4 + 1SO4 + 2Na

Hyb, Sia
Fuc, Sia
Bia, Sul

X
X

X
X

1773.5794

Hex5HexNAc3NeuAc1 + 2Na

Hyb, Sia

X

X

1792.6240
1793.6444
1809.6393
1814.6059
1815.5593

Hex4HexNAc4NeuAc1 + 1Na
Hex4dHex2HexNAc4 + 1 Na
Hex5dHex1HexNAc4 + 1Na
Hex4HexNAc4NeuAc1 + 2 Na
Hex4dHex1HexNAc3NeuAc1 + 1SO4 + 1Na

Bia, Sia
Fuc, Bia
Fuc, Bia
Bia, Sia
Fuc, Sia, Sul

X

1823.4950
1825.6342
1831.5542

Hex5HexNAc4 + 2SO4 + 1Na
Hex6HexNAc4 + 1Na
Hex5HexNAc3NeuAc1 + 1SO4 + 1Na

1837.5413
1850.6659
1853.5362

Hex4dHex1HexNAc3NeuAc1 + 1SO4 + 2Na
Hex4dHex1HexNAc5 + 1Na
Hex5HexNAc3NeuAc1 + 1SO4 + 2Na

Bia

X
X
X
X
X
X
X

Sul

X

Sul

X

Fuc
Man
Man
Fuc

X

X

Composition

Glycosylation Class

2287.8192
2289.7361
2303.8141
2304.8345
2319.8090
2320.8294
2325.7961
2326.5943
2333.7318

Hex4dHex2HexNAc5NeuAc1 + 1Na
Hex5HexNAc4NeuAc2 + 3Na
Hex5dHex1HexNAc5NeuAc1 + 1Na
Hex5dHex3HexNAc5 + 1Na
Hex6HexNAc5NeuAc1 + 1Na
Hex6dHex2HexNAc5 + 1Na
Hex5dHex1HexNAc5NeuAc1 + 2Na
Hex5dHex2HexNAc4NeuAc1 + 1SO4 + 1Na
Hex6HexNAc6 + 1SO4 + 2Na

Fuc, Bis, Sia
Bia, Sia
Fuc, Bis, Sia
Fuc, Bis
Tri, Sia
Fuc, Tri
Fuc, Tri, Sia
Fuc, Bia, Sia, Sul
Tet, Sul

X

X

X
X
X
X

X
X

X

X

X

X
X

X

Fuc, Tri, Sul

Hex4dHex1HexNAc7 + 1SO4 + 1Na

Fuc, Bis, Tet, Sul

X

Hyb, Sia, Sul
Tri, Sia
Bia, Sia, Sul

X
X
X

X

X

2348.7314

Hex5dHex2HexNAc4NeuAc1 + 1SO4 + 2Na

Fuc, Bia, Sia, Sul

X

X

2361.6767

Hex8HexNAc3NeuAc1 + 1SO4 + 3Na

Hyb, Sia, Sul

X

X

X

X

X

X
X

X
X
X
X
X

X

X

2369.6929

Hex5HexNAc4NeuAc2 + 1SO4 + 3Na

Bia, Sia, Sul

X

Hex6dHex1HexNAc6 + 1Na
Hex5dHex1HexNAc4NeuAc2 + 1Na
Hex5dHex3HexNAc4NeuAc1 + 1Na
Hex7HexNAc6 + 1Na
Hex8dHex1HexNAc3NeuAc1 + 2Na
Hex5dHex1HexNAc4NeuAc2 + 2Na
Hex5dHex3HexNAc4NeuAc1 + 2Na
Hex6HexNAc5NeuAc1 + 1SO4 + 2Na
Hex5dHex1HexNAc4NeuAc2 + 3Na
Hex6dHex1HexNAc5NeuAc1 + 1Na
Hex6dHex3HexNAc5 + 1Na
Hex4dHex1HexNAc4NeuAc2 + 1SO4 + 1Na
Hex4HexNAc7NeuAc1 + 1SO4 + 1Na
Hex6dHex1HexNAc5NeuAc1 + 2Na

Fuc, Tet
Fuc, Bia, Sia
Fuc, Bia, Sia
Tet
Fuc, Hyb, Sia
Fuc, Bia, Sia
Fuc, Bia, Sia
Tri, Sia, Sul
Fuc, Bia, Sia
Fuc, Tri, Sia
Fuc, Tri
Fuc, Bia, Sia, Sul
Bis, Tet, Sia, Sul
Fuc, Tri, Sia

X
X
X

X
X
X
X
X
X
X

X

2495.7846
2503.8009
2506.8935

Hex7HexNAc6 + 1SO4 + 2Na
Hex4HexNAc7NeuAc1 + 1SO4 + 2Na
Hex5dHex1HexNAc6NeuAc1 + 1Na

Tet, Sul
Bis, Tet, Sia, Sul
Fuc, Tet, Sia

X
X
X

2515.7508

Hex4dHex1HexNAc4NeuAc2 + 1SO4 + 3Na

Fuc, Bia, Sia, Sul

X

2522.8884
2523.9088
2537.7328
2539.9037
2544.8704

Hex6HexNAc6NeuAc1 + 1Na
Hex6dHex2HexNAc6 + 1Na
Hex4dHex1HexNAc4NeuAc2 + 1SO4 + 3Na
Hex7dHex1HexNAc6 + 1Na
Hex6HexNAc6NeuAc1 + 2Na

Tet, Sia
Fuc, Tet
Fuc, Bia, Sia, Sul
Fuc, Tet
Tet, Sia

X
X
X
X
X

2545.8237
2547.9200
2550.7904

Hex6dHex1HexNAc5NeuAc1 + 1SO4 + 1Na
Hex4dHex1HexNAc7NeuAc1 + 1Na
Hex5HexNAc5NeuAc2 + 1SO4 + 2Na

Fuc, Tri, Sia, Sul
Fuc, Bis, Tet, Sia
Bis, Sia, Sul

X
X
X

X

Hex6dHex1HexNAc5NeuAc1 + 1SO4 + 2Na

Fuc, Tri, Sia, Sul

X

Bis, Sia, Sul
Fuc, Bia, Sia
Fuc, Tri, Sia, Sul
Tri, Sia
Fuc, Tri, Sia

Bia, Sul
Bia, Alp
Hyb, Sia, Sul

X
X
X

X
X

X

X

X

2612.9452
2616.8915
2625.7805

Hex6dHex4HexNAc5 + 1Na
Hex5dHex1HexNAc5NeuAc2 + 2Na
Hex6dHex1HexNAc5NeuAc1 + 2SO4 + 1Na

Fuc, Tri
Fuc, Bis, Sia
Fuc, Tri, Sia, Sul

Fuc, Sia, Sul
Fuc, Bis
Hyb, Sia, Sul

X
X
X

X
X

X
X

X
X

X

2632.8864
2633.9068
2638.8734

Hex6HexNAc5NeuAc2 + 2Na
Hex6dHex2HexNAc5NeuAc1 + 2Na
Hex5dHex1HexNAc5NeuAc2 + 3Na

Tri, Sia
Fuc, Tri, Sia
Fuc, Bis, Sia

X

X
X

X

1866.6608

Hex5HexNAc5 + 1Na

Bis

1875.5182

Hex5HexNAc3NeuAc1 + 1SO4 + 3Na

Hyb, Sia, Sul

X

X

X

X
X

2641.8425

X
X

X

X
X
X
X
X

X

X

X
X

X

X

X

X

X

X

X

X

X

X
X

X
X

X
X

X
X

X

X
X

X

X

X

X

X

X
X
X
X
X
X

X
X
X
X
X

X

X

X

X

X

X

X

X

X

X

X
X

X
X

X

X

X

X

X

X
X

X

X

X

X

X

X

X

X

X

X
X
X
X
X

X
X
X

X
X
X
X
X
X
X
X

X

Fuc, Tet, Sul
Fuc, Tri, Sia
Tet, Sia
Fuc, Tet, Sul

X
X
X
X

X
X

Hex7dHex1HexNAc6NeuAc1 + 1Na
Hex7dHex3HexNAc6 + 1Na
Hex7dHex1HexNAc6NeuAc1 + 2Na
Hex8dHex1HexNAc7 + 1Na
Hex7dHex1HexNAc6 + 2SO4 + 2Na
Hex6HexNAc5NeuAc3 + 3Na
Hex6dHex2HexNAc5NeuAc2 + 3Na
Hex6HexNAc5NeuAc3 + 4Na
Hex7dHex4HexNAc6 + 1Na
Hex6dHex2HexNAc6NeuAc1 + 2Na

Fuc, Tet, Sia
Fuc, Tet
Fuc, Tet, Sia
Fuc, Pol
Fuc, Tet, Sul
Tri, Sia
Fuc, Tri, Sia
Tri, Sia
Fuc, Tet
Fuc, Tet, Sia

X
X
X
X

X

X

X

X

X

X
X
X
X

X

3011.9414

Hex7HexNAc7NeuAc1 + 1SO4 + 3Na

Bis, Tet, Sia, Sul

X

X
X

3012.8947
3034.0785
3035.0989
3048.0577
3049.0781
3051.0938
3070.0397
3071.0601
3092.0217
3093.0421
3099.9574

Hex7dHex1HexNAc6NeuAc1 + 2SO4 + 2Na
Hex7dHex1HexNAc7NeuAc1 + 1Na
Hex7dHex3HexNAc7 + 1Na
Hex6dHex1HexNAc5NeuAc3 + 1Na
Hex6dHex3HexNAc5NeuAc2 + 1Na
Hex8dHex2HexNAc7 + 1Na
Hex6dHex1HexNAc5NeuAc3 + 2Na
Hex6dHex3HexNAc5NeuAc2 + 2Na
Hex6dHex1HexNAc5NeuAc3 + 3Na
Hex6dHex3HexNAc5NeuAc2 + 3Na
Hex7HexNAc6NeuAc2 + 1SO4 + 3Na

Fuc, Tet, Sia, Sul
Fuc, Bis, Tet, Sia
Fuc, Bis, Tet
Fuc, Tri, Sia
Fuc, Tri, Sia
Fuc, Tet
Fuc, Tri, Sia
Fuc, Tri, Sia
Fuc, Tri, Sia
Fuc, Tri, Sia
Tet, Sia, Sul

X
X
X
X
X

X
X
X

2190.7664
2198.7827
2202.6735

Hex7HexNAc5 + 1Na
Hex4HexNAc6NeuAc1 + 1Na
Hex5dHex1HexNAc4NeuAc1 + 1SO4 + 1Na

Tri, Alp
Tet, Sia
Fuc, Bia, Sia, Sul

X
X
X

3100.9778
3114.0037
3122.0945

Hex7dHex2HexNAc6NeuAc1 + 1SO4 + 3Na
Hex6dHex1HexNAc5NeuAc3 + 4Na
Hex7dHex1HexNAc6NeuAc2 + 1Na

Fuc, Tet, Sia, Sul
Fuc, Tri, Sia
Fuc, Tet, Sia

X
X
X

X

2212.7055
2215.7980
2224.6555
2231.7930
2245.7722
2246.7926
2256.8246
2259.7379
2265.6820
2267.7542
2268.7746
2276.7103
2284.7695

Hex4HexNAc7 + 1SO4 + 2Na
Hex5dHex1HexNAc6 + 1Na
Hex5dHex1HexNAc4NeuAc1 + 1SO4 + 3Na
Hex6HexNAc6 + 1Na
Hex5HexNAc4NeuAc2 + 1Na
Hex5dHex2HexNAc4NeuAc1 + 1Na
Hex4dHex1HexNAc7 + 1Na
Hex8HexNAc3NeuAc1 + 2Na
Hex4dHex1HexNAc5NeuAc1 + 1SO4 + 3Na
Hex5HexNAc4NeuAc2 + 2Na
Hex5dHex2HexNAc4NeuAc1 + 2Na
Hex6dHex1HexNAc5 + 1SO4 + 2Na
Hex6dHex1HexNAc4NeuAc1 + 2Na

Tet, Bis, Sul
Fuc, Tet
Fuc, Bia, Sia, Sul
Tet
Bia, Sia
Fuc, Bia, Sia
Fuc, Tet, Bis
Hyb, Sia
Fuc, Bis, Sia, Sul
Bia, Sia
Fuc, Bia, Sia
Fuc, Tri, Sul
Fuc, Bia, Sia, Alp

X
X

3123.1149
3124.1102
3144.0765
3145.0969
3166.0585
3218.1133
3270.1681
3416.2260
3479.1359
3562.2839
3635.3003
3708.3418

Hex7dHex3HexNAc6NeuAc1 + 1Na
Hex9HexNAc8 + 1Na
Hex7dHex1HexNAc6NeuAc2 + 2Na
Hex7dHex3HexNAc6NeuAc1 + 2Na
Hex7dHex1HexNAc6NeuAc2 + 3Na
Hex8dHex1HexNAc7NeuAc1 + 2Na
Hex9dHex1HexNAc8 + 1Na
Hex9dHex2HexNAc8 + 1Na
Hex7dHex1HexNAc6NeuAc3 + 4Na
Hex9dHex3HexNAc8 + 1Na
Hex10dHex1HexNAc9 + 1Na
Hex9dHex4HexNAc8 + 1Na

Fuc, Tet, Sia
Tet
Fuc, Tet, Sia
Fuc, Tet, Sia
Fuc, Tet, Sia
Fuc, Tet, Sia
Fuc, Tet
Fuc, Tet
Fuc, Tet, Sia
Fuc, Tet
Fuc, Tet
Fuc, Tet

X

X

X
X
X

X
X

X

X

X

X

X
X
X
X
X
X
X
X
X
X

X
X

X

X
X
X
X
X

X
X

X
X

X
X

X
X

X

X

X

X
X

X

X

X

X
X
X

X
X

X

X

X

X

X

X

X
X
X

X
X
X

X

X

X

X

X

X

X
X
X

X
X

X

X
X

X

X

X
X
X
X

Fuc, Tri, Sia
Fuc, Bis
Fuc, Hyb, Sul
Bis, Sia
Fuc, Bis
Fuc, Bis, Sia
Fuc, Hyb, Sul
Fuc, Tri
Bis, Sia
Fuc, Bia, Sia, Sul
Tri, Sul

X
X

X

X

Bia, Sia, Alp

X

X
X

X

X

Hex6HexNAc4NeuAc1 + 2Na

X
X

X
X

X
X
X

Hex4dHex1HexNAc5NeuAc1 + 1Na
Hex4dHex3HexNAc5
Hex7dHex2HexNAc2 + 1SO4 + 1Na
Hex5HexNAc5NeuAc1 + 1Na
Hex5dHex2HexNAc5 + 1Na
Hex4dHex1HexNAc5NeuAc1 + 2Na
Hex8dHex1HexNAc3 + 1SO4 + 1Na
Hex6dHex1HexNAc5 + 1Na
Hex5HexNAc5NeuAc1 + 2Na
Hex5dHex1HexNAc4NeuAc1 + 1Na
Hex6HexNAc5 + 1SO4 + 1Na

X
X
X

X

X
X

2138.7116

X
X
X
X

X

X
X

2141.7613
2142.7817
2156.6803
2157.7562
2158.7766
2163.7432
2172.6752
2174.7715
2179.7382
2180.6915
2188.6272

X
X
X
X
X
X

X

X

X

X
X
X

Hex7dHex2HexNAc6 + 1SO4 + 2Na
Hex6dHex1HexNAc5NeuAc2 + 3Na
Hex6HexNAc6NeuAc2 + 1Na
Hex7dHex1HexNAc6 + 1SO4 + 1Na

2830.9991
2832.0195
2852.9811
2905.0359
2924.8787
2945.9638
2946.9842
2967.9458
2978.0774
2999.0390

X
X
X
X

X

X

X
X
X
X
X
X

X
X
X
X
X
X

X
X
X

2787.9004
2800.9263
2813.9838
2822.9399

X
X
X

X

X

X

X

Bia, Sia, Sul
Fuc, Tet, Bis
Hyb, Sia
Fuc, Bia, Sia
Fuc, Bia
Tet, Bis
Fuc, Bis, Sul
Bia, Sia, Alp
Fuc, Bia, Sia
Tri, Sul

X

X

X

X
X
X

Fuc, Bia, Sia, Sul
Tri
Fuc, Tet
Fuc, Bia, Sia, Sul

X

X

X

X

X

Hex5HexNAc4NeuAc1 + 1SO4 + 2Na
Hex3dHex1HexNAc7 + 1Na
Hex7HexNAc3NeuAc1 + 2Na
Hex5dHex1HexNAc4NeuAc1 + 1Na
Hex5dHex3HexNAc4 + 1Na
Hex4HexNAc7 + 1Na
Hex5dHex1HexNAc5 + 1SO4 + 2Na
Hex6HexNAc4NeuAc1 + 1Na
Hex5dHex1HexNAc4NeuAc1 + 2Na
Hex6HexNAc5 + 1SO4 + 2Na

X
X

X

X
X
X
X
X

X

Hex4dHex1HexNAc4NeuAc1 + 1SO4 + 1Na
Hex6HexNAc5 + 1Na
Hex3dHex2HexNAc6 + 1Na
Hex4dHex1HexNAc4NeuAc1 + 1SO4 + 2Na

X

X
X

X

X

2056.6156
2094.7718
2097.6850
2100.7347
2101.7551
2110.7667
2114.6575
2116.7296
2122.7167
2130.6524

X

X

X

X
X
X

Tri, Sia, Sul

2018.6387
2028.7136
2037.7503
2040.6206

X

PL

X
X

X

Fuc, Tri, Sia, Sul
Fuc, Tet
Fuc, Tri, Sia
Fuc, Tri, Sia
Tet
Fuc, Tri, Sia
Fuc, Tri, Sia
Tet, Sia, Sul

2735.8456
2742.9831
2756.9623
2757.9827
2758.9780
2778.9443
2779.9647
2786.8800

X
X

X

Hex6HexNAc5NeuAc2 + 1SO4 + 3Na

2734.8252

X
X
X
X
X
X
X

X

X
X

X

Hex6dHex2HexNAc5NeuAc1 + 1SO4 + 3Na
Hex7dHex1HexNAc6 + 1Na
Hex6dHex1HexNAc5NeuAc2 + 1Na
Hex6dHex3HexNAc5NeuAc1 + 1Na
Hex8HexNAc7 + 1Na
Hex6dHex1HexNAc5NeuAc2 + 2Na
Hex6dHex3HexNAc5NeuAc1 + 2Na
Hex7HexNAc6NeuAc1 + 1SO4 + 2Na

X

X

X

X

Fuc, Bia, Sul

X
X

X

X

X
X
X
X
X
X
X

Fuc, Bia, Alp
Bia, Sia
Hyb, Sia, Sul
Bis, Sia
Fuc, Bis
Fuc, Hyb, Sul
Fuc, Bis
Bis, Sia

X
X

X

X
X

Tri, Sia
Fuc, Tet, Sia
Fuc, Tet
Tet, Sia
Fuc, Tet
Fuc, Tet, Sia
Fuc, Tet, Sul
Fuc, Bia, Sia
Tet, Sia
Tri, Sia, Sul

Hex6dHex1HexNAc4 + 1Na
Hex5HexNAc4NeuAc1 + 2Na
Hex6HexNAc3NeuAc1 + 1SO4 + 1Na
Hex4HexNAc5NeuAc1 + 1Na
Hex4dHex2HexNAc5 + 1Na
Hex7dHex1HexNAc3 + 1SO4 + 1Na
Hex5dHex1HexNAc5 + 1Na
Hex4HexNAc5NeuAc1 + 2Na

X
X
X

X

X
X

Tet, Sia, Sul

Hex5dHex1HexNAc4 + 2SO4 + 1Na

X
X
X

X

X
X

Fuc, Bis, Tet, Sia, Sul

1971.6921
1976.6588
1993.6071
1995.7034
1996.7238
2010.6224
2012.7187
2017.6853

X

X

Hex6HexNAc5NeuAc2 + 2Na
Hex6dHex1HexNAc6NeuAc1 + 1Na
Hex6dHex3HexNAc6 + 1Na
Hex7HexNAc6NeuAc1 + 1Na
Hex7dHex2HexNAc6 + 1Na
Hex6dHex1HexNAc6NeuAc1 + 2Na
Hex7dHex1HexNAc6 + 2SO4 + 1Na
Hex5dHex3HexNAc4NeuAc2 + 2Na
Hex7HexNAc6NeuAc1 + 2Na
Hex6HexNAc5NeuAc2 + 1SO4 + 2Na

1969.5529

X
X

PT

X

Hex6HexNAc6NeuAc1 + 1SO4 + 3Na

X
X
X

X
X

EPSev

X

Hex4dHex1HexNAc7NeuAc1 + 1SO4 + 2Na

Bia, Sia, Sul
Man
Fuc, Bia, Sul
Hyb, Sia
Fuc, Bia, Sia
Tet, Bis
Fuc, Bis, Sul
Bia, Sia
Fuc, Bia
Fuc, Bia, Sia

X

FU

X
X
X

2649.8588

Fuc, Tet

Hex4HexNAc4NeuAc1 + 1SO4 + 1Na
Hex9HexNAc2 + 1Na
Hex5dHex1HexNAc4 + 1SO4 + 2Na
Hex6HexNAc3NeuAc1 + 2Na
Hex4dHex1HexNAc4NeuAc1 + 1Na
Hex3HexNAc7 + 1Na
Hex4dHex1HexNAc5 + 1SO4 + 2Na
Hex5HexNAc4NeuAc1 + 1Na
Hex5dHex2HexNAc4 + 1Na
Hex4dHex1HexNAc4NeuAc1 + 2Na

X

X
X

MU

2654.8684
2668.9463
2669.9667
2684.9412
2685.9616
2690.9283
2699.8173
2705.9279
2706.9232
2712.8432

Hex3dHex1HexNAc6 + 1Na

1894.5627
1905.6339
1911.5781
1935.6322
1938.6819
1948.7139
1952.6047
1954.6768
1955.6972
1960.6638

X
X
X

Fuc, Tet, Sul

X
X
X
X
X
X
X
X
X

2646.8092

1891.6924

X
X
X
X
X
X

Hex7dHex1HexNAc6 + 1SO4 + 2Na

dEPS

X

2377.8509
2391.8301
2392.8505
2393.8458
2405.7958
2413.8121
2414.8325
2421.7478
2435.7940
2465.8669
2466.8873
2471.7869
2481.8189
2487.8489

Hex5HexNAc5NeuAc2 + 1SO4 + 2Na
Hex5dHex2HexNAc4NeuAc2 + 3Na
Hex6dHex1HexNAc5NeuAc1 + 1SO4 + 3Na
Hex6HexNAc5NeuAc2 + 1Na
Hex6dHex2HexNAc5NeuAc1 + 1Na

X

X

Hex6dHex1HexNAc5 + 2SO4 + 1Na
Hex8HexNAc3NeuAc1 + 1SO4 + 2Na
Hex6HexNAc5NeuAc1 + 2Na
Hex5HexNAc4NeuAc2 + 1SO4 + 2Na

2567.8057

X
X
X

X
X
X
X
X
X

2336.7814

2572.7723
2581.8519
2589.7877
2610.9044
2611.9248

X

Presence in Samples
uEPS

2339.6947
2341.7910
2347.7110

2334.6851

X
X
X
X
X
X
X
X
X
X
X
X
X

X

Theoretical
Mass

X
X
X
X
X
X

X

X

X

X
X
X

X

X

X

X

X
X
X
X

X

X

Table 2. N-glycans observed in urine and prostatic fluids. An "X" means the
glycan was detected in that sample. Fuc = fucosylation, Sia = sialylation, Man =
high-mannose, Hyb = hybrid, Bia = biantennary, Bis = bisecting, Tri =
triantennary, Tet = tetraantennary, Sul = sulfation, Alp = alpha-galactose, uEPS
= urine expressed prostatic secretion, dEPS = direct expressed prostatic fluid,
MU = male urine, FU = female urine, EPSev = expressed prostatic secretion
extracellular vesicles, PT = prostate tissue, PL = prostate lumen.
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4.4 Results
To complement previous proteomic studies of proximal prostatic fluids
obtained in the urology clinic as related to prostate cancers 116,256–258 a series of
different EPSu, EPSd and EPSev samples were used to develop a MALDI-based
N-glycan profiling method. The goal was to have a workflow that required
minimal sample processing and could be completed in a 6-8 hour timeline, in
contrast to current glycomic analysis workflows for urine and prostatic fluids that
require multiple processing, derivatization and purification steps prior to analysis.
A previous slide-based approach used for serum and plasma N-glycan profiling
279

was the starting point, and a workflow summarized in Figure 16 was

developed for EPSu. A key feature is use of an amine reactive slide chemistry
that covalently binds target glycoproteins, facilitating washing steps to remove
lipid and salts prior to spraying of a molecular coating of PNGase F PRIME to
release N-glycans. An additional concentration and buffer exchange step was
added for EPSu and EPSd, using a 10000 MW cut-off spin cartridge to
concentrate and allow buffer exchange of the sample prior to addition to the
amine-reactive slide. This step results in a 3-4 fold increase in concentration of
glycoproteins in the biofluid. An SDS-polyacrylamide gel image showing protein
loading examples for the EPSu, EPSd and EPSev samples are provided in
Figure 17.
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.
Figure 16. Workflow for slide-based urine and prostatic fluid N-glycan profiling by
MALDI IMS.
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Figure 17. SDS gel separation of the samples. One microliter (approximately 1015 ug protein) of each sample was added in 10 ul SDS loading buffer and
separated on a 10% Genescript ExpressPlus polyacrylamide gel in MOPS buffer.
SeeBlue Plus2 pre-stained molecular weight standards from Invitrogen were also
loaded. Proteins were visualized by silver staining. EPSu (labelled with a “u”) and
EPSd (labelled with a “d”) sample pairs, and EPSev (labelled with “ev”). Sample
labels with an asterisk were used for mass spectra comparison, and sample
labels with a red box were used as representative samples.

Initial experiments focused on optimizing detection of N-glycans in EPSu
and EPSd sample pairs obtained from the same donors, as well as existing
EPSev pool samples. Similar to what was previously determined for serum or
plasma preparation on the amine-reactive hydrogel slides, the key for optimal Nglycan detection was inclusion of the Carnoy’s solution wash after spotting, which

107

serves to remove lipids and salts, as well as denature the bound glycoproteins
facilitating access for PNGase F. Thus far, a total of 35 EPSu, 10 EPSd and 8
EPSev samples have been analyzed with the workflow shown in Figure 16.
Cumulatively, the resulting N-glycans detected in each sample type are
summarized in Table 2, and structural class groupings are shown in Figure 18.
Broadly, the EPSu samples had the most N-glycan species detected (n = 182)
versus EPSd (n=135). These numbers include multiple versions of the same Nglycan compositions for sialylated and sulfates species, which can vary in mass
due to varying numbers of sodium ions associating with the charged groups.
These glycoforms were included in Table 2 but were generally detected at lower
intensity values.
There was a range of protein concentrations across the samples in each
sample type examined. While this created differences in the total intensity of the
N-glycan profile and number of N-glycans that could be detected, these
differences were accounted for by only comparing relative intensities, i.e. an
individual N-glycan’s intensity relative to the total intensity of the N-glycans in that
sample that were also seen in all sample types being compared. Representative
samples with the most N-glycans detected were selected and compared from
each sample type to display the breadth the N-glycan profiles.
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Figure 18. N-glycan profile of prostatic fluids (EPSu, EPSd, and EPSev). (A)
Glycan class abundances of representative samples determined by summing the
relative intensities of the N-glycans assigned to that class. Error bars represent
the standard deviation. (B) Distributions of representative samples’ N-glycans
assigned into groups based on composition. (C) Distribution of total N-glycan
intensity by individual N-glycan, with N-glycans comprising at least 1% of the
total intensity displayed and annotated.
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The intensity of the N-glycan classes varied across the prostatic fluid
samples (Figure 18 A). EPSd and EPSev N-glycan classes had similar
intensities, except for the higher amount of high-mannose N-glycans in EPSev.
For all samples, the majority of the N-glycans were biantennary and/or
fucosylated. EPSu had approximately 15% and 20% less sialylation than the
EPSd and EPSev, respectively, but had an increased amount of tetraantennary
and sulfated N-glycans. Many of these findings were replicated when grouping
the N-glycans detected in each sample based on composition (Figure 18 B).
About half of the N-glycans in EPSu were fucosylated with no sialic acid
compared to approximately 30% in the EPSd and EPSev samples. The EPSd
and EPSev samples had higher levels of N-glycans with sialic acids and no
fucose. When examining the intensity of individual N-glycans in the prostatic fluid
samples, the most abundant N-glycans were typically biantennary with two
galactoses (Figure 18 C). In concordance with the N-glycan class comparison,
EPSev had more high abundance high-mannose N-glycans than the other
samples, and m/z 1419.4755 (Hex6HexNAc2 + 1Na) was the second most
abundant N-glycan. The sulfated N-glycan m/z 2056.6156
(Hex5HexNAc4NeuAc1 + 1SO4 + 2Na) had a relative intensity of 6.3% in the
EPSu, compared to 1.2% in EPSd and less than 1% in EPSev.
In order to compare mass spectra and absolute intensity values of Nglycan peaks, an EPSu and EPSd sample with similar protein levels from the
same cohort were prepped together and imaged in the same run (Figure 19).
Substantial differences were seen in most of the high-intensity N-glycan peaks,
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except for m/z 1809.6393 (Hex5dHex1HexNAc4 + 1Na), m/z 2465.8669
(Hex6dHex1HexNAc5NeuAc1 + 1Na), and m/z 2800.9263
(Hex6dHex1HexNAc5NeuAc2 + 3Na). The increased levels of sialylated Nglycans in the EPSd sample and increased fucosylated species in the EPSu
sample is also evident.
The advantage of developing the assay using EPSu samples are the
inherently higher protein concentrations present from the prostatic fluid mixture in
these samples relative to normal urine. Therefore, for comparison, control urine
samples from pools of 4 healthy male and 4 healthy female donors were
processed and analyzed using this workflow. This required 4 ml of starting fluid
for concentration and desalting using larger filtration tubes, but was otherwise the
same workflow as described for EPSu/d samples. Overall, N-glycan class
intensities were similar for both samples (Figure 20 A). There were high levels of
biantennary, fucosylated, and sialylated N-glycans and low levels of hybrid Nglycans. The rest of the N-glycan classes had approximately 10% intensity. The
biggest difference between the male and female samples was the slightly lower
level of fucosylation in the female sample. The distribution of N-glycans based on
composition displayed very similar profiles (Figure 20 B). The biggest difference
was a 3.2% increase in high-mannose N-glycans in the female sample.
Accordingly, m/z 1419.4755 (Hex6HexNAc2 + 1Na) was the sixth most abundant
N-glycan in males and the second most abundant in females (Figure 20 C).
Similar to the EPSu samples, the most abundant N-glycans are primarily
biantennary with two galactoses.
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As the glycoprotein constituents of the EPSu and EPSd samples are
secreted by prostate glands, a comparative N-glycan comparison of prostate
tissues was done using previously reported N-glycan MALDI IMS approaches
245,280,281.

In the example shown in Figure 21 A, a pair of non-tumor and tumor

tissues from the same donor were evaluated. Use of the non-tumor tissue from
the same donor is done to demonstrate the specificity of tumor specific N-glycans
detected in the tumor containing tissue (a Gleason grade 8 (4+4), stage pT3b).
The tumor region is quite distinct, localized to the bottom left corner of the tissue.
Additional H&E images of both tissues with increasing magnification are provided
in Figure 22. In Figure 21 B and C are shown representative N-glycan classes
and their tissue distributions, from a total of 73 N-glycans detected. These
structures include tumor-associated paucimannose (Hex3HecNAc2), high
mannose (Hex5-Hex9HexNAc2), and branched fucosylated species
(Hex7HexNAc6Fuc2)(Figure 21 C), consistent with previous reports 281. Two of
the most abundant sialylated biantennary N-glycans detected are stromaassociated, as shown in the overlay image with a tumor N-glycan (in red),
Hex5HexNAc4NeuAc1 in blue and Hex5HexNAc4Fuc1NeuAc1 in green (Figure
21 B, and individually in Figure 21 C). A segmentation analysis of the 73 Nglycans is shown in Figure 21 D, illustrating how different N-glycan classes are
associated with different histopathology features.
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Figure 19. Mass spectra of representative EPSu (top) and EPSd (bottom)
samples with annotations for a set of putative N-glycan structures. The N-glycan
compositions are represented by blue squares for N-acetylglucosamine, green
circles for mannose, yellow circles for galactose, purple diamonds for sialic acid,
red triangles for fucose, and an “S” for sulfate.
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Figure 20. N-glycan profile of pooled healthy male and female urine analyzed my
MALDI IMS. (A) Glycan class abundances of representative samples determined
by summing the relative intensities of the N-glycans assigned to that class.
Sample were analyzed in technical quadruplicate. Error bars represent the
standard deviation. (B) Distributions of representative samples’ N-glycans
assigned into groups based on composition. (C) Distribution of total glycan
intensity by individual N-glycan, with N-glycans comprising at least 1% of the
total intensity displayed and annotated.
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Figure 21. N-glycan imaging of FFPE prostate cancer and non-cancer tissues.
(A) H&E stain of the two tissues from the same donor, non-cancer tissue on the
left side and tumor on the right side. The tumor region, a Gleason grade 8/stage
p3Tb, is highlighted with red outline and a red T. (B) An overlay MALDI image of
three N-glycans, two stroma-associated ones, Hex5HexNAc4NeuAc1 in blue and
Hex5HexNAc4Fuc1NeuAc1, and a tumor glycan Hex7HexNAc6Fuc2 (in red).
(C) Six representative individual N-glycan images representative of different
structural classes are shown, and glycan structure: Hex3HecNAc2, Hex5Hex9HexNAc2, Hex5HexNAc4NeuAc1, Hex5HexNAc4Fuc1NeuAc1,
Hex4HexNAc4Fuc1 and Hex7HexNAc6Fuc2. (D) Segmentation analysis, using
Manhattan and k-bisecting classifications, was applied to the 73 N-glycans
detected in the tissues. Spectra groupings are shown in the adjacent data tree.
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Figure 22. Higher resolution images of the H&E-stained prostate tissues. Images
were obtained following H&E staining of each slide and scanning into a
Hamamatsu Nanozoomer 2.0RS digital slide scanner. Images of 2X and 8X are
shown for selected regions, highlighted in the preceding image with a red box
outline.

This representative tissue was selected for another feature, as it was
noted that there was a distinct intra-lumen glandular N-glycan signature that
could be detected. As shown in Figure 23 A, the two sialylated biantennary Nglycans provide a stromal scaffold image. This was used to detect which Nglycan species were present in the lumen regions, as illustrated in Figure 23 B,
and in Figure 23 C for a highlighted gland region. Doing this, 38 N-glycans were
detected in the lumen of glands.
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Figure 23. Detection of intralumenal N-glycans in non-tumor prostate glands. (A)
Two distinct stroma-associated glycans, Hex5HexNAc4NeuAc1 in blue and
Hex5HexNAc4Fuc1NeuAc1 in green, were chosen to highlight the locations of
the prostate glands. (B) An example of a lumenal glycan is shown in red
(Hex7HexNAc6), overlayed with the stroma glycans. (C) Highlighted region of the
tumor tissue, bottom right corner, to illustrate the glycan distributions inside the
glands. The analogous region in the H&E stained slide is also shown. Structures
are bordered with the color that matches their tissue localizations.
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Using the lists of 73 tissue N-glycans and the subset of 38 lumen Nglycans, these were compared to the N-glycans detected in EPSu and EPSd
samples. As shown in the Venn diagram in Figure 24, 44 N-glycans were present
in the tissues and both EPS samples (Figure 24 A), and 18 N-glycans were
shared in the lumen and EPS samples (Figure 24 B). Structurally, these shared
N-glycans were the high mannose and the most abundant branched fucosylated
N-glycans.

Figure 24. Comparison of detected N-glycans across sample sets. (A) The
number of unique and common N-glycans detected in EPSu, EPSd, and across
the entire prostate tissues. (B) The number of unique and common N-glycans
detected in EPSu, EPSd, and within the lumen of the prostate tissues.
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4.5 Discussion
The goal of our study was to develop and optimize a more efficient and rapid
method to evaluate N-glycosylation by MALDI-MS in urine and EPSu samples.
The workflow is similar to what was developed for serum and plasma 279, utilizing
an amine reactive slide to capture glycoproteins on a solid surface. An additional
1 hour step of sample processing by molecular weight filtration and centrifugation
for urine was included in order to concentrate and solvent exchange. Spotting
only 1 ul, the urine glycoprotein spots are sprayed with a molecular coating of
PNGase F, followed by analysis on a MALDI-FTICR or MALDI-QTOF mass
spectrometer. The method is applicable to urine, EPSu and EPSd samples. An
EPSev prep was spotted directly onto the amine reactive slides without any preprocessing. Routinely, 100 or more N-glycans can be detected depending on the
sample type.
The N-glycan profiling of the prostatic fluid samples displayed more highmannose N-glycans in the EPSev compared to the EPSu and EPSd, reflected in
the intensities of the N-glycan classes and the most abundant individual Nglycans (Figure 18). Relatively high intensities of high-mannose N-glycans have
been noted in non-EPS urinary exosomes as well 282. The similarity of the EPSd
and EPSev N-glycan profiles suggests that a significant portion of the EPS
glycoproteins may be within exosomes. In conjunction with these findings, direct
comparison of mass spectra from EPSu and EPSd with similar protein levels
displayed distinct N-glycan profiles for EPSu and EPSd (Figure 19). While male
and female urine N-glycan profiles and individual N-glycan abundances
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displayed few differences, there was a slightly higher amount of fucosylation in
the male sample. This trend has previously been identified in male and female
plasma samples 77. Similar levels of sulfation were detected in the urine controls
and EPSu, which was higher than the EPSd and EPSev, indicating that the
sulfated N-glycans in EPSu may be originating from urine glycoproteins.
A comprehensive MS analysis of the N-glycans present in adult and
pediatric urine samples has been published 112. In this study, PNGase F released
N-glycans were isolated, labeled with aminobenzoic acid, and methylamidated
prior to analysis by LC-MS/MS. The authors reported 116 N-glycan compositions
could be detected, and a subset of 46 N-glycans that were reproducibly detected
and further quantified 112. This study provides an optimal benchmark for our
current study to evaluate how many of the 46 N-glycans could be detected by our
solid-phase and single day MALDI MS workflow. Comparing the MALDI data
from the male and female urine standards, the majority of N-glycans are
detected, especially the biantennary, high mannose and fucosylated species.
The MALDI-based assay is not as effective for detection of larger tri- and tetrasialylated N-glycans, and for N-glycans with molecular masses above 3700 m/z.
One observation noted from our data was that the intensity levels of Nglycans detected were variable, even when protein concentrations were
comparable. There was also not a large variation in the types of N-glycan
structures detected in the samples, especially for the most abundant species.
These variations could reflect significantly different protein levels of individual
glycoprotein species, or variations in the amount of the most abundant protein in
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human urine, uromodulin. Uromodulin, also called Tamm−Horsfall protein, has
eight N-glycosylation sites and has been comprehensively studied for Nglycosylation content and composition 113. Interestingly in this study, N-glycan
analysis comparisons of a uromodulin depleted urine versus non-depleted
sample indicated little difference in the N-glycan compositions detected in both
samples 113. Our study only represents a few sample numbers, so no
conclusions can be reached until statistically relevant sample numbers are
analyzed. The rapidity and efficiency of the slide based MALDI assay will
facilitate evaluation of larger cohorts. Possibly pairing the N-glycan data with the
quantitative MRM proteomic assay developed for EPSu proteins could address
both the changes in N-glycan levels and protein concentrations in the same
sample 259,260. It also does not preclude direct targeting of specific glycoproteins
present for N-glycan content analysis, as is done so often for PSA. We have
already reported a solid-phase antibody array approach to N-glycan profile
individual serum glycoproteins captured by their specific antibodies 20,248. A
similar approach targeting the abundant urine and EV glycoproteins like PSA is in
progress.
The N-glycans obtained from a representative FFPE prostate cancer
tissue were also included to illustrate the N-glycans that can be detected in the
lumen of the prostate glands, representing prostatic fluid still present during
tissue fixation. Based on hundreds of prostate cancer tissues analyzed by Nglycan IMS, to be reported separately, detection of luminal N-glycans in these
tissues is highly variable. Fluid remnants can be seen in the H&E stains, but not
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all gland lumens contain this, and can be completely absent in many tissues.
Presumably this variation reflects how much fluid was present at the time of
prostatectomy but could also reflect differences in FFPE tissue preparation and
processing. While this is a variable that may lack clinical diagnostic significance,
the selected tissue in Figure 23 highlights the tumor-associated and secreted Nglycans (n=38) in tissue that can potentially be detected in the EPSu, EPSd and
EPSev samples. These are primarily paucimannose, high mannose and
branched multi-fucosylated N-glycans.
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Chapter 5: Classifying Suspicious Mammogram Findings by
Serum and IgG N-glycan Profiling
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This chapter was adapted from a manuscript submitted to Scientific Reports,,
September 2022. CRKB and RRD conceived the experiments. CL supervised
clinical sample collection and clinical data. CRKB conducted the experiments
with consultation with RRD, PMA, and ASM. CRKB and EGH analyzed the
results.

Integrating age, BMI, and serum N-glycans detected by MALDI imaging
mass spectrometry to classify suspicious mammogram findings as benign
lesions or breast cancer

Calvin R. K. Blaschke, Elizabeth G. Hill, Anand S. Mehta, Peggi M. Angel,
Christine Laronga, and Richard R. Drake.
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5.2 Introduction
Breast cancer has the highest incidence rate of all cancers, and is the
second leading cause of cancer deaths in US women.148 The stage of the breast
cancer at diagnosis has a large impact on the prognosis of the patient,
highlighting the need for early detection strategies.148 Accordingly, the
implementation of mammography as a screening tool has decreased breast
cancer mortality.230 While mammograms have a high cancer detection rate,
issues of overdiagnosis and false-positives continue to affect their clinical
utility.283 Due to the similar presentations of benign lesions and breast cancer in a
mammogram, abnormal interpretations are followed up with additional imaging or
a biopsy. A study of over 1.6 million mammograms found that 1.2% of
mammograms were classified as suspicious or highly suggestive of malignancy,
but after the recommended biopsy, only 71.6% of those patients had breast
cancer.171 With over 39 million mammograms performed in the US every year,
this results in over 345,000 unnecessary biopsies yearly in the US alone.172 To
improve breast cancer screening, a supplemental assay is needed to aid in the
discrimination of benign lesions and breast cancer.
While mammography is an essential tool in breast cancer screening,
issues of low specificity frequently result in unnecessary biopsies or follow-up
imaging. These false positives have significant financial costs on a national and
individual patient level, as well as a psychological cost for the patient.174,284–286 A
minimally or non-invasive biomarker for breast cancer detection is needed to
increase the specificity of breast cancer screening. Alternative imaging modalities
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have displayed improvements in cancer detection, especially for women with a
higher breast density, but suffer from increased radiation exposure, high costs
and low availability, or similar issues with false-positives for digital breast
tomosynthesis (DBT), magnetic resonance imaging (MRI), and ultrasound (US),
respectively.175,287–292 Using blood-based biomarkers for screening benefits from
cost-effective and minimally invasive collection. The currently used blood-based
biomarkers for breast cancer, such as cancer antigen (CA) 15-3, CA 27.29,
carcinoembryonic antigen (CEA), and soluble human epidermal growth factor
receptor 2 (sHER2), are primarily used for prognosis, staging, and therapy
monitoring, but have limited utility in detection.178,179,189–193,180–187 These
limitations prompt an investigation into other blood-based biomarkers that can
detect differences in the systemic response to breast cancer and benign lesions.
Serum is a rich source of potential biomarkers because of the variety of
molecules circulating in the body with altered abundance, activation, and/or
composition due to the effects of a disease. Serum biomarkers can be readily
adapted into clinical assays because non-invasive collection is cost-effective and
large cohorts are available for thorough and accurate analysis of diagnostic
potential. The composition of serum collected during blood draws reflects a
dynamic biofluid comprised of thousands of proteins, lipids, metabolites, and
nucleic acids. A large portion of serum consists of glycosylated proteins
produced by the liver and immunoglobulins secreted by B-cells.72 Glycosylation is
a highly regulated metabolic process shown to have essential roles in protein
folding, molecular trafficking, protein clearance, and many other
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processes.242,243,293–295 Being closely aligned with function, altered glycoforms of
serum proteins can be dynamic indicators of systemic responses to disease and
have been interrogated for potential clinical applications for decades.75–77
The creation and optimization of high-throughput techniques for the
profiling of serum N-glycans, i.e. a class of glycans linked to a protein via an
asparagine residue, has enabled the interrogation of large sample cohorts for
robust detection of N-glycan alterations associated with diseases and
conditions.91,93 Recently, our group has adapted matrix-assisted laser
desorption/ionization (MALDI) imaging mass spectrometry techniques for
analysis of serum, urine, prostatic fluids, cultured cells, and antibody-captured
serum proteins.18–20,279,296,297 Here, we utilized a high-throughput MALDI imaging
mass spectrometry technique279 to identify significant differences in the serum Nglycan profiles of 199 women with benign lesions from 99 women with breast
cancer. The relative intensity of individual N-glycans and N-glycan classes were
compared and evaluated for the ability to discriminate between benign and
cancerous conditions, with and without stratification by age and BMI.

5.3 Methods
5.3.1 Serum Samples
Donors were women who reported to the breast surgical clinic at the
Moffitt Cancer Center & Research Institute for a breast biopsy after a Breast
Imaging Reporting and Data System (BI-RADS) 4 imaging designation. The
samples were collected after H. Lee Moffitt Cancer Center & Research Institute
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institutional review board approval and informed consent from the donors. All
experiments were performed in accordance with this protocol following the
approved, relevant guidelines and regulations. Serum samples were collected
immediately prior to tissue biopsy and deidentified. Age, body mass index (BMI),
ethnicity/race, and pathology results of benign lesions (fibroadenomas,
fibrocystic, etc.) and breast cancers (invasive or ductal carcinoma in situ (DCIS))
were linked with each specimen. Patients with both an invasive breast cancer
and DCIS were treated as invasive. Patients self-identified their ethnicity, and
patients identifying as non-Hispanic were asked to self-identify race. The benign
samples (n=199) and breast cancer samples (n=99) were stratified by age
groups according to the current United States Preventative Services Task Force
mammogram recommendations (younger than 40, 40 - 49, 50 - 74, older than
74) and the established BMI classifications (less than 18.5,18.5 - 24.9, 25 to
29.9, more than 29.9).298 The clinical characteristics of the samples analyzed in
this study are summarized in Table 3.
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Ethnicity / Race

BMI

Age

Pathology

Benign
(n=199)

Cancer
(n=99)

Caucasian

151

85

Hispanic

38

10

African American

8

1

Asian

2

3

Mean ± SD

28.3 ± 5.9

28.7 ± 6.19

< 18.5

1

2

18.5 - 24.9

68

21

25 - 29.9

60

42

> 30

70

34

Mean ± SD

56.7 ± 11.3

57.3 ± 11.9

< 40

14

7

40 - 49

35

17

50 - 74

140

68

> 74

10

7

DCIS

-

30

Invasive

-

69

Table 3. Clinical characteristics of patients by diagnosis. BMI = Body Mass Index.
SD = Standard Deviation. DCIS = Ductal Carcinoma In Situ.

5.3.2 Materials
Trifluoroacetic acid (TFA), sodium bicarbonate, and α-cyano-4hydroxycinnamic acid (CHCA), octyl-β-D-glycopyranoside (OGP), bovine serum
albumin (BSA) were purchased from Sigma-Aldrich (St. Louis, MO). Ethanol was
purchased from Decon Labs (King of Prussia, PA). Acetonitrile, phosphate
buffered saline, HPLC grade water, citraconic anhydride, xylene, methanol,
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glacial acetic acid, and chloroform were purchased from Fisher Scientific
(Hampton, NH). The amine-reactive slides (Nexterion® Slide H) were purchased
from Applied Microarray (Tempe, AZ). The attachable well chambers (ProPlate
Multi-Array Slide System, 64-well) were purchased from Grace Bio-Laboratories
(Bend, OR). Peptide-N-glycosidase F (PNGase F Prime) was purchased from NZyme Scientifics (Doylestown, PA). Antihuman IgG was obtained from Bethyl
Laboratories (Montgomery, TX).

5.3.3 Serum Sample Preparation
Serum sample preparation was performed as previously described.279
Serum samples were diluted in sodium bicarbonate and spotted onto an aminereactive slide. Each slide had spot of PBS diluted in sodium bicarbonate added
as a blank. Additionally, a standard healthy serum sample was added to each
slide for normalization across slides. All samples and standards were spotted in
technical triplicate. The slide was then placed into a humidity chamber for 1 hour
to bind the serum proteins to the slide. Well chambers were attached to the slide
to isolate each sample, and the samples were washed with Carnoy’s solution and
water to remove lipids and salts, respectively. After drying the slides, PNGase F
was sprayed across the slide with an automated sprayer (M5 TM-Sprayer, HTX
Technologies, Chapel Hill, NC) and incubated in a humidity chamber at 37°C for
2 hours to enzymatically cleave the N-glycans from the captured serum
glycoproteins. The HTX M5 sprayer was then used to spray CHCA matrix across
the slide.
130

5.3.4 IgG Sample Preparation
The IgG N-glycan analysis of the samples in this cohort was based on the
protocol described previously.20 Antihuman IgG antibody was spotted onto an
amine-reactive slide in 0.75 uL spots of 150 ng/nL antibody in PBS. The antibody
spots were immobilized to the slide after a 1-hour incubation in a humidity
chamber. The slide was dried in a desiccator for 15 minutes, a 24-well chamber
module was attached to the slide, and the slide was washed with a 0.1% OGP in
PBS solution for 1 minute. To block the rest of the slide, a 2% BSA/0.1% OGP in
PBS solution was added to each well, and the slide was gently shaken for 1 hour.
After the blocking, the wells were washed with two 2-minute washes of PBS and
a 1-minute water wash. After desiccating the slide for 30 minutes, 1 uL of serum
was diluted in 99 uL of PBS, and the diluted samples were added to the wells.
For each slide, 3 antibody spots had a blank of only PBS added to the well. The
slide was placed in a humidity chamber with gentle shaking for 2 hours to allow
for antibody capture of the IgG in the serum samples. The wells were washed
twice with 0.1% OGP in PBS for 1 minute, twice with PBS for 3 minutes, and
twice with water for 1 minute. After the final washes, the slides were desiccated
until dry, detached from the well modules, and sprayed with PNGase F and
CHCA using the HTX M5 sprayer in the same fashion as previously described for
the serum sample preparation. An overview of this workflow is shown in Figure
25.
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Figure 25. IgG analysis workflow overview.

5.3.5 Mass Spectrometry Data Collection
The slides were imaged with a timsTOF fleX MALDI-QTOF mass
spectrometer (Bruker, Billerica, MA) with a SmartBeam 3D laser operating at
10,000 Hz and 20 µm laser spot size. There were 300 laser shots collected per
pixel, and a 150 µm raster was used. A 700-4000 m/z range was scanned in
positive ion mode.
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5.3.6 Data Processing
The mass spectra were imported into SCiLS Lab software (2022b Pro,
Bruker, Billerica, MA). Total ion current was used to normalize the images. Nglycan peaks were selected manually using theoretical mass values. Putative
structures were assigned to N-glycan peaks based on previously reported
assignments.98,280,299 N-glycans are reported as m/z values and using the Oxford
nomenclature for the putative structures, where A represents the number of
antennae present, F indicates the fucose, B indicates the presence of a bisecting
N-acetylglucosamine, G represents galactoses, and S denotes sialic acids.300 Nglycan compositions and mass error are reported in Table 4. Maximum peak
values were extracted and used for N-glycan absolute intensities. For each slide,
the intensity of the blank sample (only sodium bicarbonate solution for serum
sample analysis, the antibody spots with no serum added for the IgG sample
analysis) was subtracted from the N-glycan intensity across the samples. Nglycans with less than 2 arbitrary units (au) of intensity after blank subtraction
were converted to 1 au to avoid 0 values for the statistical analysis. If a N-glycan
was less than 2 au for more than 20% of samples, it was excluded from further
analysis. Next, the standard sample was used to create normalization factors for
each N-glycan on each slide, where the intensity of the individual slide’s standard
was divided by the average intensity of the standards across all slides. Each
slide’s N-glycans were then multiplied by the corresponding normalization factor.
The intensities were then converted to relative intensities by dividing individual Nglycan intensities by the summed intensities of all the N-glycans in that sample.
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N-glycan class intensities were calculated by summing the relative intensities of
the N-glycans containing the structural or compositional traits of the N-glycan
class.

5.3.7 Statistics
Linear regression was used to model log-transformed N-glycan relative
intensities as a function of disease status, controlling for age, ethnicity/race, and
BMI. Logarithmic transformation was used to induce approximate normality and
stabilize variance. Differences in log-relative intensities across disease status
levels were evaluated using model-based contrasts. A 5% false-discovery rate
was used to adjust for test multiplicity.301,302 A similar modeling approach was
used to evaluate the association between N-glycan intensities and age or BMI.
Loess smoothing was used for graphical exploration of the functional relationship
prior to modeling.303 The performance of N-glycans to classify disease status was
evaluated using the area under the receiver operating characteristic curve
(AUROC) of a logistic regression model of the patient pathology as a function of
the selected N-glycans, N-glycan classes, and clinical characteristics. AUROCs
are reported with 95% confidence intervals. Optimal sensitivity and specificity
were defined as the sensitivity and specificity of the threshold at the cutoff point
of the curve closest to (0,1). All statistical analyses were performed using R
version 4.1.0.

134

5.4 Results
Serum N-glycan profiles of women with either a benign lesion or breast
cancer detected after a mammogram were determined by MALDI imaging mass
spectrometry of enzymatically cleaved N-glycans from serum glycoproteins
captured and washed on an amine-reactive slide as previously described (Figure
26).279 After data processing and application of data quality criteria, 55 N-glycans
were detected across the samples with an average coefficient of variation (CV) of
7.9% across the technical triplicates (Table 4). The clinical descriptions of the
patients included ethnicity/race, age, and BMI, and had no significant differences
between the benign and cancerous samples (Table 3).

Figure 26. Sample collection, processing, and analysis overview.
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Theoretical
m/z

Observed
m/z

Error
(ppm)

Composition

1136.3964

1136.3994

2.64

Hex3HexNAc3 + Na1

A1

Theoretical
m/z

Observed
m/z

Error
(ppm)

Composition

Oxford
Nomenclature

Glycosylation Traits

2157.7562

2157.7901

15.71

Hex5HexNAc5NeuAc1 + Na1

A2BG2S1

Sialylated, Bisected

1257.4226

1257.4235

0.72

Hex5HexNAc2 + Na1

M5

High Mannose

2163.7432

2163.7430

0.09

Hex4dHex1HexNAc5NeuAc1 + Na2

A2BF1G1S1

Fucosylated, Sialylated,
Bisected

1282.4543

1282.4532

0.86

Hex3dHex1HexNAc3 + Na1

A1F1

1298.4492

1298.4546

4.16

Hex4HexNAc3 + Na1

A1G1

Fucosylated

2174.7715

2174.7737

1.01

Hex6dHex1HexNAc5 + Na1

A3F1G3

Fucosylated, Triantennary

2179.7382

2179.7378

0.18

Hex5HexNAc5NeuAc1 + Na2

A2BG2S1

1339.4757

1339.4777

1.49

Hex3HexNAc4 + Na1

A2

Sialylated, Bisected

Biantennary

2267.7542

2267.7533

0.38

Hex5HexNAc4NeuAc2 + Na2

A2G2S2

Sialylated, Biantennary

1419.4755

1419.4788

2.32

Hex6HexNAc2 + Na1

M6

High Mannose

2287.8192

2287.7695

21.72

Hex4dHex2HexNAc5NeuAc1 + Na1

A2BF2G1S1

Fucosylated, Sialylated,
Bisected

1444.5071

1444.5094

1.59

Hex4dHex1HexNAc3 + Na1

1485.5336

1485.5347

0.74

Hex3dHex1HexNAc4 + Na1

A1G1F1

Fucosylated

2289.7361

2289.7430

3.01

Hex5HexNAc4NeuAc2 + Na3

A2G2S2

Sialylated, Biantennary

A2F1

Fucosylated, Biantennary

2303.8141

2303.8222

3.52

Hex5dHex1HexNAc5NeuAc1 + Na1

A2BF1G2S1

Fucosylated, Sialylated,
Bisected

1501.5286

1501.5302

1.07

1611.5266

1611.5230

2.23

Hex4HexNAc4 + Na1

A2G1

Biantennary

2319.8090

2319.8084

0.26

Hex6HexNAc5NeuAc1 + Na1

A3G3S1

Sialylated, Triantennary

Hex4HexNAc3NeuAc1 + Na2

A1G1S1

Sialylated

2325.7961

2325.8012

2.19

Hex5dHex1HexNAc5NeuAc1 + Na2

A2BF1G2S1

Fucosylated, Sialylated,
Bisected

1622.5548

1622.5512

2.22

Hex6HexNAc3 + Na1

1647.5865

1647.5918

3.22

Hex4dHex1HexNAc4 + Na1

M5A1G1

Hybrid

2341.7910

2341.7993

3.54

Hex6HexNAc5NeuAc1 + Na2

A3G3S1

Sialylated, Triantennary

A2G1F1

Fucosylated, Biantennary

2377.8509

2377.8568

2.48

Hex6dHex1HexNAc6 + Na1

A4F1G3

Fucosylated,
Tetraantennary

1663.5814

1663.5847

1.98

Hex5HexNAc4 + Na1

1688.6130

1688.6168

2.25

Hex3dHex1HexNAc5 + Na1

A2G2

Biantennary

2393.8458

2393.8539

3.38

Hex7HexNAc6 + Na1

A4G4

Tetraantennary

A2BF1

Fucosylated, Bisected

2413.8121

2413.8176

2.28

Hex5dHex1HexNAc4NeuAc2 + Na2

A2F1G2S2

Fucosylated, Sialylated,
Biantennary

1757.5845

1757.5832

0.74

Hex4dHex1HexNAc3NeuAc1 + Na2

A1F1G1S1

Fucosylated, Sialylated

2435.7940

2435.7983

1.77

Hex5dHex1HexNAc4NeuAc2 + Na3

A2F1G2S2

Fucosylated, Sialylated,
Biantennary

1809.6393

1809.6432

2.16

Hex5dHex1HexNAc4 + Na1

A2F1G2

Fucosylated, Biantennary

2471.8540

2471.8567

1.09

Hex5dHex2HexNAc5NeuAc1 + Na2

A2BF2G2S1

Fucosylated, Sialylated,
Bisected

1850.6659

1850.6736

4.16

Hex4dHex1HexNAc5 + Na1

A2BF1G1

Fucosylated, Bisected

2487.8489

2487.8517

1.13

Hex6dHex1HexNAc5NeuAc1 + Na2

A3F1G3S1

Fucosylated, Sialylated,
Triantennary

1866.6608

1866.6673

3.48

Hex5HexNAc5 + Na1

A2BG2

Bisected

2522.8884

2522.9265

15.10

1935.6322

1935.6335

0.67

Hex6HexNAc3NeuAc1 + Na2

M5A1G1S1

Hybrid, Sialylated

2537.8880

2537.8431

17.69

Hex6HexNAc6NeuAc1 + Na1

A4G3S1

Sialylated, Tetraantennary

Hex5dHex2HexNAc4NeuAc2 + Na1

A2F2G2S2

1938.6819

1938.6845

1.34

Hex4dHex1HexNAc4NeuAc1 + Na1

A2F1G1S1

Fucosylated, Sialylated,
Biantennary

2539.9037

2539.9123

3.39

Hex7dHex1HexNAc6 + Na1

A4F1G4

Fucosylated, Sialylated,
Biantennary
Fucosylated,
Tetraantennary

1954.6768

1954.6764

0.20

Hex5HexNAc4NeuAc1 + Na1

A2G2S1

Sialylated, Biantennary

2616.8915

2616.8977

2.37

Hex5dHex1HexNAc5NeuAc2 + Na2

A2BF1G2S2

Fucosylated, Sialylated,
Bisected

1955.6972

1955.6833

7.11

Hex5dHex2HexNAc4 + Na1

A2F2G2

Fucosylated, Biantennary

2632.8864

2632.8964

3.80

Hex6HexNAc5NeuAc2 + Na2

A3G2S2

Sialylated, Triantennary

Putative
Structure

Oxford
Nomenclature

Glycosylation Traits

Putative
Structure

1960.6638

1960.6690

2.65

Hex4dHex1HexNAc4NeuAc1 + Na2

A2F1G1S1

Fucosylated, Sialylated,
Biantennary

2638.8734

2638.8798

2.43

Hex5dHex1HexNAc5NeuAc2 + Na3

A2BF1G2S2

Fucosylated, Sialylated,
Bisected

1976.6588

1976.6622

1.72

Hex5HexNAc4NeuAc1 + Na2

A2G2S1

Sialylated, Biantennary

2668.9463

2668.9884

15.77

Hex6dHex1HexNAc6NeuAc1 + Na1

A4F1G3S1

Fucosylated, Sialylated,
Tetraantennary

2012.7187

2012.7252

3.23

Hex5dHex1HexNAc5 + Na1

A2BF1G2

Fucosylated, Bisected

2778.9443

2778.9537

3.38

Hex6dHex1HexNAc5NeuAc2 + Na2

A3F1G3S2

Fucosylated, Sialylated,
Triantennary

2028.7136

2028.7191

2.71

Hex6HexNAc5 + Na1

A3G3

Triantennary

2800.9263

2800.9384

4.32

Hex6dHex1HexNAc5NeuAc2 + Na3

A3F1G3S2

Fucosylated, Sialylated,
Triantennary

A2F1G2S1

Fucosylated, Sialylated,
Biantennary

3114.0037

3114.0199

5.20

Hex6dHex1HexNAc5NeuAc3 + Na4

A3F1G3S3

Fucosylated, Sialylated,
Triantennary

A2F1G2S1

Fucosylated, Sialylated,
Biantennary

2100.7347

2122.7167

2100.7399

2122.7228

2.48

2.87

Hex5dHex1HexNAc4NeuAc1 + Na1

Hex5dHex1HexNAc4NeuAc1 + Na2

Table 4. N-glycans observed in serum samples of patients.

As the clinical characteristics and prognosis of DCIS and invasive breast
cancer vary greatly, initial analysis was focused on detecting differences between
benign, DCIS, and invasive breast cancer. No differences were detected
between the N-glycan classes, with the majority of the N-glycan profile intensity
being attributed to biantennary, fucosylated, and/or sialylated N-glycans (Fig. 27).
As no differences in the overall N-glycan structural class profiles were detected,
individual N-glycan intensities were investigated.
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Figure 27. N-glycan class intensities of serum samples with benign lesions,
DCIS, and invasive breast cancer. (A) High, (B) medium, and (C) low intensity
serum N-glycan classes of benign, DCIS, and invasive samples. Data was
analyzed by linear regression modeling of log-transformed relative intensities
controlled for age, ethnicity/race, and BMI to identify differences across disease
status. Using a 5% false-discovery rate, no significant associations were found.
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There were two N-glycans (2179.738 m/z (A2BG2S1) and 2413.812 m/z
(A2G2F1S2)) with significantly different intensities in the benign and DCIS serum
samples (Figure 28, Table 5). The 2179.738 m/z N-glycan has a bisected and
sialylated structure and had a lower intensity in the DCIS samples. The 2413.812
m/z N-glycan has a fucosylated and multiply sialylated biantennary structure, and
had a higher intensity in the DCIS samples (Figure 28 a,b). Based on a logistic
model using the intensities of these two N-glycans, age, ethnicity/race, and BMI,
an AUROC of 0.732 (0.644 - 0.819) was found for the discrimination of benign
and DCIS samples (Figure 28 c). Using the same variables, an AUROC of 0.613
(0.538 - 0.688) was found for the discrimination of benign and invasive samples
(Figure 28 c). For the evaluation of the entire set based on clinical designation,
there were no N-glycan classes or individual N-glycans with differences between
the benign and invasive or benign and all cancerous samples.

m/z

Composition

Putative Structure

Oxford Nomenclature Intensity in In Situ Fold Change

2179.7382

Hex5HexNAc5NeuAc1 + Na2

A2BG2S1

Lower

0.826

2413.8121

Hex5dHex1HexNAc4NeuAc2 + Na2

A2G2F1S2

Higher

1.201

Table 5. Serum N-glycans with significant differences between benign and DCIS
patients.
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Figure 28. Serum N-glycan differences between benign, DCIS, and invasive
samples. Log-transformed relative intensity values of the (A) 2179.738 m/z and
(B) 2413.812 m/z N-glycans had significant differences in benign and DCIS
samples using a 5% false discovery rate. (C) Using the log-transformed relative
intensities of these N-glycans, age, BMI, and ethnicity/race, benign and DCIS
samples could be distinguished with an AUROC of 0.732, and benign and
invasive samples could be distinguished with an AUROC of 0.613.
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Additional analysis identified significant relationships between N-glycan
intensities and patient age or BMI. There were 24 N-glycans associated with age,
as well as the triantennary, tetraantennary, and fucosylation N-glycan classes
(Table 6). Additionally, there were 12 N-glycans associated with BMI, as well as
the biantennary, triantennary, and tetraantennary N-glycan classes (Table 7).
While some of these associations were present in both benign and cancerous
samples (Figure 29 a,c), others were only present in benign samples or
displayed differences between the samples at certain ranges (Figure 29 b,d).
These findings prompted an in-depth analysis of the samples stratified by age
and BMI.

m/z

Composition

Intensity Change as
Age Increases

m/z

Composition

1136.3964

Hex3HexNAc3 + Na1

A1

Increases

2122.7167

Hex5dHex1HexNAc4NeuAc1 + Na2

A2F1G2S1

Decreases

1339.4757

Hex3HexNAc4 + Na1

A2

Increases

2163.7432

Hex4dHex1HexNAc5NeuAc1 + Na2

A2BF1G1S1

Increases

1444.5071

Hex4dHex1HexNAc3 + Na1

A1G1F1

Decreases

2267.7542

Hex5HexNAc4NeuAc2 + Na2

A2G2S2

Increases

1485.5336

Hex3dHex1HexNAc4 + Na1

A2F1

Increases

2319.8090

Hex6HexNAc5NeuAc1 + Na1

A3G3S1

Increases

1501.5286

Hex4HexNAc4 + Na1

A2G1

Increases

2341.7910

Hex6HexNAc5NeuAc1 + Na2

A3G3S1

Increases

1647.5865

Hex4dHex1HexNAc4 + Na1

A2G1F1

Decreases

2377.8509

Hex6dHex1HexNAc6 + Na1

A4F1G3

Increases

1688.6130

Hex3dHex1HexNAc5 + Na1

A2BF1

Increases

2471.8540

Hex5dHex2HexNAc5NeuAc1 + Na2

A2BF2G2S1

Decreases

1757.5845

Hex4dHex1HexNAc3NeuAc1 + Na2

A1F1G1S1

Decreases

2522.8884

Hex6HexNAc6NeuAc1 + Na1

A4G3S1

Increases

1809.6393

Hex5dHex1HexNAc4 + Na1

A2F1G2

Decreases

2539.9037

Hex7dHex1HexNAc6 + Na1

A4F1G4

Increases

1850.6659

Hex4dHex1HexNAc5 + Na1

A2BF1G1

Increases

2632.8864

Hex6HexNAc5NeuAc2 + Na2

A3G2S2

Increases

Putative Structure Oxford Nomenclature

Putative Structure Oxford Nomenclature

Intensity Change as
Age Increases

1866.6608

Hex5HexNAc5 + Na1

A2BG2

Increases

Fucosylation

-

-

-

Decreases

1955.6972

Hex5dHex2HexNAc4 + Na1

A2F2G2

Increases

Triantennary

-

-

-

Increases

2012.7187

Hex5dHex1HexNAc5 + Na1

A2BF1G2

Decreases

Tetraantennary

-

-

-

Increases

2100.7347

Hex5dHex1HexNAc4NeuAc1 + Na1

A2F1G2S1

Decreases

Table 6. Serum N-glycans with significant associations with age.
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m/z

Composition

Putative Structure Oxford Nomenclature

Intensity Change as
BMI Increases

m/z

Composition

Putative Structure Oxford Nomenclature

Intensity Change as
BMI Increases

1501.5286

Hex4HexNAc4 + Na1

A2G1

Increases

2668.9463

Hex6dHex1HexNAc5NeuAc1 + Na2

A3F1G3S1

Increases

1809.6393

Hex5dHex1HexNAc4 + Na1

A2F1G2

Decreases

2778.9443

Hex6dHex1HexNAc6NeuAc1 + Na1

A4F1G3S1

Increases

2163.7432

Hex4dHex1HexNAc5NeuAc1 + Na2

A2BF1G1S1

Increases

2800.9263

Hex6dHex1HexNAc5NeuAc2 + Na2

A3F1G3S2

Increases

2303.8141

Hex4dHex1HexNAc5NeuAc1 + Na2

A2BF1G1S1

Increases

3114.0037

Hex6dHex1HexNAc5NeuAc2 + Na3

A3F1G3S2

Increases

2413.8121

Hex7HexNAc6 + Na1

A4G4

Increases

Biantennary

Hex6dHex1HexNAc5NeuAc3 + Na4

A3F1G3S3

Decreases

2435.7940

Hex5dHex1HexNAc4NeuAc2 + Na2

A2F1G2S2

Increases

Triantennary

-

-

-

Increases

2487.8489

Hex5dHex1HexNAc4NeuAc2 + Na3

A2F1G2S2

Increases

Tetraantennary

-

-

-

Increases

Table 7. Serum N-glycans with significant associations with BMI.

Figure 29. Correlation of serum N-glycan intensities with the patient age and
BMI. The patient BMI and the intensities of (A) 1501.529 m/z and (B) 2778.944
m/z N-glycans. The patient age and the intensities of both (C) 1809.639 m/z and
(D) 1688.613 m/z N-glycans were significantly associated.
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The samples were separated by age (less than 40, 40 - 49, 50 - 74, and
older than 74) and/or by BMI (less than 18.5, 18.5 - 24.9, 25 - 30, and more than
30). There were no significant findings between the benign and cancerous
samples in any individual or combination of these groups, except for the patients
that were 50 - 74 years old and within 18.5 - 24.9 BMI. These samples had
significant differences in intensity between benign (n = 45) and cancerous
samples (n = 11) for two N-glycans with, 1850.666 m/z (A2BG1F1) and 2163.743
m/z (A2BG1F1S1), and the bisecting N-glycan class (Figure 30 a-c, Table 8).
Based on a logistic model using the intensities of 1850.666 m/z and 2163.743
m/z, age, and BMI an AUROC of 0.899 (0.801 - 0.997) found for the
discrimination of benign and cancerous samples with an 82% sensitivity and 84%
specificity (Figure 30 d).

m/z

Composition

1850.6659

Hex4dHex1HexNAc5 + Na1

2163.7432

Hex4dHex1HexNAc5NeuAc1 + Na2

Bisecting

-

Intensity in
Cancer

Fold Change

A2BG1F1

Lower

0.726

A2BG1F1S1

Lower

0.733

-

Lower

0.772

Putative Structure Oxford Nomenclature

-

Table 8. Serum N-glycans with significant differences between benign and
cancer patients of age 50 - 74 and BMI 18.5 - 24.9.
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Figure 30. Serum N-glycan differences between benign and cancer samples
from patients aged 50 – 74 and with a BMI of 18.5 – 24.9. Log-transformed
relative intensity values of the (A) 1850.666 m/z and (B) 2163.743 m/z N-glycans
and (C) bisecting N-glycan class had significant differences in benign and cancer
samples using a 5% false discovery rate. (D) Using the log-transformed relative
intensities of the two individual N-glycans, age, and BMI, benign and cancer
samples were classified using the AUROC of the logistic regression model.
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For the IgG analysis of the samples, 34 N-glycans were reliably and
consistently detected across all the samples (Table 9). Across all samples, the
overall IgG N-glycan profile was mostly composed of biantennary and
fucosylated N-glycans (Figure 31). High mannose, hybrid, and triantennary Nglycans compromised less than 1% of the IgG N-glycan profile across the
benign, DCIS, and invasive samples. There were no significant differences
detected in the individual N-glycans or N-glycan classes between the benign
samples and the DCIS or invasive samples, individually or combined. The
samples were stratified into the same groups by BMI and age as described for
the serum sample analysis, and there were no statistically significant differences
in these groups either.

Theoretical
m/z

Observed
m/z

Error
(ppm)

Composition

1136.3964

1136.3989

2.20

Hex3HexNAc3 + Na1

Putative
Structure

Oxford
Nomenclature

Theoretical
m/z

Observed
m/z

Error
(ppm)

Composition

Oxford
Nomenclature

Glycosylation Traits

1809.6393

1809.6387

0.33

Hex5dHex1HexNAc4 + Na1

A2F1G2

Fucosylated, Biantennary

1257.4226

1257.4287

4.85

Hex5HexNAc2 + Na1

M5

1282.4543

1282.4584

3.20

Hex3dHex1HexNAc3 + Na1

A1F1

High Mannose

1850.6659

1850.6689

1.62

Hex4dHex1HexNAc5 + Na1

A2BF1G1

Fucosylated, Bisected

Fucosylated

1866.6608

1866.6625

0.91

Hex5HexNAc5 + Na1

A2BG2

1298.4492

1298.4533

3.16

Hex4HexNAc3 + Na1

A1G1

Bisected

1954.6768

1954.6807

2.00

Hex5HexNAc4NeuAc1 + Na1

A2G2S1

Sialylated, Biantennary

1339.4757

1339.4762

0.37

Hex3HexNAc4 + Na1

A2

1419.4755

1419.4768

0.92

Hex6HexNAc2 + Na1

M6

Biantennary

1960.6638

1960.6712

3.77

Hex4dHex1HexNAc4NeuAc1 + Na2

A2F1G1S1

Fucosylated, Sialylated,
Biantennary

High Mannose

1976.6588

1976.6608

1.01

Hex5HexNAc4NeuAc1 + Na2

A2G2S1

Sialylated, Biantennary

1444.5071

1444.5073

0.14

Hex4dHex1HexNAc3 + Na1

A1G1F1

Fucosylated

2012.7187

2012.7194

0.35

Hex5dHex1HexNAc5 + Na1

A2BF1G2

Fucosylated, Bisected

1460.5020

1460.5064

3.01

Hex5HexNAc3 + Na1

M4A1G1

Hybrid

2100.7347

2100.7453

5.05

Hex5dHex1HexNAc4NeuAc1 + Na1

A2F1G2S1

Fucosylated, Sialylated,
Biantennary

1485.5336

1485.5397

4.11

Hex3dHex1HexNAc4 + Na1

A2F1

Fucosylated, Biantennary

2122.7167

2122.7268

4.76

Hex5dHex1HexNAc4NeuAc1 + Na2

A2F1G2S1

Fucosylated, Sialylated,
Biantennary

1501.5286

1501.5278

0.53

Hex4HexNAc4 + Na1

A2G1

Biantennary

2157.7562

2157.7725

7.55

Hex5HexNAc5NeuAc1 + Na1

A2BG2S1

Sialylated, Bisected

1542.5551

1542.5594

2.79

Hex3HexNAc5 + Na1

A2B

Bisect

2163.7432

2163.7686

11.74

Hex4dHex1HexNAc5NeuAc1 + Na2

A2BF1G1S1

Fucosylated, Sialylated,
Bisected

1581.5283

1581.5302

1.20

Hex7HexNAc2 + Na1

M7

High Mannose

2174.7715

2174.7895

8.28

Hex6dHex1HexNAc5 + Na1

A3F1G3

Fucosylated, Triantennary

1622.5548

1622.5561

0.80

Hex6HexNAc3 + Na1

M5A1G1

Hybrid

2179.7382

2179.7612

10.55

Hex5HexNAc5NeuAc1 + Na2

A2BG2S1

Sialylated, Bisected

1647.5865

1647.5885

1.21

Hex4dHex1HexNAc4 + Na1

A2G1F1

Fucosylated, Biantennary

2303.8141

2303.8216

3.26

Hex5dHex1HexNAc5NeuAc1 + Na1

A2BF1G2S1

Fucosylated, Sialylated,
Bisected

1663.5814

1663.5812

0.12

Hex5HexNAc4 + Na1

A2G2

Biantennary

2319.8090

2319.8177

3.75

Hex6HexNAc5NeuAc1 + Na1

A3G3S1

Sialylated, Triantennary

1688.6130

1688.6131

0.06

Hex3dHex1HexNAc5 + Na1

A2BF1

Fucosylated, Bisected

2325.7961

2325.8098

5.89

Hex5dHex1HexNAc5NeuAc1 + Na2

A2BF1G2S1

Fucosylated, Sialylated,
Bisected

1704.6080

1704.6120

2.35

Hex4HexNAc5 + Na1

A2BG1

Bisect

2341.7910

2341.8061

6.45

Hex6HexNAc5NeuAc1 + Na2

A3G3S1

Sialylated, Triantennary

Glycosylation Traits

A1

Putative
Structure

Table 9. N-glycans observed in IgG from serum samples of patients.
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Figure 31. N-glycan class intensities of IgG from serum samples with benign
lesions, DCIS, and invasive breast cancer. (A) High and (B) low intensity serum
N-glycan classes of benign, DCIS, and invasive samples. Data was analyzed by
linear regression modeling of log-transformed relative intensities controlled for
age, ethnicity/race, and BMI to identify differences across disease status. Using a
5% false-discovery rate, no significant associations were found.

5.5 Discussion
In this study, the serum and IgG N-glycan profiles of patients with an
abnormality detected by a mammogram were compared to evaluate their ability
to distinguish benign lesions from breast cancer. The samples were processed
using recently developed high-throughput MALDI imaging mass spectrometry
workflows.20,279 When analyzing the serum N-glycan profiles of all the samples,
two N-glycans had significant differences in the benign and DCIS samples.
Incorporating the intensities of these N-glycans with age, ethnicity/race, and BMI
had moderate diagnostic potential for DCIS samples but not invasive samples.
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There were many N-glycan intensities that had altered associations with age or
BMI, depending on the diagnosis of the patient. Stratifying the samples by age
and BMI identified two N-glycans and two N-glycan classes with significant
intensity differences in the benign and cancerous samples of patients aged 50 74 with a BMI of 18.5 - 24.9, and when combined with age and BMI had high
diagnostic ability for this patient subset.
Inflammatory stimuli due to the presence of a disease can cause an
alteration in the glycosylation of plasma cells and hepatocytes, which produce
the bulk of serum proteins.304,305 Altered serum N-glycan profiles have been
associated with a range of diseases and conditions, including ulcerative colitis,
diabetes, Crohn’s disease, gastric cancer, ovarian cancer, Alzheimer’s disease,
hepatocellular carcinoma, and multiple myeloma.96,101,104,306–310 Serum analysis
of breast cancer patients have identified N-glycan changes associated with
circulating tumor cell counts, breast cancer subtypes, prognosis, breast cancer
progression, and lymph node metastasis.206,207,210,217,219,229 While several studies
have investigated breast cancer detection by serum N-glycan analysis, they have
either had healthy women donors as controls, used methods unable to identify
individual N-glycans, or only analyzed certain types of N-glycans.102,206,216,218,220
To properly address the issue of false-positives in mammograms, the samples
from patients with breast cancer need to be compared to samples from patients
with a lesion detected by a mammogram that requires a biopsy, because healthy
women with no abnormalities detected by mammogram do not suffer from the
issues of false-positives. This cohort can appropriately investigate the potential of
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serum N-glycan analysis for breast cancer detection because of the clinical
relevance of the benign samples, the controlled surgical collection site, and the
availability and incorporation of age, ethnicity/race, and BMI into the analysis.
Age and BMI have strong associations with breast cancer risk, as well as
specific alterations in the serum N-glycan profile.81–83,155,311–314 In this study, there
were 24 N-glycans with significant associations with age, and 12 N-glycans with
significant associations with BMI (Table 6 and Table 7). Age and BMI were
controlled for in the initial analysis to account for these associations and isolate
N-glycan intensity differences that were due to the presence of breast cancer.
Further investigation found that only samples within certain ranges of age and
BMI had disease-associated serum N-glycan changes (Figure 29 b,d). To identify
any disease-associated serum N-glycan intensities changes only present in a
subset of the cohort, the samples were stratified according to age and BMI. To
remain clinically relevant, the samples were grouped based on the USPSTF
mammogram recommendation for age and the BMI classifications for
underweight, healthy weight, overweight, and obese.298
The subset of samples from patients with a BMI of 18.5 - 24.9 and aged
50 - 74 could be readily distinguished as having a benign lesion or breast cancer
using the intensities of two N-glycans, age, and BMI (Figure 30 d). While this is a
subset of the population, it is makes up a significant portion of the U.S. women
that will have mammogram screening for breast cancer. For women with an
average-risk of breast cancer, the USPSTF recommends only women aged 50 74 to have biennial mammography screening and make up the bulk of women
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that will have a mammogram.298 Results from the 2017 - 2018 National Health
and Nutrition Examination Survey (NHANES) indicated that approximately one
third of U.S. adult women are within the 18.5 - 24.9 BMI range.315 The healthy
weight women may have had the best N-glycan biomarker performance due to
the lack of systemic inflammation that is present in overweight and obese
women.316 The plasma cells and hepatocytes, from which the majority of serum
glycoproteins originate, undergo significant cellular changes in presence of
inflammatory stimuli. The serum N-glycan changes found in cancer patients may
be masked, altered, or negated by the N-glycan changes due to the obesityinduced inflammatory stimuli.
There were several limitations to this study. Breast cancer is an incredibly
heterogeneous disease, that includes multiple molecular and genomic subtypes
with distinct clinical behavior and biological characteristics: luminal-A, luminal-B,
HER2-positive, and basal-like. The risk factors for breast cancer, including age,
body mass index (BMI), onset of menopause, parity, family-history, and personal
history of benign breast disease differ in effect for each molecular subtype.164 As
subtype information was not available for this cohort, there may be N-glycan
alterations only in certain subtypes that are not being detected. Additionally,
there were fewer samples from Asian or African American patients. This makes it
more difficult to account for variances due to ethnicity/race, especially after
stratifying the cohort into smaller subsets.
The inability to identify any IgG N-glycan profile alterations across the
sample groups, stratified or not, was unexpected for several reasons. Many of
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the distinctive N-glycans from the serum N-glycan analysis make up a significant
portion of the typical IgG N-glycan profile, and IgG contributes a large portion of
serum’s protein abundance.317 One possible explanation for the lack of altered
IgG N-glycans or classes could be that, as described above, the inflammatory
stimuli from other clinical factors were masking the breast cancer-associated Nglycan alterations, and/or the methodology was not robust or sensitive enough to
detect the alterations in the smaller sample subsets. The workflow used in this
study did not account for the contribution of the antibody’s N-glycans to the
samples. While hypothetically this should be equal across all samples, the small
volumes used for the antibody spotting are more susceptible to differences in
total antibody amount spotted. Future studies utilizing this IgG N-glycan analysis
workflow should test if deglycosylating the antibody spots prior to adding the
samples affects target protein capture efficiency and specificity.
Additional studies identifying IgG or other protein(s) that could have
distinctive N-glycans could increase the performance of the N-glycans as breast
cancer detection biomarkers. Recent glycoproteomic approaches have made
high-throughput analysis of complex biological fluids quicker and more
sensitive.318 Glycopeptide analysis of this cohort could identify the proteins that
contain the cancer-associated N-glycans identified in this study. Isolating lowabundant proteins shed from breast cancer cells or released from dying cancer
cells could identify N-glycan changes with a higher specificity across all age and
BMI ranges. To further investigate the fucosylated bisecting N-glycans that had a
significant association with breast cancer, the location of the fucose could be
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determined by applying Endoglycosidase F3 to the samples instead of PNGase F
to detect only core fucosylated N-glycans.279
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Chapter 6: Conclusions, Limitations, and Future Studies
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6.1 Overall Findings
As the understanding of the role of N-glycosylation in disease and immune
recognition develops, there becomes a greater need for high-throughput assays
capable of analyzing cohorts with hundreds or thousands of samples. The work
presented in this dissertation addresses this need by describing the development
and validation of a novel method for N-glycan profiling of serum and plasma
(Chapter 3), as well as urine and prostatic fluids (Chapter 4). The utility of this
biofluid N-glycan profiling was demonstrated by the identification of serum Nglycan differences between women with benign masses or breast cancer that
could aid breast cancer screening (Chapter 5). The conclusions, limitations, and
future research opportunities of each of these works are discussed in greater
detail below.

6.2 Serum and Plasma N-glycan Profiling by MALDI-IMS
6.2.1 Conclusions
The development of this novel method was based on traditional histology
and mass spectrometry imaging workflows. Current high-throughput N-glycan
profiling methods overcome the noise and ionization suppression caused by the
complex and abundant array of biomolecules present in serum and plasma using
lengthy derivatizations and clean up steps using chromatography. This method
was able to circumvent the need for these steps by using a slide-based assay.
The key step in the workflow is the binding of the serum glycoproteins to an
amine-reactive slide with a covalent bond. This allowed for the samples to be
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quickly washed to remove the lipids and salts that would reduce or completely
diminish the ionization of the enzymatically released N-glycans.
Being a slide-based assay, this method utilizes the well-established and
optimized protocols for tissue N-glycan profiling to achieve a high sensitivity and
data acquisition speed. Using an enzyme to release the N-glycans from the
serum or plasma glycoproteins provides flexibility to the method. PNGase F can
be used to analyze all N-glycans, while using Endo F3 will target only the core
fucosylated N-glycans. Endoglycosidases can be paired with exoglycosidases to
target specific N-glycan structures. Doing so with sialidase and PNGase F
increased the sensitivity and number of low abundant polylactosamine structures
detected. The simple processing, adaptability, and high-throughput of this
method will facilitate large-scale biomarker detection studies using patient serum
or plasma samples.

6.2.2 Limitations and Future Studies
The method described in this chapter achieves short processing times by
avoiding derivatizing typically needed for extracting or increasing the ionization
efficiency of the released N-glycans, but one of the other benefits of
derivatization is that a linkage-specific addition of chemical groups can be
incorporated. Due to the difference in mass of the chemical groups, this allows
for identification of N-glycan structural isomers by calculating the mass shift. The
non-MS based high-throughput serum N-glycan profiling methods can separate
isomers using either HILIC columns for UHPLC or the different migration speeds
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through the polymer-filled capillary under an electric field for xCE. With the output
of this method being the m/z and no derivatization steps included, this method
cannot identify N-glycan isomers. Future research will focus on overcoming this
by performing an amidation-amidation derivatization, as has been described and
optimized for tissue MSI N-glycan analysis, after the samples have been
covalently bound to the slide.319 The inclusion of this processing step may require
optimization of reaction components, concentrations, and lengths. An alternative
approach for gaining structural information would be to sequentially digest the Nglycans with varying glycosidases as has been done for UHPLC analysis. The
benefits of structural isomer identification would come at the cost of increased
processing times. These factors would need to be weighed when designing the
experimental approach.
In its current format, the diluting, spotting, and washing steps of this
method require hands-on time that can be laborious. While this has been partially
mitigated with the use of an electronic pipette with a multi-dispense feature for
sample spotting and a multichannel pipette for the wash steps, these steps could
be automated with a liquid handling robot. This would not only decrease the
hands-on time, but it would also increase the precision of the workflow and make
the processing even more simple than it already is. All of these factors are
important for developing a workflow that could be implemented in a clinical
setting as a diagnostic assay.
While this method has currently been used for N-glycan analysis, other
biomolecules could be targeted. This can be done by switching the enzyme that
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is applied to the samples to either chondroitinase, collagenase, or trypsin for
glycosaminoglycan and proteomic analysis. Effective manners of applying these
enzymes and analyzing their products have already been established for MALDI
analysis. These enzymes could be incorporated into a multiplexed workflow for
the analysis of biofluid samples in a manner similar to what has been established
for tissue analysis by MALDI mass spectrometry.320 Once the sample is bound to
the slide, it can be analyzed with one enzyme, the matrix can be washed away,
and then another enzyme could be used.

6.3 Urine and Prostatic Fluid N-glycan Profiling by MALDI-IMS
6.3.1 Conclusions
In chapter 2, an N-glycan profiling workflow applicable to urine and
prostatic fluids was presented. This workflow was adapted from the serum and
plasma N-glycan profiling workflow discussed in chapter 1 and only required an
additional filtering step using a molecular weight filter and a benchtop centrifuge.
Like the serum and plasma method, this method can also be used with other
enzymes besides PNGase F, like endoglycosidase F3 specific to core fucoses,249
or other glycosidases specific to other N-glycan structural classes. The method
was developed using pooled urine samples from either healthy male or healthy
female individuals. The male and female urine N-glycan profiles looked very
similar but contained a larger number of sulfated N-glycans than typically seen in
serum or plasma. Correspondingly, prostatic fluids collected directly had a much
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lower intensity of sulfated N-glycans when compared to prostatic fluids voided in
urine.
The investigation of prostatic fluids is a promising approach for biomarker
discovery studies of prostatic diseases, because of the presence of shed cells
and secreted proteins either directly from the diseased tissue or from surrounding
tissue. Interestingly, MSI analysis of N-glycans in the luminal compartments of
prostate tissue glands found a significant overlap in N-glycans detected in
prostatic fluids, confirming the validity of this approach. The sensitivity of this
method allowed for the detection of N-glycans that have large differences in
intensities. This is a promising finding as the disease-associated N-glycan
alterations may cause minor changes in the overall N-glycan profile.

6.3.2 Limitations and Future Studies
Just as the serum and plasma method was adapted, nearly each step of
this workflow can also be modified for targeted analysis of specific N-glycans,
proteins, or biofluids. The use of the concentration and solvent/buffer exchange
step in the workflow can be adapted to other biofluids with protein concentrations
similar to urine, i.e., saliva, cerebrospinal fluid, bronchial lavage. Additionally,
instead of a molecular weight filter, an affinity column could be used to extract
abundant proteins for analysis of low-abundant proteins. This could specifically
be helpful for removing albumin as it is one of the most abundant proteins in
urine and is not N-glycosylated. Alternatively, uromodulin, the most abundant
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protein in urine, could be extracted either for direct analysis of its N-glycan profile
or to allow for higher sensitivity of other lower concentration urine glycoproteins.
The filtration step can be modified to change the protein concentrations of
the samples prior to spotting. In this way, the sensitivity of the method to lowabundant N-glycans in the starting material can be increased by increasing the
amount of starting material. One of the limitations of this study is that there can
be wide variation in the protein concentration of urine samples. It is very difficult
to obtain absolute protein concentration measurements and adding this process
to the workflow would significantly add to the labor and processing time. To avoid
this, the intensities of the N-glycans are converted into relative intensities to
account for differences in protein concentrations. Future development of this
method could incorporate an internal standard in the form of a protein whose Nglycans can be distinguished by a mass shift introduced through a
methylamidation derivatization.

6.4 Classifying Suspicious Mammogram Findings by Serum and IgG Nglycan Profiling
6.4.1 Conclusions
In this chapter, a MALDI imaging mass spectrometry approach was
utilized to detect serum and IgG N-glycans and N-glycan classes that could
distinguish patients with an abnormal mammogram result as having a benign
lesion or breast cancer. For a significant portion of the women screened by
mammogram, fucosylated bisecting N-glycans could readily distinguish patient
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groups. A surprising result was that no IgG N-glycans or N-glycan classes could
be used to distinguish patients that had benign lesions, DCIS, or invasive breast
cancer. Even when stratifying the population based on age and BMI, there were
no significant differences.
While many studies have identified N-glycan differences in healthy women
compared to women with breast cancer, this study is one of the first to address
the issue of breast cancer screening false-positives. The samples were collected
from women at a surgical clinic after a suspicious mammogram finding making
this cohort ideal for investigating this unmet clinical need. Using samples
collected at a single site reduced the impact of confounding factors such as
inconsistent collection or storage methods. Incorporating clinical factors that have
well-established associations with breast cancer with certain N-glycans led to a
more robust classification of samples. This highlights the importance of collecting
and utilizing biological characteristics when investigating serum N-glycan profiles.

6.4.2 Limitations and Future Studies
One of the factors that was incorporated into the initial analysis of all the
samples was ethnicity/race. There were greater than 5 samples for each
ethnicity/race (Caucasian, Hispanic, African American, and Asian), but when the
samples were stratified by BMI and age, there were some groupings that had no
samples from either African American or Asian women. As this was the case,
ethnicity/race was not included in the logistic regression model used to classify
samples as being from a woman with a benign lesion or breast cancer. This does
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limit the conclusions that can be made from this data. Compared to other
ethnicity and racial groups, African-American women have a higher mortality
rate, are diagnosed at a younger age, and are more likely to have unfavorable
tumor characteristics, such as having triple-negative breast cancer.321 Future
studies should look to increase sample size and distributions of different
ethnicity/races to not only broaden conclusions, but increase the likelihood of
identifying N-glycan alterations that may be ethnicity/race-specific.
While the ideal biomarker can be universally applied, the strongest use of
N-glycans as classifiers of disease status was in a subset of women aged 50-74
that were within the healthy weight range. This may be due to breast cancerassociated alterations in the N-glycan profile being masked by the significant
effects of age and BMI-induced inflammation on N-glycosylation patterns of
highly abundant serum proteins, such as IgG. The lack of significant alterations in
the IgG N-glycan profile, indicates that the differentially expressed N-glycans in
the serum are most likely carried by proteins originating from the liver. Future
research should focus on using antibody-panel based N-glycan profiling of these
proteins.
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6.5 Final Thoughts
Overall, this dissertation has described the development of a novel biofluid
N-glycan profiling technique and its application for the identification of N-glycan
alterations that can be used to distinguish women with benign lesions from
women with breast cancer. The workflow described in chapter 3 has the potential
to become a platform for N-glycan analysis of various biofluids. This was
validated in chapter 4 when the workflow was adapted for urine and prostatic
fluids. The utility and clinical relevance of this approach was demonstrated by its
application to breast cancer biomarker detection in chapter 5. The general
workflow described in this dissertation constitutes a novel MALDI analysis
platform for N-glycan profiling of multiple biofluids that has the potential for
multiplexed analysis of other biomolecules. This work represents another
advancement in MALDI mass spectrometry, which itself is quickly becoming a
technology that can be used as a comprehensive strategy for clinical research by
analysis of tissues, cells, targeted proteins, and biofluids.
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